


Laboratory Report No. 16



CLINICAL INVESTIGATION PROGRAM MA101634 ANNUAL PROGRESS REPORT

30 September 80



FITZSIMONS ARMY MEDICAL CENTER AURORA, COLORADO 80045

REPORT DOCUMENTATION PAGE	READ INSTRUCTIONS BEFORE COMPLETING FORM			
	3. RECIPIENT'S CATALOG NUMBER			
16 A D- A D D	1 634 -			
4. TITLE (and Subittia)	F. TYPE OF C. FRIOD COVERED			
Annual Research Program, Annual Research Progress Report.				
Annual Research Progress Report	6. PERFORM ON A STATE ORG. REPORT NUMBER			
7. AUTHOR(4)	8. CONTRACT OR GRANT NUMBER(a)			
Donald G. Corby, M.D., COL, MC	N/A			
9. Las, Tory	ptinoiy6(Final)			
9. PERFORMING ORGANIZATION NAME AND ADDRESS Department of Clinical Investigation (HSF-CI)	10. PROGRAM ELEMENT, PILLIECT, TASK AREA & WORK UNIT NUMBERS			
	various work unit numbers as			
	indicated on detail sheets			
Office of Deputy Commander (HSF-DC)	30 SEP 1980 / 121/			
Fitzsimons Army Medical Center	19. MAMBER OF PAGES			
Aurora, CO 80045 14. MONITORING AGENCY NAME & ADDRESS(If different from Controlling Office)	15. SECURITY CLASS. (of this report;			
U.S. Army Health Services Command				
ATTN: HSPA-I Fort Sam Houston, TX 78234 .	UNCLASSIFIED			
, , , , , , , , , , , , , , , , , , , ,	154. DECLASSIFICATION/DOWNGRADING SCHEDULE N/A			
16. DISTRIBUTION STATEMENT (of this Report)				
Approved for public release; distribution unlimit	ed.			
	1			
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from	n Report)			
N/A	100 PM			
	1			
18. Supplementary notes The findings of subject report are not to be cons	trued as an official			
Department of the Army position unless so designated by other authorized				
documents.				
19. KEY WORDS (Continue on reverse side if necessary and identify by block number)				
Clinical Investigations, all medical specialties experimental projects (planning, coordination, staff supervision, execution,				
review and monitoring)	arr supervision, execution,			
research protocols				
in-house research (continued on reverse side)				
20. ABSTRACT (Continue on reverse elde it necessary and identity by block number) Subject report identifies the research activities conducted by Fitzsimons Army				
Medical Center investigators through protocols approved by the institutional				
Review Committee and registered with the Department of Clinical Investigation during Fiscal Year 1980 and other known presentations and publications by				
the Fitzsimons Army Medical Center professional staff. The research protocols				
described were conducted under the provisions of A ical Investigation Program, AR 40-7, Use of Invest	AR 40-38, as amended, Clin-			
AR 70-25, HSC Reg. 40-23, as amended (continued or	reverse side)			
DO FORM	ASSIFIED			

UNCLASSIFIED

Block 19. Key Words

publications, presentations of research data (at national, international and regional science meetings)
post graduate educational programs
protocol training and support programs
protocol registration
protocol status (ongoing, completed, terminated)
technological base (personnel and equipment)
experimental design (statistical tools, etc.)

Block 20. Abstract

Management of Clinical Investigation Protocols and Reports, Use of Volunteers as subjects of research and AR 40-38, as amended, Department of Clinical Investigation, policies and procedures, to insure the medical well-being, preservation of rights and dignity of human subjects who participated in these investigations.

UNCLASSIFIED

APPROVED FOR PUBLIC RELEASE: DISTRIBUTION UNLIMITED.

DESTROY THIS REPORT WHEN NO LONGER NEEDED. DO NOT RETURN IT TO THE ORIGINATOR.

THE FINDINGS IN THIS REPORT ARE NOT TO BE CONSTRUED AS AN OFFICIAL DEPARTMENT OF THE ARMY POSITION UNLESS SO DESIGNATED BY OTHER AUTHORIZED DOCUMENTS.

DEPARTMENT OF CLINICAL INVESTIGATION REPORT CONTROL SYMBOL MED-300

CLINICAL INVESTIGATION PROGRAM

ANNUAL PROGRESS REPORT

30 SEPTEMBER 1980

CLINICAL INVESTIGATIONS (U)

FITZSIMONS ARMY MEDICAL CENTER
AURORA, COLORADO 80045

Approved for public release; distribution unlimited.

FOREWORD

This report identifies the research activities conducted by Fitzsimons Army Medical Center investigators through protocols approved by the Institutional Review Committee and registered with the Department of Clinical Investigation during Fiscal Year 1980 along with other known presentations and publications by FAMC professional staff.

The research protocols described in this report were conducted under the provisions of AR 40-38, as amended, Clinical Investigation Program, AR 40-7, Use of Investigational Drugs in Humans, AR 70-25, Use of Volunteers as Subjects of Research, and HSC Reg. 40-23, as amended, Management of Clinical Investigaton Protocols and Reports, to insure the medical safety, well being, preservation of rights and dignity of human subjects who participated in these investigations.

In conducting the research described in this report, the investigator(s) adhered to AR 70-18, Laboratory Animals, Procurement, Transportation, Use, Care, and Public Affairs and the "Guide for Laboratory Animal Facilities and Care," as promulgated by the Committee or the Guide for Laboratory Animal Resources, National Academy of Sciences, National Research Council.

The Department of Clinical Investigation is especially grateful to MAJOR GENERAL Raymond H. Bishop, MC and BRIGADIER GENERAL William R. Dwyre, MC, Commanding Generals of Fitzsimons Army Medical Center, their professional and administrative staffs, and to the Commanding Officers and staffs of other supporting activities for the cooperation and assistance provided this Department of Clinical Investigation in our efforts to accomplish our mission. Finally, I would like to recognize the outstanding work, dedication, and wholehearted corroboration of my entire staff. I would especially like to thank my Proto/Ed Asst, Ms. Val McCrill and Mrs. Nancy Moran, Secy, without whose assistance and support this report would not have been possible.

Sonda & long DONALD G. CORBY, M.D.

COL. MC

Chief, Department of Clinical Investigation

PUBLICATIONS

PUBLICATIONS

DEPARTMENT OF MEDICINE

Allergy Service

Carpenter, G.B., Bunker, A.L., Nelson, H.S.: An Evaluation of Combined H₁ and H₂ Antagonists in the Treatment of Seasonai Allergic Rhinitis. (Abst) J of Allergy and Clin Immunol 65:187, 1980. (C)

Dantzler, B.S., Tipton, W.R., Nelson, H.S., O'Barr, T.P.: Tissue Threshold Changes During the First Months of Immunotherapy. Annals of Allergy 45:213, 1980. (C)

Jacobson, K.W., Branch, L.B., Nelson, H.S.: Laboratory Tests in Chronic Uticaria. J.A.M.A. 243:1644, 1980. (C)

Mansfield, L.E., Ledieux, R., Lima, J., Brown, G.S.: An Inhibition Method Utilizing the Laser Nephelometer to Measure Human Specific "Blocking Antibodies. Annals of Allergy 45:228, 1980. (C)

Mansfreid, L., McDonnell, J., Morgan, W. Souhrada, J.F.: Airway Response in Asthmatic Children During and After Excercise. Respiration 38:135, 1979. (C)

Martin, B.G., Mansfield, L.E., Nelson, H.S.: Patterns of Cross Allergenicity among Grasses. (Abst) J of Allergy and Clin Immunol 65:229, 1980 (C)

Nelson, H.S.: A Comparison of Long-Term Immunotherapy with Aqueous and Alum Precipitated Grass Extracts. Annals of Allergy, December 1980. (C)

Nelson, H.S.: "Allergens, Antigenic Makeup". Textbook of Clinical Allergy, Editor: R. Lockey, Medical Examination Publishing Company, 1979.

Nolson, H.S.: Pregnancy and Allergic Diseases. Chapter 51 in Allergic Diseases of Infancy, Childhood and Adolescence, Edited by C.W. Bierman & D.S. Pearlman, W.B. Saunders Company, Philadelphia, 1980.

Nelson, H.S.: The Effect of Dilution and Conditions of Storage on Allergy Extract Potency. J of Allergy and Clinical Immunol, (In Press). (C)

Smith, J.A., Mansfield, L.E., deShazo, R.D., Nelson, H.S.: An Evaluation of the Pharmacologic Inhibition of the Immediate and Late Cutaneous Reaction to Allergen. J of Allergy and Clin Immunol 65:118, 1980. (C)

Stein, M.R., Towner, T.G., Weber, R.W., Mansfield, L.E., Jacobson, K.W., McDonnell, J.T., Nelson, H.S.: The Effect of Theophylline on the Lower Esophageal Sphincter Pressure. Annals of Allergy 45:238, 1980. (C)

Tipton, W.R.: Influence of Histamine Controls on Skin Tests with Hymenoptera Venom. Annals of Allergy 44:204, 1980. (C)

⁽C) Direct result of approved registered protocol.

Allergy Service - continued

Tipton, W.R.: The Development of Specific and Cross Sensitivity in the Tracheal Tissue of Guinea Pigs Treated with Isoproterenol and Amirophylline. (Accepted for publication in Lung)(C).

Cardiology Service

Febres-Roman, P.R., Bourg, W.C., Crone, R.A., Davis, R.C., Williams, T.H.: Chronic Intravascular Hemolysis After Aortic Valve Replacement with Ionescu-Shiley Xenograft: Comparative Study with Bjork-Shiley Prosthesis. Am J Cardiol 46:735-738, 1980.

Febres-Roman, P.R., Haas, J.M., Cowen, G.D.: Hemodynamic Assessment of the Ionescu-Shiley Pericardial Xenograft in the Mitral Position. Cathet Cardiovasc Diagn 6:233-245, 1980.

Trnka, K.E., Febres-Roman, P.R., Cadigan, R.A., Crone, R.A., and Williams, T.H.: Total Occlusion of the Left Main Coronary Artery: Clinical Catheterization Findings. Clin Cardiol 3:352-355, 1980.

Dermatology Service

Aeling, J.L.: Dermatologic Therapeutic Survey. J of the Assoc of Mil Derma, Vol 5, No. 2, Fall 1979.

Aeling, J.L., Andreozzi, R. and Thorne, E.G.: Epidermodysplasia Verruciformis. J of the Assoc of Mil Derma, Vol 5, No. 2, Fall 1979.

Duke, D.W., Palmintier, J.S., Aeling, J.L., et al: Peripheral Atheroembolism, Presenting as Unilateral Livedo Reticularis. J of the Assoc of Mil Derma, Vol 5, No. 2, Fail 1979.

Fitzpatrick, J.E., Tyler, H., Gramstad, N.O.: Treatment of Chancroid: Comparison of Trimethoprim-Sulfamethoxazone to Recommended Therapies. (Submitted for publication to the J of the AMA)

Gentry, R.H., Aeling, J.L., Chalet, M.D.: Zinc: Basic Science and Deficiency Syndromes. J of the Assoc of Mil Derma, Vol 5, No. 2, Fall 1979.

Grimwood, R.E.: The Complement System. J or the Assoc of Mil Derma, Vol 5, No. 2, Fall 1979.

Grimwood, R.E., Aeling, J.L., Kort, W.T.: Eosinophilic Fasciitis. J of the Assoc of Mil Derma, Vol 5, No. 2, Fall 1979.

Grimwood, R.E., Arroyave, C.M., Weston, W.L., Aeling, J.L.: Herpes Gestationis Associated with the C3 Nephritic Factor. Archives of Derma, Vol 116, No. 9: 1045-1047, Sep 1980.

⁽C) Direct result of approved registered protocol.

Dermatology Service - continued

Fatterson, J.W.: Pilar Tumor. A Case Report and Review. J of the Assoc of Mil Derma, Vol 6, No. 1, Spring 1980.

Thompson, P.B., Aeling, J.L., Chalet, M.D.: Collagen: Basic Science and Related Diseases. J of the Assoc of Mil Derma, Vol 5, No. 2, Fall 1979.

Endocrinology Service

Abrams, R., Hofeldt, F.D., Adler, R., O'Barr, T.P., Morse, P.: Late Reactive Hpoglycemia in Hypothyroidism. (Submitted for publication to The Am J of Med Sciences) (C)

Charles, M.A., Sharma, B., Dodson, L.E., Ownbey, J., Noble, S., Waldeck, N., Brown, G., True, E., Nakane, P.: Mechanisms of Rat Pancreatic Islet Allograft Rejection. (Submitted for publication to J of Clin Investigation)(C).

Charles, M.A., Dodson, L.E., O'Barr, P., Waldeck, N., Hofeldt, F.D., Ghaed, V., Telepak, R.: Serum Thyroglobulin Levels Predict Total Body Iodine Scan Findings in Patrones with Treated Well Differentiated Thyroid Carcinoma. Am J Med 69:401-407, 1980. (C)

Charles, M.A., Snarma, B., Waldeck, N., Dodson, L.E., Brown, G.: In Vitro Cytotoxicity Stadies in Diabetic Patients. (Submitted for publication to J of Clin Investigations) (\mathbb{C})

Charles, M.A., nofeldt, F.D., Dodson, L.E., Shackelford, A., Waldeck, N., Banker, D., Coggins, J.T., Eichner, H.: Comparison of Glucose Tolerance Tests and Mixed Meals in Patients with Idiopathic Reactive Hypoglycemia: Absence of Hypoglycemia After Mixed Meals. (Submitted for publication to Annal of Int Med) (C)

Gade, G.N., Hofelds, F.D. Response to combination Therapy with Amitriptyline and Fluphenazina. JAMA 243:1160, 1980

Garrett, C.R., West, S.G., West, F.D.: Covert Hypothyroidism Presenting as a Cardiova-cular Event. Am J Med (In Press)

Georgitis, W.J., widd, G.S., & foldt, F.D.: Euthyroid Sick Syndrome. J of the Maine Med Assoc (in Frees.)

Georgitis, W.J., Treece, 6.L., and Hofeldt, F.J.: Resolution of Recurrent Thyroid Cysts with Tetracyclin. Instillation. JAMA (In Press)

Georgitis, W.J., Traeco, G.E., Hofeldt, F.D.: Resolution of Recurrent Thyroid Cysts with Tetracycline Instituation. (Abst.) Joint Meetings of the American Federation for Clinical Research, Carmel, CA, 1980.

(C) Direct result of approved it distered protocol.

Endocrinology Service

- Hofeldt, F.D., Kelly, M.: Low-dose Insulin Regimens in the Management of Diabetic Ketoacidosis. Efficacy and Pitfalls. Minnesota Medicine (In Press), 1980.
- Hofeldt, F.D.: Why Control Blood Glucose Values? Arizona Medicine 36: 750, 1979.
- Hofeldt, F.D., Levin, S., Becker, N., Von Weider, K., Hane, S., Forsham, P.H.: Response of the Hypothalamic-Pituitary-Adrenal Axis in Acromegaly. (Submitted for publication to JCEM)
- Hofeldt, F.D.: Nutritional Support of the Patient: Endocrine Aspects. Am J Clin Nutrition (Suppl) (In Press)
- Hofeldt, F.D.: Preventing Reactive Hypoglycemia: The Great Medical Dilemma. Textbook, Warren Green Publishers (In Press)(C)
- Jones, R.E., Askew, & W., Hecker, A.L., Hofeldt, F.D.: Salicylic Acid Stimuration of Palmitic acid Oxidation by Rat Skeletal Muscle Mitochondria. (Submitted for publication to Biochem Biophys Acca) (C)
- Jones, R.E., Hofeldt, F.D.: Total Parenteal Nutrition with the Assistance of a Programmable Calculator. (Submitted for publication to Physicians' Microcomputer Report)
- Jones, R.E., Hoteldt, F.D.: Detection of High Oxygen Affinity Hemoglobinopathies by Computer Assisted P50 Calculations. (Submitted for publication to Physicians' Microcomputer Report)
- nes R.E., Hofeldt, f.D.: Rapid Calculations of Drug Infusion Rates by a Programmable Calculator. (Submitted for publication to Physicians' Microcomputer Report)
- Jones, R.E., Hofeldt, F.D.: Scimulation of Mitochondrial Long Chain Fatty Acid:CoAsh Ligase (AMP) by Salicylic Acid. J Colorado-Wyoming Academy Sci (In Press)(C)
- Kidd, G.S., Schaaf, M., Adler. E.A., Lasserman, M., Wray, H.L.: Skeletal Responsiveness in Pseudohypogenathyroidism: A Spectrum of Clinical Disease. Am J Med 68:772-781, 1980.
- Kidd, G.S., Dimond, R., Whorton, N., and Vigersky, A.: The Dynamics of Pituitary Hormone Secretion in the Amenorrhea-Galactorrhea Syndromes. (In Press)
- Kidd, G.S., Smith, C., Wray: H.L.: Effect of Thyroid Status on the Renai Responses to Vasopressin. (In Press)
- (C) Direct result of approved registered protocol.

Endocrinology Service - continued

McDermott, M., Piegari, G., and Hofeldt, F.D.: Acute Renal Failure Occurring in McArdle's Disease: Case Report and Literature Review. (Submitted for publication to Arch Lut Med)

Sanders, L., Hofeldt, F.D., Kirk, M., and Levin, J.: Food Abuse as a Cause of Reactive Hypoglycemia. Am J of Clin Nutr (In Press)(C)

Weled, B.J., Ball, J., and Hofeldt, F.D.: The Hypoglycemic Hazards of Propranolol in Diabetic Patients. Military Medicine 145:705, 1980.

Wray, H.L., Smallridge, R.C., Butler, V., Byrn, K., Kidd, G.S.: Correlation Between Nephrogenous Cyclic GMP and Tubular Resorption of Calcium during Parathyroid Hormone Infusion. International Conference on Cyclic Nucleotides, 1979.

Zwillich, C., Martin, B., Rose, E., Charles, M.A., Hofeldt, F.D., Berman, K.: The Effects of Dense Beta Sympathetic Blockade of Ventilation and Metabolic Rate in Normal Man. JCEM (In Press)(C)

Zwillich, C., Sandes, E., Fraciste, C., Hofeldt, F.D., Weil, J.: Prolonged Apnea and Hypoxemia during Sleep in Myxedema. (Abst) Clin Res 28:86A, 1980(C)

Hematology/Uncolour Service

burgess, R.E., Burgess, V.F., DiBella, N.J.: Clinical Parameters Associated with Brain Metastases in Patients with Small Cell Carcinoma of the Lung. DMA 242:2084-2086, 1979. (C)

de Shazo, R.D., Norres, D.A., Morris, R.J., Bourg, W.C., III, Johnston, R.B.: Immunologic and Functional Features of the Leukemic Cell of Hairy Cell (2008) Femia: Evidence for a cell Hypothesis. The Am J of Med Sci, Vol 279:134 May/June 1980.

DiBella, N.J.: Vincristing induced Orthostatic Hypotension: A Prospective Clinical Study. Cancer tremports, Vol. 64, No. 2-3:359-360, Feb/Har 1980. (C)

Pulmonary function Lab

Kindig, N.B., Perry, M. E., i Fming, R.J.: DLCO, Correction Using PaCO Back Pressure Predicted from Vones Blood. (Abst) AAMI, 15th Annual Meeting, San Francisco, CA, Pg 107, April 1980. (C)

Kindig, N.B., Perry, M.E., Filley, G.F.: Gas Mixing Deadspace: Measurement with Tracer Gases. (Abst) M.S. Planck Institute for Experimental Medicine, July 1980. (C)

Perry, M.E., Zimmerer, R. . . Browning, R.J.: Non-Invasive Alveolar Pressure/ Flow Pattern Determination of Computerized Plethysmography. (Abst.) Symposium on Computers in Critical of the Pulmonary Medicine, Pg. 47, June 1980. (C)

⁽C) Direct realt of appeared registered protocol

Pulmonary Function Lab - continued

Perry, M.E., Zimmerer, R.W., Nelson, R.A., Browning, R.J.: Non-Invasive Determination of Alveolar Pressure-Flow Relationship. (Abst) Am Review of Res Dis, Vol 121:389, April 1380. (C)

Zimmerer, R.W., Perry, M.E., Browning, R.J.: Expiratory Pressure/Flow Assessment by Plethysmography. (Abst) AAMI, 15th Annual Meeting, San Francisco, CA, Pg 246, April 1980. (C)

DEPARTMENT OF CLINICAL INVESTIGATION

Bikle, D.D., Askew, E.W., Zolock, D.T., Morrissey, R.H., Herman, R.H.: Calcium Accumulation by Chick Intestinal Mitochondria: Regulation by Vitamin D₃ and 1,25-dihydroxyvitamin D₃. Biochem Biophys Acta 598: 561-574, 1980. (C)

Bikle, D.D., Morrissey, R.L., Zolock, D.T., Herman, R.H.: Stimulation of Chick Gut Alkaline Phosphatase Activity by Actinonycin D and 1,25 dihyroxyvitamin D_3 : Evidence for Independent Mechanisms. J Lab Clin Med 94: 88-94. 1979. (C)

Bikle, D.D., Morrissoy, R.L., Zolock, D.T.: The Mechanism of Action of Vitamin D in the Intestine. Am J Clin Nutr 3::2322-2338, 1979. (C)

Corby, D.G., o'Barr, T.P.: The stated Alpha-Adrenergic Receptors in Newborn Platelets: Cause or account Response to Epinephrine. Dev Pharmacol & Ther (In Press) (C)

Corby, D.G., O'Barr, C.F.. Neomatal Platelet Function: A Membrane-Related Phenomen. Hauskost ois (In Press) (C)

dorby, D.G., O'Barn, force a whoma Platelet Function. Chapter in Book "Acquired Bleeding Discours a in Childhood". Masson Publ (In Press) (C)

Decker, W.J., Corby, D.G.: Activated Charcoal Adsorbs Aflatoxin B_j. Vet & Human Foxicol, (1: Pr.ss) (8)

Glab, W.N., Corby, D.G., Proker, W.J., Coldiron, V.R.: Decreased Absorption of Proposyphone by Activated Charcoal. J of Fundamental & Appl Toxicol (In Press) (6)

Glab, W.N., Corby, D.G., and Art of L., Coldinon, V.R.: Prevention of Propoxyphene Absorption by Activated Charcoal in Rats: Clinical and Pharmacological Correlations. Vet & Human Toxicol (In Press) (C)

Harbell, J.W.: Insulin Action on Normal and Transformed GR/A Strain Mouse Mammary Tissues. In Vitto 16(3):247, 1980. (C)

⁽C) Direct result of mental to stered protocol

Department of Clinical investigation - continued

Morrissey, R.L., Zolock, D.T., Mellick, P.W., Bikle, D.D.: Influence of Cycloheximide and 1,25-dihydroxyvitamin D₃ on Mitochondrical and Vesicle Mineralization in the intestine. Cell Calcium 1:69-79, 1980. (C)

Rothlauf, M.V., Brown, G.L., Blair, E.G.: Isolation of Mycobacteria from Undecontaminated Specimens with **Selective** 7H10 Medium. J of Clin Micro (In Press) (C)

Zolock, D.T., Askew, E.W.: Carbohydratemetabolism of the Red Blood Cell during Exercise in Rats. Federation Proceedings 39:2145, 1980. (C)

DEPARTMENT OF NURSING

Haag, G.P.: Anesthetist Update Series: Another Lock at Anticholinergics. Biomedia, Inc., Princeton, NJ, 2:9, 1980.

Haag, G.P.: Anesthetist Update Series: Anesthesia and the Geriatric Patient, Biomedia, Inc., Princeton, NJ 2:13, 1930.

Zegarski, J.J.: Anastherist Update Series: Malignant Hyperthermia, Biomedia, Inc., Princeton, NJ, Aug 1980.

Robinson, R.L.: Laboratory Findings in the Differential Diagnosis of Acute Renal Filure. Critical Care Quarterly 2(3):87-98, 1979.

DEFARTMENT OF OB-GYN

Bobitt, J.R., Brown, G.L., Tull, A.H.: Group B Streptococcal Neonatal Infection: Clinical Review of Plans for Prevention and Preliminary Report of Quantitative Antepartum Cultures. Obstetrics & Gynecology 55:5, pg 1715, May 1980. (C)

Boultt, J.R., Damato, J.J., Hayslip, C.C.: Amniotic Fluid Infection in Premature Labor Patients with Intact Membrances: As Determined by Transabdominal Amniocentesis. Submitted for publication (C)

Simsen, D.A., Shirts, S.R., Howard, F.M., Sims, J., Hill, J.M.: Endometrial Findings in Asymptomatic Postmenopausal Women on Exogenous Estrogens - A Preliminary Report. J of Syn-Oncol (In Press) (C)

DEPARTMENT OF PEDIATRICS

Allen, W.R., Brouhard, B.H., Lynch, R.E.: Effect of Diazoxide on Proximal Tubular Sodium Reabsorption. Ped Res 14:8, pg 989, #77, Aug 1980.

Bowen, D., Parry, W.H.: Bronchopulmonary Foregut Malformation in Goldenhar's Anomalad. Am J Rad 134:186-187, 1980.

Gumbiner, C., Mallins, C., McNamara, D.: Pulmonary Artery Sling. Am J Cardiol 45:311, 1980.

⁽C) Direct result of approved registered protocol

Gumbiner, C.G., Gillette, P., Shih, J.: The Electrophysiologic Effects of Chronic Digoxin Administration in the Healthy Awake Puppy. (Abst) Pediatr Res 14:445, 1980.

Gumbiner, C., Gutgesell, H.: Effect of Isometric Exercise on Left Ventricular Volume Overload (LVVO). (Abst) Pediatr Cardiol, 1:1974, 1979-1980.

Gumbiner, C., Mullins, T., McNamara, D.: Pulmonary Artery Sling. (Abst) Pediatr Cardiol 1:175, 1978-1980.

Kilbride, H.W., Merenstein, G.B., Weisman, L.E., Hill, J.M.: Herpes Simplex Genitalis Infections. (Ltr) Am j of Ob-Gyn 137:1, 1980.

Kilbridge, H.W., Merenstein, G.B., Way, G.L., Whitfield, J.M.: Myocardial Infarction in the Neonate with Normal Heart and Coronary Arteries. Am J of Dis of Children 134:759, 1980.

Merenstein, G.B., Todd W.A., Brown, G., Yost, C.C., Euzier, T.: Group B Beta-Hemolytic Streptococcus: Randomized Controlled Treatment Study at Term. Ob-Gyn 55:135, 1980. (C)

Mosijczuk, A.D., Ruymann, F.B., Mease, A.D., Bernier, R.D.: Anthracycline Cardiomyopathy in Children: Report of Two Cases. Cancer, Nov 1979.

Mosijczuk, A.D., Ruymann, F.B.: Second Malignancy in Childhood ALL: Review of 29 Cases. Am J of Dis in Children (In Press)

Parry, W.H., Madden, W.A.: Bacterial Laryngotracheitis. Letter to the Editor, AJR, pp 216-17, July 1980.

Parry, W.H., Madden, W.A.: Bronchoscopy in the Neonatal Intensive Care Unit. (Abst) 2nd World Congress of Bronchology (In Press)

Parry, W.H., Madden, W.A.: Bronchoscopic Finding in Bacterial Laryngo-tracheobronchitis. (Abst) 2nd World Congress of Bronchology (In Press)

Quattromani, F., Parry, W.H.: Airway Obstruction in the Pediatric Patient.
1. Upper Airway Obstruction. Resp Therapy 10:28-33, 1980.

Sanders, J.: Health Needs of Adolescents in the Military Service. Pediatr Clin of N Am, Vol 26, No.1, Feb 1980.

Shih, J-Y, Gillette, P., Carson, A., Gumbiner, C., Driscoll, D.: The Prognosis of Atrial Flutter in Children. (Abst) Pediatr Res 14:450, 1980.

Shih, J-Y, Gillette, P., Carson, A., Gumbiner, C., McNamara, D.: The Effect fo Procainamide on Atrial Tachycardia in Nonsedated, Chronically-Instrumented Beagle Pappiers. (Abst) Pediatr Res 14:450, 1980.

⁽C) Direct result of approved registered protocol

Way, G.L., Pierce, J.R., Wolfe, R.R., McGrath, R., Merenstein, G.B.: ST Depression Suggesting Subendocardial Ischemia in Neonates with Respiratory Distress Syndrome. J of Pediatr 94:609, 1979.

Way, G.L., Wolfe, R.R., Eshaghdour, E., Bender, R.L., Jaffe, R.B.: The Natural History of Hypertrophic Cardiomyopathy in Infants of Diabetic Mothers. J of Pediatr Vol 95, No., 1020-1025, Dec 1979. (C)

DEPARTMENT OF RADIOLOGY

Fisk, J.D.: Gastrointestinal Radiographic Features of Human Graft-Versus Host Disease. Am J of Roentgenology (In Press)

Hopper, K.D.: Thyroid Carcinoma Secondary to Previous Infant and Childhood Head and Neck Irradiation. The 7th Army Medical Bulletin, 3-14, Sep 80

McNeill, D.H.: Dissection of the Internal Carotid Artery: Its Conservative Management with Heparin Sodium. Archives of Neurology 37:54-5, Jan 1980.

Russell, J.R.: "Box" Technique for Irradiation of Esophageal Cancer and Breast Cancer: Comparison of Two Fractionation Schemes for Postoperative Radiation Therapy. Radiation Therapy Division, Collected Papers, Ninth Annual Radiation Therapy Clinical Research Seminar, Gainesville, Florida, Apr. 1979.

Williams, B.D., Fisk, J.D.: Ultrasonic Diagnosis of Giant Urachal Cyst in the Adult. Am J of Roenigenology (In Press)

DEFARTMENT OF SURGERY

General Surgery Service

Davies, R.S.: Reflux Esophagitis. Chapter in book "Prognosis of Surgical Disease". W.B. Saunders Co., B. Eiseman, Editor, 1980.

Ferraris, V.A., Sund, James: Retrospective Study of the Surgical Management of Reflux Esophagitis. Surg, Ob & Gyn, (In Press) (C)

Hirata, R.M.: Carcinom. of the Oral Cavity. Chapter in book "Prognosis of Surgical Discase, C. Eiseman, Editor, W.B. Saunders Co., 1980.

Mologne, L.: Varicesa Voins. Chapter in book "Prognosis of Surgical Disease, B. Eiseman, Editor, W.B., Saunders Co., 1980.

Ophthalmology Service

Cottingham, Jr., A.J.: The Initial Fifty Intraocular Lens Implantations in an Ophthalmology Residency Iraining Program. Submitted for publication to Am J of Ophth. (C)

(C) Direct result of approved registered protocol

Department of Surgery - continued

Otolaryngology Service

Hasbrouck, J.M.: Performance of Students with Auditory Figureground Disorders under Conditions of Unilateral and Bilateral Ear Occlusion. J of Learning Disabilities (In Press)

Hasbrouck, J.M.: Speech Production and Perception as Related to the Assessment and Remediation of Auditory Perceptual Disorders. The Proceedings of the 18th Congress of Logopedics and Phoniatrics. (In Press)

Hasbrouck, J.M.: Speech Production and Perception as Related to the Assessment and Remediation of Auditory Perceptual Disorders. (Abst) Folia Phoniatrica 32:194, 1980.

Plastic Surgery Service

Rich, J.D., Shesol, B.F., Horne, D.W.: Basal Cell Carcinoma Arising in a Smallpox Vaccination Site. J of Clin Path, Feb 1980.

Rich, J.D., Zbylski, J.R., LaRossa, D.D.: Dermatofibrosarcoma Protuberans of the Head and Neck. The Am Surgeon, April 1980.

Shesol, B., Clarke, J.S.: Intrathoracic Application of the Latissimus Dorsi Musculocutaneous Flap. J of Plastic and Reconstructive Surgery (In Press)

Urology Service

Dobbs, R.M.: Clotting Predisposition in Carcinoma of the Prostate. J of Urology, 123:706, 1980. (C)

Fauver, H.E., Donohue, R.E., Whitesel, J.A., Augspurger, R.R., Pfister, R.: Prostatic Carcinoma - A Different Distribution. J of Urology, 122:397, 1979.

Fauver, H.W.: Pyelchephritis. Conn's Current Therapy (In Press)

Wilson, Torrence M., Fauver, H.W.: Leiomyosarcoma of Bladder. Urology 13:575, 1979.

⁽C) Direct result of approved registered protocol

PRESENTATIONS

PRESENTATIONS

DEPARTMENT OF MEDICINE

Allergy Service

Carpenter, G.B.: An Evaluation of Combined H₁ and H₂ Antagonists in the Treatment of Seasonal Allergic Rhinitis. Presented: Annual Meeting, American Academy of Allergy, Atlanta, GA, 16-20 Feb 1980. (C)

Dantzler, B.S.: Tissue Threshold Changes during the First Months of Immunotherapy. Presented: Annual Meeting, American Academy of Allergy, Atlanta, GA, 16-20 Feb 1980. (C)

Mansfield, L.E.: Canine Bronchoconstriction Provoked by Esophageal Distention and Acid Infusion. Presented: Annual Meeting, American Academy of Allergy, Atlanta, Ga, 16-20 Feb 1980. (C)

Mansfield, L.E.: Measurement of Blocking Antibody by Laser Nephelometry. Presented: Annual Meeting, American College of Allergists, Miami, FL, 22 Jan 1980. (C)

Martin, B.G.: Patterns of Cross Allergenicity Among Grasses. Presented: Annual Meeting, American Academy of Allergy, Atlanta, GA, 16-20 Feb 1980.(C)

Nelson, H.S.: Allergens: Selection and Handling. Presented: Annual Post-graduate Program Association for the Care of Asthma, Miami, FL, 18 Jan 1980.

Nelson, H.S.: Allergy Immunotherapy. Presented: 8th Annual Symposium NJH/NAC, Keystone, CO, 8 Jan 80.

Nelson, H.S.: Hyposensitization: Practical Considerations in Future Prospects. Presented: Kansas City Allergy Society Annual Meeting, Kansas City, MO, 3 May 1980.

Nelson, H.S.: Practical Application of Standardization and Studies of Extracts Stability. Presented: Annual Meeting. Kansas City Allergy Society, Kansas City, MO, 3 May 1980. (C)

Nelson, H.S.: Present Concepts of Aspirin Sensitivity in Asthma. Presented: Annual Scientific Meeting, American Thoracic Society, Washington, DC, 14 May 1980. (C)

Smith, J.A.: The Effect of an H₁ and H₂ Receptor Antagonist Alone and in Combination on Dermographism. Presented: Annual Meeting, American Academy of Allergy, Atlanta, GA, 16-20 Feb 1980. (C)

Spaulding, H.S.: Variability of Allergy Extract Prescribing. Presented: Annual Meeting American College of Allergists, Miami, FL, 22 Jan 1980.

⁽C) Direct result of approved registered protocol

Allergy Service - continued

Tipton, W.R.: Titrated Skin Tests, RAST and Blocking Antibody Changes with Rush Immunotherapy. Presented: Annual Meeting, American College of Allergists, Miami, FL, 22 Jan 1980. (C)

Cardiology Service

Crone, R.A.: The Effect of Volume Overload and LV Function on the Preoperative Evaluation of Subvalvular Fibrosis in Mitral Stenosis. Presented: The 9th Annual Association of Army Cardiology Meeting, Letterman Army Medical Center, San Francisco, CA, May 1980.

Febres-Roman, P.R.: Intravascular Hemolysis after Aortic Valve Replacement with the Ionescu-Shiley Xenograft. Presented: The 9th Annual Association of Army Cardiology Meeting, Letterman Army Medical Center, San Francisco, CA, May 1980.

Trnka, K.E.: Total Occlusion of the Left Main Coronary Artery. Presented: The 9th Annual Association of Army Cardiology Meeting, Letterman Army Medical Center, San Francisco, CA, May 1980.

Dermatology Service

Aeling, J.L.: An Approach to the Histopathologic Diagnosis. Presented: Practical Skin Pathology Course, Colorado Springs, CO, Oct 1980.

Aeling, J.L.: Sun Rashes and Sun Screens. Presented: University of Colorado Family Practice Review, Estes Park, CO, April 1980.

Aeling, J.L.: Superficial and Deep Fungi, Contaminants and Yeast Infections. Presented: Owen Pre-Board Slide Seminar, Chicago, IL, Sep 1980.

Eubanks, S.W.: Pseudolymphoma. Presented: Annual Meeting of the American Academy of Dermatology, Chicago, IL, Dec 1979.

Gentry, R.H.: Eruptive Collagenoma. Presented: Annual Meeting of the American Academy of Dermatology, Chicago, IL, Dec 1979.

Graff, G.E.: Current Concepts of Dermatitis Herpetiformis. Presented: 85th Annual Convent on and Seminar, American Osteopathic Association, Las Vegas, Nevada, Nov 1980.

Graff, G.E.: Perforating Granuloma Annulare. Presented: Annual Meeting of the American Academy of Dermatology, Chicago, IL, Dec 1979.

Grimwood, R.E.: Herpes Gestationis. Presented: Annual Meeting of the American Academy of Dermatology, Chicago, IL, Dec 1979.

⁽C) Direct result of approved registered protocol

Dermatology Service - continued

May, D.L.: Common Problems in Dermatology. Presented: Regional H.E.W. Meeting, Boulder, CO, Mar 1980.

May, D.L.: Interpreting Special Stains and Artifacts. Presented: Practical Skin Pathology Course, Colorado Springs, CO, Oct 1980.

McCoy, J.A.: Localized Mycosis Fungoides. Presented: Annual Meeting of the American Academy of Dermatology, Chicago, IL, Dec 1979.

Patterson, J.W.: Bowenoid Papulosis. Presented: AFIP Annual Lectures, Washington, DC, May 1980.

Patterson, J.W.: Bowenoid Papulosis. Presented: American Society of Dermatopathology/International Academy of Pathology, New Orleans, LA, Feb 1980.

Thompson, P.B.: Desmoplastic Trichcapithelioma. Presented: Annual Meeting of the American Academy of Dermatology, Chicago, IL, Dec 1979.

Endocrine Service

Hofeldt, F.D.: Blood Glucose Control: Is It Worth It? Presented: Recent Advances in Diabetes Management Symposium, Denver, CO, 15 Oct 1980.

Hofeldt, F.D.: Osteoporosis Update 1980. Presented: Annual Meeting Colorado Academy of Family Physicians, Vail, CO, 1-3 Aug 1980.

Hofeldt, F.D.: The Estrogen Controversy. Presented: Annual Meeting of Colorado Society of Osteopathic Medicine. Broadmoor Hotel, Colorado Springs, CO, 17 May 1980.

Hofeldt, F.D.: The Lipid Controversy. Presented: Regional Conference in Internal Medicine, FAMC, Aurora, CO, 6-8 February 1980.

Jones, R.E.: Salicylic Acid Stimulation of Palmitic Acid Oxidation by Rat Skeletal Muscle Mitochondria. Presented: Hugh Mahon Lectureship Award, FAMC, Aurora, CO, 14 Jun 1980. (C)

Kidd, G.S.: Unusual Manifestations of Hyperthyroidism. Presented: USA Regional Short Course, FAMC, Aurora, CO, Jan 1980.

Hematology/Oncology Service

DiBella, Nicholas, J.: Advances in Chemotherapy. Presented: American Cancer Society Seminar for Nurses and Allied Personnel, Denver, CO, 23 Feb 80.

⁽C) Direct result of approved registered protocol

Endocrine Service - continued

DiBella, N.J.: Cancer Research Protocols - How and Why. 12th Annual Radiation Therapy Symposium for Technologists, 14-15 Mar 1980.

DiBella, N.J.: Myeloproliferative Disorders and Leukemias. Presented: Postgraduate Conference in Clinical Laboratory Practice, Colorado Association Continuing Medical Laboratory Education, Boulder, CO, 30 June - 3 July 1980. (C)

DiBella, N.J.: Pain Control in the Cancer Patient, Psychosocial Support of the Cancer Patient. Presented: Interim Session, Colorado Medical Society, Denver, CO, 29 Feb - 2 Mar 1980.

Pulmonary Function Lab

Kindig, N.B., Perry, M.E., Browning, R.J.: DLCO_{SS} Correction Using PaCO Back Pressure Predicted from Venous Blood. Presented: AAMI, 15th Annual Meeting, San Francisco, CA, April 13-17, 1980. (C)

Kindig, N.B., Perry, M.E., Filley, G.F.: Gas-Mixing Deadspace: Measurement with Tracer Gases. Presented: Symposium on Gas Exchange Function of Normal and Diseased Lungs. Max Planck Institute for Experimental Medicine, Goettingen, Germany, July 9-11, 1980. (C)

Perry, M.E., Zimmerer, R.W., Browning, R.J.: Non-Invasive Alveolar Pressure/Flow Pattern Determination by Computerized Plethysmography. Presented: Annual Computers in Critical Care and Pulmonary Medicine, Lund, Sweden, June 3-6, 1980. (C)

Zimmerer, R.W., Perry, M.E., Browning, R.J.: Expiratory Pressure/Flow Assessment by Plethysmography. Presented: AAMI, 15th Annual Meeting, San Francisco, CA, April 13-17, 1980. (C)

DEPARTMENT OF CLINICAL INVESTIGATION

Damato, J.J.: Biochemical Methods for Differentiating Mycobacteria. Presented: Colorado State University, Ft. Collins, CO, May 1980. (C)

Damato, J.J., Rothlauf, M.V., McClatchy, J.K.: Differentiation of Tubercle Bacilli and Nontuberculous Mycobacteria by a Radiometric Method. Presented: Annual Meeting of the American Society for Microbiology, Miami Beach, FL, May 1980. (C)

Damato, J.J., Rothlauf, M.V., McClatchy, J.K.: Differentiation of Tubercle Bacilli and Nontuberculous Mycobacteria by a Radiometric Method. Presented: National Jewish Hospital and Research Center, Denver, CO, June 1980. (C)

⁽C) Direct result of approved registered protocol

Department of Clinical Investigation - continued

Glab, W.N., Corby, D.G., Decker, W.J., Coldiron, V.R.: Prevention of Propoxyphene Adsorption by Activated Charcoal in Rats: Clinical and Pharmacological Correlations. Presented: AACT/AAPCC/CACAT Meeting "Clinical Toxicology '80", Minneapolis, MN, 6 Aug 1930. (C)

Harbell, J.W.: Insulin Action on Normal and Transformed GR/A Mouse Mammary Tissues. Presented: 31st Annual Meeting, Tissue Culture Association, St. Louis, MO, 4 June 1980. (C)

Zolock, D.T., Askew, E.W.: Carbohydrate Metabolism of the Red Blood Cell during Exercise in Rats. Presented: American Society of Biological Chemists, New Orleans, LA, June 1980. (C)

DEPARTMENT OF NURSING

Ellis, C.J.: Ethical Decisions of Neonatal Intensive Care. Presented: Academy of Health Sciences, Ft. Sam Houston, TX, August 1980. (C)

Turner, B.S.: Development of a Regionalized Neonatal Outreach Education Program at a Major Medical Center. Presented: Academy of Health Sciences, Ft. Sam Houston, TX, August 1980.

Turner, B.S.: Nursing Implications in Utilization of T_{tc} 0₂ Monitoring in the Critically III Neonate. Presented: Colorado Nurses Association, Denver, CO, April 1980.

DEPARTMENT OF OB-GYN

Bobitt, J.R., Brown, G.L., Full, A.H.: Group & Streptococcal Neonatal Infection: Clinical Review of Plans for Prevention and Preliminary Report of Quantitative Antepartum Cultures. Presented: OB-GYN Infectious Disease Symposium, Boca Raton, FL, Dec 1979. (C)

Bobitt, J.R., Damato, J.J., Hayslip, C.C.: Amniotic Fluid Infection in Premature Labor Patients with Intact Membranes: As Determined by Transabdominal Amniocentesis. Presented: 29th Annual Armed Forces Seminar & 19th Annual Armed Forces District Heeting of Obstetricians and Gynecologists, Orlando, FL, Oct 1980. (C)

DEPARTMENT OF PEDIATRICS

Brouchard, B.H., Berger, M., Cunningham, R.J., Petruskick, T.W., Allen, W.R., Travis, L.B.: Peritoneal Dialysis in Children. Presented: ASAIO, New York, 1979.

Cadol, R.: An Overview of Developmental Problems in Germany. Presented: Uniformed Services Pediatric Seminar, Seattle, WA, March 1980.

⁽C) Direct result of approved registered protocol

Gumbiner, C., Gutgesell, H.P.: Effect of Isometric Exercise of Left Ventricular Function in Children with Left Ventricular Volume Overload. Presented: American Academy of Pediatrics Annual Meeting, Cardiology Section, San Francisco, CA, Oct 1979.

Gumbiner, C., Mullin, C., McNamara, D.: Pulmonary Artery Sling. Presented: American Academy of Pediatrics Annual Meeting, Cardiology Section, San Francisco, CA, Oct 1979.

Gumbiner, C., et al: The Electrophysiologic Effects of Chronic Digoxin Administration in the Healthy Awake Puppy. Presented: Society of Pediatric Research, San Antonio, TX, May 1980.

Kilbride, H.W.: Controlled Trial on the Use of Transcutaneous Oxygen Monitoring in Infants with RDS. Presented: Aspen Conference on Perinatal Research, Aspen, Colorado, July 1980.

Kilbride, H.W.: Trancutaneous Oxygen Monitoring. Presented: Aspen Conference on Perineral Research, Aspen, CO, July 1980. (C)

Madden, W.A., Parry, W.H.: Use of the Fiberoptic Bronchoscopy in the Neonatal Intesive Care Unit. Presented: District VIII, AAP, Perinatal Meeting, Park Cit,, Utah, Apr 1980. (C)

Merenstein, G.B.: Neonatal Update. Presented: Symposium of Children's Orthopedics, Aurora, CO, 9-11 Jan 1980.

Merenstein, G.B.: Transport and Intraventricular Hemorrhage. Presented: 3rd Annual Conference on Neonatal Transport, Children's Hospital, Denver, CO, 9-11 Apr 1980.

Merenstein, G.B.: Neonal Transport: Where We Have Been. Presented: 3rd Annual Conference on Neonatal Transport, Children's Hospital, Denver, Co, 9-11 Apr 1980.

Merenstein, G.B.: Mechatal/Maternal Transport: Where Are We Going?

Presented: 3rd Annual Conference on Neonatal Transport, Children's Hospital,
Denver, CO, 9:11 Apr. 1980.

Merenstein, G.B.: Spacetim of Group B Streptococcal Disease. Presented: Aspen Conference on Perinatal Research, Aspen, CO, July 1980. (C)

Merenstein, G.B.: Prevention of Group B Streptococcal Disease. Presented: American Academy of Padiatrics Section on Perinatal Padiatrics in Park City, Utah, 15-17 May 1980. (C)

Parry, W.H., Madden, W.A.: Bronchoscopy in the Neonatal Intensive Care Unit. Presented: 2nd World Congress of Bronchology Dusseldorf, West Germany, June 1980.

⁽C) Direct result of approved registered protocol

- Parry, W.H., Madden, W.A.: Bronchoscope Findings in Bacterial Laryngo-tracheobronchitis. Presented: 2nd World Congress of Bronchology, Dusseldorf, West Germany, June 1980.
- Pierce, J.R.: Streptococcal Sudden Unexpected Death Syndrome. Presented: American Academy of Pediatrics Section on Perinatal Pediatrics in Park City, Utah, 15-17 May 1980. (C)
- Sanders, J.: The Office Approach to the Adolescent Patient. Presented: (Visiting Professor) William Beaumont Army Medical Center, El Paso, TX, Jan 1980.
- Sanders, J.: Sexually Transmitted Diseases. Presented (Visiting Professor) William Beaumont Army Medical Center, El Paso, TX, Jan 1980.
- Sanders, J.: Office Approach to the Adolescent Patient. Presented: American Academy of Pediatrics CME Course, Scottsdale, Arizona, Jan 1980.
- Sanders, J.: Contraception and the Adolescent. Presented: AAP CME Course, Scottsdale, Arizona, Jan 1980.
- Sanders, J.: Sexually Transmitted Disease. Presented: AAP CME Course, Scottsdale, Anizona, Jan 1980.
- Sanders, J.: Sexually Funsmitted Diseases. Presented: 89th Annual Meeting, Arizona Medical Association, Phoenix, April 1980.
- Sanders, J.: Feenage Sexuality. Presented: 89th Annual Meeting, Arizona Medical Association, Phoenix, Arizona, April 1980.
- Sanders, J.: Common Gynacofogical Problems of Adolescent Girls. Presented: 29th Annual Assembly, Kentucky Chapter AAFB, Louisville, KY, May 1980.
- Sanders, J.: Psychosopial Growth Tasks of Adolescence. Presented: 29th Annual Assembly, Kentucky Chapter AAFB, Louisville, KY, May 1980.
- Sanders, J.: Talking to Teenagers about Sexuality. Presented: Spring Meeting Colorado Chapter AAP, Colorado Springs, CO, May 1980.
- Sanders, J.: Sexually Transmitted Diseases. Presented: Region VIII Conference, National Health Service Corps, Boulder, CO, March 1980.
- Wells, D., Sanders, J.: Adolescent Gynecology. Presented: 4th Annual Air Force Nurse Practitioner Workshop, Colorado Springs, CO, Jan 1980.

⁽C) Direct result of approved registered protocol

Wells, D., Sanders, J.: Teenage Pregnancy. Presented: 4th Annual Air Force Nurse Practitioner Workshop, Colorado Springs, CO, Jan 1980.

Yeatman, G.: Subtle Presentation of Chromosomal Disorders in Older Children and Adolescents. Presented: Section on Military Pediatrics, American Academy of Pediatrics, San Francisco, CA, Oct 1979.

DEPARTMENT OF PSYCHIATRY

Golosow, N.: DSM III. Presented: AMEDD Military Psychiatry Course, William Beaumont Army Medical Center, El Paso, TX, April 1980.

DEPARTMENT OF RADIOLOGY

Fisk, J.D.: Gastrointestinal Radiographic Features of Human Graft-Versus Host Disease. President's Award Paper 1980. Presented: American Roetgen Ray Society Annual Meeting, Las Vegas, NV, April 1980.

Fisk, J.D.: Gastroi registed Radiographic Features of Human Graft-Versus Host Disease. President read Paper 1980. Fresented: The Rocky Mountain Radiological Society, Denver, CO, Aug 1980.

McNeill, Daha, etc. Cragnosis of Carotid Artery Dissection/? Therapy. Presented: The Rocky Mountain Radiological Society's 42nd Midsummer Radiological Conference (Active), 60, Aug 1980.

Ordert, J.: CPA CT Gamuts Presented: Radiological Society of North America, Atlanta, 67, Nov. 1979.

Russell, J.R.: "Box" featurique for Irradiation of Esophageal Cancer and Secast Cancer: Comparium of Two Fractionation Schemes for Postoperative Radiation Therapy. Prosected: Ninth Annual Radiation Therapy Clinical Research Seminar, Gainer (Ille, Et., 26-28 April 1979.

Russell, J.R.: Saleran, Hand Tomors. Presented: Tenth Annual Radiation Thorapy Clinical Research Schinar, Gainesville, FL, 24-26 April 1980.

SHE DAL WORK SERVICE

Robichand, W.J., 1997 - Frank of the Fitzsimons Army Medical Center Discharge Planking Frank - 12 Sented: Biennial US Army Social Work Symposium, Ft. Som Houston, 18, March 1980.

PERSONALITY OF SURGERY

General Surgery Service

Ferraris, V.A., Sube, E. A. respective Study of the Surgical Management of Reflux Esophagitis — (c. sented: William Beaumont Army Medical Center, El Paso, TX, March, 1904—(c)

(C) Direct result of a continuous tered protocol

Department of Surgery - continued

Cottingham, Jr., A.A.: Residual Astigmatism-Postoperative Keratoplasty. Presented: American Academy of Ophthalmology, Chicago, IL, 7 Nov 1980. (C)

1

Otolaryngology Service

Bender, D.R., Causey, G.D.: The Effects of Several Competing Signals on Aided Hearing Performance. Presented: American Speech and Hearing Association Convention, Atlanta, GA, November 1979.

Hasbrouck, N.J.: Speech Production and Perception in Relation to Understanding, Evaluating and Treating Auditory Perceptual Disorders. Presented: University of Montana, Missoula, Montana, April 1980.

Hasbrouck, J.M.: Speech Production and Perception in Relation to Understanding, Evaluating and Treating Auditory Perceptual Disroders. Presented: Montana Speech and Hearing Association, Butte, Montana, April 1980.

Hasbrouck, J.M.: Speech Production and Perception as related to Assessment and Remediation of Auditory Perceptual Disroders. Presented: 18th Congress of the International Association of Logopedics and Phoniatrics, Washington, DC, August 1980.

Jarchow, R.C.: ENT Emergencies. Presented: National Public Health Service Symposium, Boulder, CO, March 1980.

Plastic Surgery Service

Gottlieb, V.: Metastatic Squamous Cell Carcinoma Presenting as a Felon. Presented: Annual Meeting, Association of Military Plastic Surgeons, Washington, DC, 1980.

Rich, J.D.: Post-traumatic Skull Defects. Presented: Annual Meeting, Association of Military Plastic Surgeons, Washington, DC, Jan 1980.

Shesol, B.: Changing Concepts of Lymphedema. Presented: Annual Meeting, Association of Military Plastic Surgeons, Washington, DC, Jan 1980.

Urology Service

Fauver, H.W.: Adverse Reactions to Drugs Used by Urologists. Presented: Postgraduate Seminar, American College of Surgeons, Chicago, IL, Oct 1979.

Fauver, H.W.: Prostatic Carcinoma: A Prospective Distribution and the Influence of Grade of Tumor or Results of Lymphadenectomy. Presented: Kimbrough Urological Seminar, Rosslyn, VA, Nov 1979.

Vaccaro, J.A.: Transrectal Prostate Biopsies-Adverse Effects of Cystoscopy. Presented: Kimbrough Urological Seminar, Rosslyn, VA, Nov 1979.

⁽C) Direct result of approved registered protocol

UNIT SUMMARY SHEET

UNIT SUMMARY SHEET

Clinical Investigation Program, FAMC

Clinical Investigation efforts by FAMC personnel in FY 80 culminated in the publication of 124 articles and 107 presentations and lectures at national, international, and regional scientific meetings. As of 30 September 1980, there were 138 research protocols on the DCI regisater. Of these, 91 projects were ongoing and 48 were new registrations.

Objectives:

To encourage the performance of clinically-oriented research by personnel assigned to the Fitzsimons Army Medical Center (FAMC). To aid in the planning, development, support, and execution of experimental clinical studies, both in patients and by directly related laboratory work, into the clinical problems of significant concerning the health care of members of the military community. To provide physician experience in research and investigative procedures by furnishing a highly educated and trained staff of specialists, laboratory facilities, administrative services and funding for: supplies, equipment, consultants, publications and reprints. To achieve continuous improvement in the quality of patient care by providing an atmosphere of inquiry, maintaining high professional standing and accreditation of advanced health programs.

The Clinical Investigation Program differs from Medical Research and Development in that the emphasis is on the health care problems existing in our patient populations, i.e.; active duty, retired, and dependents and not solely on medical problems affecting combat readinness and the fighting strength. It is, by its nature, an integral part of the triad of patient care and medicine. It promotes and supports the finest ideals and traditions of Arritary Medicine and enhances the vitality of the teaching programs which in turn elevates the standard of medical care. The research program operates on the premise that all approved protocols will be supported to the fullest extent allowed by current funding. This concept allows for a larger number of physicians and ancillary personnel to participate in research rather than as in the grant system used elsewhere. This means that virtually every investigator is given a chance to pursue his research without having to compete for funds with "established" names in the field.

Technical Approach

This support, direction and management is carried out under the aegis of AR 40-38, as amended, Clincial investigation Program; AR 40-7, Use of Investigational Drugs in Humans; AR 70-25, Use of Volunteers as Subjects in Research; AR 70-18, Laboratory Animals, Procurement, Transportation, Use, Care, and Public Affairs; HSC Reg 40-23, Management of

Clinical Investigation Protocols and Reports, as amended. This Department provides guidance, assistance, and coordinates the FAMC program with higher headquarters and other facilities.

Manpower: Current authorized strength is outlined.

Description	<u>Grade</u>	MOS	<u>Br</u>	Auth	Actual	Name
C, Dept of Clin Invest	06	60P9B	MC	1	1	Corby
C, Immuno Service	03	68A00	MS	1	1	Whiteaker
Internist	05	61F9C	MC	0	1	Charles
Lab Admin	04	68F00	MS	1	1	Quigg
C, Surg Rsch Labs Svc	03	(8J00	MS	1	l	Harbell
C, Micro Svc	05	68A00	MS	1	1	Engelkirk
Veterinarian	03	64F00	УC	i	Ţ	Stockberger
C, Biochem Svc	03	68000	MS	1	1	Zołock
NCOIC	£7	92B4R		1	i	Underhill
Sr, Med Lab NCO	£7	9284R		1	1	Engle
Sr. O.R. SP	£6	91 D3R		1	i	Smith, N.
Bio Sci Asst	E6	01H2O		0	1	Glab
Bio Sci Asst	E5	01H2O		i	ì	Kramer
Bio Sci Asst	E5	01H2O		1	1	Kessens
Bio Sci Asst	E6	01H2O		Ī	1	Chadwick
Bio Sci Asst	E5	01H2 0		1	1	Harrington
Bio Sci Asst	E5	01H 2O		0	1	Jone s
Bio Sci Asst	E4	01H2O		0	1	Nicholson
Vet SP	£6	91T3R		ì	ì	Rich
Supervisory Res Chem	13	1320 GS		1	1	0'Barr

Description	Grade	MOS	<u>.</u> .	Br	<u> Auth</u>	Actual	Name		
Microbiologist	11	0403	GS		2	2	Lima Paine		
Microbiologist	09	0403	GS		4	4	Morse Nelson Rangel Rothlauf		
Med Technologist	09	0644	GS		1	1	Rush		
Research Chemist	09	1320	GS		4	4	McNamara Noble Swanson Waldrup		
Microbiologist	07	0403	GS		3	2	Feuerstein Ledoux		
Bìo Lab Tech	07	0404	GS		1	1	Hakes		
Animal Bio Lab Tech	08	0404	GS		t	1	Jones		
Animal Tech	0]	0404	GS		1	1	Mercill		
Ed Asst	06	0318	GS		ı	i	McCrill		
Animal Caretaker	05	7706	WG		2	2	Beltran Hitchcock		
Clerk-steno	04	0318	GS		l	1	Moran		
	FY 78		FY 79		FY 79		79	FY 8	0
Civilian Pay	363,962	381,352		352	434,9	11			
Travel	3,660)	5,584		5,2	40			
Supplies	161,431	l	179,883		883	189,9	98		
Equipment	28,500)	108,165		108,165 104,		104,3	11	
Contracts	16,429	9		16,	397	18,5	98		
Other(Military)	293,43	2	3	49,	116	345,8	59		

Progress

DCI received from Health Services Command (HSC) a microbiology training position. This program brings in a qualified aspirant at the GSO5 entrance level and, upon successful completion of a rigorous training programs, allows for non-competitive promotion to GSO7 and finally the GSO9 Microbiologist journeyman level.

Historically, Fitzsimons Army Medical Center has provided leadership in the identification and treatment of tuberculosis in the military community. Indepth mycobacterial studies on patients, i.e., serum drug levels, serum inhibition tests, identification of mycobacteria other than M. tuberculosis, and drug susceptibility testing, are provided. In accordance with the Commanders' directive, DCI provides mycobacteriology (TB) support (processing clinical specimens and/or reference cultures) to the following centers:

MEDDAC Units: Ft. Carson, Ft. Leavenworth, Ft. McPherson. Ft. Ord, Ft. Riley, Ft. Sill

Army Medical Conters: Letterman, Madigan, Tripler

USAF Facilities: Baker's Field, Minot AFB, Scott AFB

Additionally, TB reference laboratory support is furnished to the PHS, Pine Ridge Reservation, S.D.

The Mycobacteriology Laboratory Section, Microbiology Service, DCI, has maintained College of American Pathologists (CAP) accreditation.

The Surgical Research Laboratories (SRL) Service supports research and training protocols and provides all of the laboratory animal care for Fitzsimons Army Medical Center. The research animal support includes a daily small animal population of approximately 800 animals, comprised of mice, rats, guinea pigs, chicks, rabbits, non-human primates, cats and dogs. It is projected that sheep, goats and swine will soon be added. The scope of support includes veterinary clinical laboratory services, radiology, histopathology, tissue culture, electron microscopy, medical photography, veterinary pharmacotherapeutics, and a full surgical support capability, including cardio-pulmonary bypass and microsurgery, as well as the pre- and post-operative care of lab animal research subjects. The urgent minor construction request for an Animal Housing Facility has been fully approved through Congress and construction is scheduled to bogin in FY 81, pending funding. A complete listing of training provided by SRL is located on DCI detail sheet, "Training Support, SRL, DCI", immediately following the DCI Annual Progress Reports.

Funding

The OMA costs have not been itemized by protocol number because it is not feasible or practical to do so.

MEDCASE items which were purchased for specific protocols are so annotated. The remaining items were purchased for general laboratory use.

<u>ITEM</u>	PROCOTOL #	COST
Zoom Stereoscope	79/118	\$6149.00
Ion Generator	78/116	\$5000.00
Poultry Cages	79/ 301	\$2929.00
Microtome/Cryostat	79/3 04	\$5494.72
Tissue Embedder	79/300	\$1948.18
Forma CO ₂ Incubator	77/300 and	\$2250.00
2	80/400	
Ultrasonic Cleaner		\$1260.00
Infusion Pump		\$1277.75
Orion PH Meter		\$1728.13
Mettler Balance		\$2710.47
Binocular Microscope		\$20 5 8.70
Beckman TJ-6R		\$2834.00
Chromatography Chamber		\$2894.00
Rabbit Cages (2)ea.		\$3200.00
Guinea Pig Cage		\$2337.31
Freeze Dryer		\$5156.10
Fraction Collector		\$1949.00
Forma Lo-Temp Freezer		\$5268.00
Puffer Hubbard 50LR Refrigerator		\$2443.00
Beckman L-8 Ultra Centrifuge		\$28,634.04

EXPLANATION of ANNUAL PROGRESS REPORT DETAIL SHEETS

- (1) DATE: Fiscal Year ending date.
- (2) PROTOCOL NO: FAMC Work Unit Number of the study.
- (3) STATUS: Indicates if the study is Ongoing, Completed or Terminated.
- (4) TITLE: Project title of the study.
- (5) START DATE: The date the study started.
- (6) ESTIMATED COMPLETION DATE: The projected completion date of the study.
- (7) PRINCIPAL INVESTIGATOR(s): List of all Principal Investigator(s) involved in the study.
- (8) FACILITY: Fitzsimons Army Medical Center
- (9) DEPARTMENT/SECTION: Department or Service the protocol originated from.
- (10) ASSOCIATE INVEST. GATOR (9): List of all Associate Investigator (s) involved in the study.
- (11) KEY WORDS: Key words pertaining to the particular area of research involved in the study.
- (12) ACCUMULATIVE MEDCASE COST: See Unit Summary Sheet Funding.
- (13) ESTIMATED ACCUMULATIVE OMA COST: See Unit Summary Sheet Funding
- (14) PERIODIC REVIEW RESULTS: Date of the continuing review by the Institution Review Committee.
- (15)STUDY OBJECTIVE: A summary of objectives to be accomplished during the study.
- (16) TECHNICAL APPROACH: A brief summary of the technical approach to be taken during the study.
- (17) PROGRESS: A summary of prior and current progress since inception of of the study.

The Continuation Sheets are used as extensions for (1) - (17) and as an accumulative listing for Publications and Presentations that are a direct result from the study.

The Detail Sheets were submitted in final form by the Principal Investigators and have not been edited.

TABLE OF CONTENTS

TABLE OF CONTENTS

REPORT NO. 16

	MEDICINE	Page
73/135	Active Antigens in House Dust (0) (P) (PR)	026
74/101	Immuno-chemical Evaluation of Myeloproliferative and	
	Plasmaproliferative Diseases (0) (P) (PR)	029
74/110	Reactive Hypoglycemia: An Analysis of Glucose-Insulin-	
	Glucagon Interrelationships and Counter Hormonal	022
7: /107	Regulatory Factors (0) (P) (PR)	032
75/107	Aqueous Grass Extract and Aluminum Precipitated Aqueous	
	Extracted Grass Extract in the Treatment of Patients with	
	Allergic Symptoms Due to Grass Allergy (0) (P) (PR)	036
75/116	Fractionation of Kochia (Kochia scoparia) Pollen with	٥٫٥
, ,,	Isolation of Kochia Pollen Extract Antigens (0)	040
75/118	A Study of the Stability of Allergy Extracts under	
	Varying Conditions (C) (P) (PR)	041
76/102	Anti-neoplastic Therapy with Methyl CCNU (NSC95441)/1-	
	(2-Chloroethyl)-3-(4-Methyl Cyclohexyl)-1-Nitrosourea(0).	044
76/103	An Objective Measure of CNS Development in Children (T) .	045
76/105	Evaluation of Testicular Function in Patients Receiving	
	Cytotoxic Therapy (T)	046
76/112	Study of the Effect of Tetracycline and Pleural Drainage	- 1 0
7(4)	on Pleural Effusion in Cancer Patients (C)	048
76/116	The Effect of Dexamethasone on Gonadotropins in Post-	01.0
77/102	Menopausal Women (0)(P) (PR)	049
77/103	Pre-seasonal and Co-seasonal vs. Post-seasonal Initia-	
	tion of Allergy Immunotherapy (0)	053
77/104	Evaluation of Immunoglobulins and Immunoglobulin Bearing	ررں
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Lymphocytes in Asthma (C)	054
77/105	An Evaluation of the Cross Allergenicity among Pollen	٠,٠
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Extracts of Members of Chenopodiaceae and Amaranthaceae	
	(C) (P) (PR)	055
77/106	The Effect of Chronic Non-immunologically Mediated Bron-	
	chial Smooth Muscle (0)	058
77/107	L-Dopa Stimulation of Glucagon in Obesity (T)	059
77/108	A Comparison of the Clinical and Immunologic Response to	
	Grass Pollen Extract with or without the Addition of	٠.,
77/110	Glycerin (C)	061
77/110	Effect of Chronic Oral Propranolol on Glucose Tolerance	062
	(T)	002

Ongoing (0), Completed (C), or Terminated (T), Published (P) or Submitted for Publication (SF), Presentations (PR).

	*	Page
77/113	A Study of Terbutaline Aerosol in the Treatment of Partients with Bronchial Asthma (C) (P) (PR)	064
77/114	Effect of Propranolol in Patients with Reactive Hypo-	- (0
78/102	glycemia (0)	068
78/104	Isoproterenol and Aminophylline (0)(SP)(PR) Study of Coagulation Parameters in Patients with Suspected Deep Vein Thrombophlebitis before and after Veno-	070
78/106	graphy (T)	073
78/107	Allergen Injections During the Pollen Season (C) An Evaluation of the Efficacy of Animal Dander Allergy	074
	Immunotherapy in Perennial Rhinitis (0)	076
78/108	An Investigation into the Generation of Antigen Specific Suppressor Ceils During Allergy Immunotherapy (T)	077
78/109	Are Chirrhotic Patients at Increased Risk for Bacteremia	
78/113	Following Upper Gastrointestinal Endoscopy? (T) Effects of Salicylic Acid on Fatty Acid Oxidation in Rat	078
	Skeletal Muscle Micochendria. (0) (P) (PR)	080
78/114	Treatment of Systemic Scleroderma with Minoxidil (U-1858) (0)	084
78/116	The Effect of Positive and Negative Air Ions on Pulmonary	085
78/117	Functions in Patients with Bronchial Asthma. (0) The Effect of Parasitic Infestation on Immediate Skin	
78/118	Test Reactions. (0)	086
70/110	Multiple Inert Gas Analysis, Comparison with Fowler's Technique and Application to Steady-State Diffusion	
	Estimates. (0) (P) (PR)	087
78/119	The Effect of Aspirin on Platelet Aggregation in Aspirin Sensitive Asthmatics. (0)	089
78/120	Diabetic Treatment Study: Assessment of Metabolic Control and Change in Quality of Life Following Short-term	
78/121	Treatment of Diabetic Patients with Tolazamide.(T) The Determination of Possible Cross Activity between	090
737121	Western Grass Polices and the More Common Northern Grass	091
78/122	Effects of biotar, incrose in Diabetes Mellitus. (0)	094
78/123	A Comparison of the limmerer and Dubcis Techniques of	
	Airway Resistance Reserrements by Body Plethysmography. (0) (P) (PR)	096
78/124	A Self-consistent Method of Single Breath DLCO Measurement. (0)(P)(PR)	100
/8/125	Adjuvant The rapy of Promenopausal Patients with EBP (+) Breast Cancer with UMF Alone Versus CMF plus Tamoxifen and EBF (-) Breast Cancer with CMF Alone Versus Adria-	100
	mydin and Vinchistrae Followed by CMF. (T)	102

Ongoing (0), Completed started for Published (P) or Submitted for Publication (SP), which is strious (PR).

		Page
78/126	The Systematic Evaluation of Urticaria. 1. Response to Therapy. 11. Evaluation with Skin Biopsy. (T)	104
78/127	Does Neoplastic Disease Produce a Positive Secretin Test? (T)	105
78/128	Assessment of Postprandial Plasma Glucose, Insulin and Glucagon Response to Different Orally Administered Complex Carbohydrates in Diabetic Subjects (UCMC, Endo-	-
78/129	crine, Cooperative Study). (C)	107
	(C)(P)	108
79/100	Investigation of the Tumor Reduction Effect of Combined Sodium-L-Ascorbate and 5-FU Chemotherapy in Transplanted B16 Melanoma of Mice. (C)	111
79/101	The Relationship of Granuloma Annulare (GA) to Diabetes	111
79/102	Mellitis (DM). (0)	113
/ 3/ 102	ative Study Fetween Fitzsimons and Endocrine Division,	
79/103	University of Colorado Medical Center). (C) An Evaluation of Combined H, and H, Receptor-blocking	114
/9/103	Agents in the Treatment of Seasonal Allergic Rhinitis(0)	
70/101	(P) (PR)	116 119
79/104 79/105	vindesine in the Treatment of Cancer (0)	117
201104	ment.(0)(F)(PR)	120
79/106	Measurement of Lung Compliance Utilizing Pulmonary Cap- illary Wedge Pressures. (0)	123
79/107	The Effects of Fructose on Reactive Hypoglycemia. (0)	125
79/108	The Effect of Beta Adrenergic Bronchodilators on Serum Immunoglobulin-G Levels. (0)	127
79/109	Control of Nausea and Vomiting with Delta-9-tetrahydro-	
	cannabinol (THC) Corrined with Standard Antimetics (A Phase II Study). (0)	128
79/110	Evaluation of Local Acesthetic Skin Testing and Pro-	
	gressive Challenge in Patients with a History of an Adverse Reaction to Godal Anesthetic. (0)	129
79/111	A Comparison of the Development of Sensitivity to Peni-	130
79/112	cillin in Normal and Atopic Individuals. (0) Use of Sodium Salt of Allopurinol to Control Hyperuri-	130
	cemia in Patrents with No Therapeutic Alternative. (0) .	132
79/113	Vindcesine in the Treatment of Metastatic Adenocarcinomas (T)	133
79/114	Vindcesine and Cisciplatinum in the Treatment of Unresectable Carcinoma of the Lung (0)	134
79/115	The Effect of Split-Course, Continuous Infusions of 5-	-
	Fluorouracil on Metastatic Colo-Rectal Cancer. (T) Adiamycin, Cyclophosphamide, and Cis-Platinum in the	135
79/116	Treatment of Diffuse Pleural and Peritoneal Mesothelioma Phase II: Combination Chemotherapy Program. (T)	136

Ongoing (0), Completed (C), a Terminated (T), Published (P) or Submitted for Publication (NP), Presentations (PR).

		Page
79/11 7	5-Fluorouracil, Cytoxan, and Aldactone in Advanced (Stage D) Carcinoma of the Prostate. (T)	137
7 9/118	Treatment of Severe Erythema Multiforme with Systemic	
79/11 9 80/10 0	Steroids. (0)	138 13%
	striction in Dogs with Esophagitis. The Effects after Therapeutic Healing of the Esophageal Lesions. (0)	140
80/101	The Evaluation of Stool Hemoccult Positivity in Patients on Coumadin-type Anticoagulants. (T)	141
80/102	Study of Coagulation Parameters Prior To and Following	
80/103	Intravenous Injection of Radiographic Contrast Media.(0) Etoposide (VP-16-213) Single Agent Chemotherapy in Small Cell Lung Cancer Patients Refractory to First-line	143
80/104	Chemotherapy. (0)	144
_	plus Vincristine of Small Cell Lung Cancer. (0)	145
80/105	Dibromodulcitol An Stage IV Metastatic Malignant Melanoma. (0)	146
80/107	Cross Allergenitity among Grasses Determined by Tissue	
80/108	Threshold Changes (0)	147
	SURGERY	1 10
	SONGEN	
71/202	Evaluation of Peripheral Nerve Injuries at Fitzsimons General Hospital (0)	149
73/219	Treatment of Urinary Tract Trauma in the Laboratory Animal (0)(P)(PR)	150
76/203	Screening Program for Military Children at High Risk for Hearing Loss (0) (FR)	153
77/204	The Anatomical and Physiological Development of the Flexor Tendon Sheaths in the Human Fetus (0)	155
78/200	Anastomosis of the Dog Vas Deferens Using Microsurgical Technique (0).	156
78/201	Clinical Study for Intraocular Lenses (0)(SP)(PR)	158
78 /2 02	Evaluation of the Mittablue Tetrazolium Test (NBT) in Pyogenic Arthritis trang Synovial Fluid. (0)	162
78/203	The Effects of Hotorotopic Lymph Node Transplantation on	
79/200	Surgically-induced Lymphedema. (T)(P)(PR)	163
	going Cardiopulmonary Bypass. (T)	165 167
79/201	reace reterior in bisease states. (b) (rk)	10,

Ongoing (0), Completed (i) or Terminated (T), Published (P) or Submitted for Publication (SP), i.e. terions (PR).

		Page
	DEPARTMENT OF SEINICAL INVESTIGATION	
72/302	Comparison of Metabolic and Functional Changes in Defects of Platelet Function (0)(P)(SP)(PR)	172
73/305	Computer storage and Analyses of Mycobacteriologic Laboratory Data from scherculous Patients (T)(PR)	177
74/300	Microbiological Research in Tuberculosis (T)(P)(SP)(PR) .	179
76/301	Pancreatic Islat Transplantation in Diabetic Animals (0)(P)(PR)	182
77/300	Immunologic Disorders in Children and Adults: I. Correlation of immune Functions in the Immunodeficiency State II. Correlation of immuno. Functions of Leukemia and	
75/301	Other Childhous Malignurgies (0) (PR)	184
	Species (c (Ph)	186
78/302	Adsorption of English time by Activated Charcoll. (C)(P) (PR)	188
78/30 3	tvaluation of these strances as Potential Gastro- intestical because marks in the Emergency Management of	
/8/304	Treatment or Francetons & Howing Treatment with Carbonyl	191
	From of Ferrous Salt it in Wistar Rats. (0)	193
79/300	A Study of the hormone tependent Growth of Human Mammary Tumors in vitro. (0)(P)(ER)	195
79/301	Basic Studies to Haste Recovery from or Help Prevent	
79/304	Bone Injury, (0)(P)(PR)	199
79/305	Sections Using Quantity is actoradiography. (C) Field Trial of New Actoring for Isolation, Identifi-	202
	cation and Suscementally Testing of Myccbacteria. (T)	203
79/306	Adequotypophysical stay with interrelationships in De- hydration. (3).	205
79/308	Quantification on the Addirenergic Receptors (Alpha AR) and Placelycs of Addirent Dumonstrating Decreased Response	203
80/300	to (; inephrine (1)	206
80/301	Quantitating (i.e. a.g. lamune-complexes in Cancer Patients. (0)	209 210
Trainin	g Support Summany () real Research Laboratories Service)	214

Ongoing (0), Completed (1) i mainated (1), Published (P) or Submitted for Parlication (PR).

		Page
	<u>OB-GYN</u>	
76/350 78/350 78/351	Evaluation of Ibuprofen (Motrin) in Dysmenorrhea (T) Inhibition of Premature Labor with Terbutaline (T) An Evaluation of the Effect of Suction Drainage on Infectious Morbidity in Patients Undergoing Cesarean	216 217
78/ 35 2	Section (C)	218
78/353	fection in Premature Labor. (0) (SP)	220
7 9/ 35 0	bidity. (0)	222
	genous Hormonal Therapy. (0)(P)	224
	PEDIATRILS	
75 /40:	Effect of Prophysic Antibiotic Therapy on Gravid Group B Bata Hemolytic <u>Streptococcus</u> Carriers (0)(P)(PR)	226
75/402	Early Digitalization in Premature Infants with Idio- pathic Respiratory Distress (IRDS) Who Have Echocardio-	220
77/402	graphic Evidence of Left Atrial Enlargement. (0) Evaluation of Ventricular Function and Pulmonary Vas-	229 231
77/403	Cular Resistance in Asphyxiated Infants. (0) Determination of Pulmonary Vascular Resistance in Newborn Infants at 5,230 Feet Using Right-Sided Systolic	
78/402	Time Intervals. (0)	232 233
78/403	The Influence of Body Positioning on Gastric Residuals in Premature Infants Ocquiring Ventilatory Assistance.	-33
78/404	Assessment of the Relationship of Serum Amino Acid	234
78/407	Levels to Episodes of Apparent Sepsis. (T) Evaluation of New Oriceria in the Diagnosis of Acute	235
78/408	Renal Failure in the Full-term and Premature Newborn.(T) The Tired Adolescent: An Amalysis of Etiology. (C)	236 237
79/400 79/400	Effect of Africage in on Platelet Function. (0)	239
79/401	An Investigation of the Eifects of Aminoglycosides and	240
79/402	Lasix upon the Innarian of the Guinea Pig. (T) An Analysis of the Health Care Needs of Teenagers Living	
79/403	in Single Parent or Reconstituted Families. (T) Evaluation of Transcotaneous Oxygen Monicoring in the	241
79/404	Acute Management of Infants with RDS. (0)(PR) The Effect of Early Meconium Evacuation on Bilirubin	242
	Levels in Breast-100 and Formula-fed Healthy Full-term Infants. (0)	244
79/405	Assessment of Material Fever in the Immediate Prenatal Period as a Prediction of Herinatal Newborn Infections(0)	245

Ongoing (0), pmpleted (1), or Terminated (T), Published (P) or Submitted for Publication (SP), Protects (ons (PR).

		<u>lage</u>
79/406	Intergroup Ewing's Sarcome of Decele and Sucrai	
	Bones. (0)	247
79/407	Intergroup Ewing's Sarcons Privice and Sacrat Sites	249
79/408	Excluded (0)	249 251
79/409	National Wilm's Tumor Study. (9)	253
79/410 80/400	Non-Hodgkin's Lymphoma (0)	255
007400	Milk and Peripheral Blood tymohocytes, (C)	257
80/401	Investigation of Heparin-Induces Plateret Aggregation	
	Secondary to Prostacyclic form allocal in the Babbit Model. (0)	254
	model. (b)	259
	PA COCIONA	
79/450	The Role of Complement A. Tvar on Postkowenests of	
	Juvenile Onse. Nabetes No. 18 lebsencent	
	Effects on the Coagulation and Seripmeral Vas- cular Complications in Deportion Patients. (6)	260
79/45!	Efficacy of Freeze the activation of Placelets for Human	
	Utilization - in vitro and in a ver from a capabil-	
	ities after Freeze Presentation in the dynamics why Istarch (HES). (0)	261
	PS (Williams)	
80/500	Health Expectancy Styles indicate the following and	262
80/501	Their Perceptions of a Police Control of the Contro	262
, 50.	Psychosis. (T)	263
71 // 22		
74/600	Bone Marrow Scintign of Some Services of Falling tion of Soft Tissue Tune Soft Soft Soft Soft Soft Soft Soft Soft	
	ride (0)	264
74/602	The Use of Indium 113 Lt., Francisco Bases	265
79/600	Spinal Fluid Pathways (by Service Service Service Spinal Fluid Pathways (by Service Se	205
7) / 000	Occlusive Vascobar Anna Anna Anna Anna Anna Anna Anna An	266
80/600	Tc99m-PIPIBA for Property of the test of the case, (0).	268
	HOURE LAS	
74/651	Establishment of and Transplant and the feet	
	Studies of Abnormal Memo	269

Organia (0), Completed (1), and the submitted for Publication (SP), Presente a

		Page
78/650	Evaluation of Thalassemia as Cause of Hypochromic Micro- cytic Anemia or in Interaction with Hemoglobin Variants	
	(0)	270
78/651	Evaluation and Structural Identification of Unusual Human	
	Hemoglobin Variants (0)	271
78/652	Alpha Thalassemia: Evaluation of the Significance of	
	Hemoglobin Bart's in the Black Neonate (T)	272
78/653	Gamma Thalassemia in the Newborn (T)	273
80/650	The Ontogenesis of Hemoglobin in the American Opossum	
	(Didelphis virginia).(0)	274

DETAIL SHEETS

MEDICINE

DEPARTMENT OF CLINICAL INVESTIGATION FITZSIMONS ARMY MEDICAL CENTER Aurora, Colorado 80045

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot	No.:	73/1	35	(3	3)	Status:	on-goin	g
(11)	Title:			-						
	Active Antigens	in Hou	se Di	ıst						
(5)	Start Date: 1973				(6) E	s: Comp	Dat	e: 198	1	_
(7)	Principal Investigator				(8) F	acility:	: F	AMC		
	Harold S. Nelson, MD									_
(9)	Dept/Sec:Medicine/All-In	nm .				As soc				
(11)	Key Words:				Lyndo	n E. Mar	isfi	eld, MD	, LTC, M	ıC
	House Dust				Bruce	Martin,	MD	, CPT,	MC, USAF	í
										_
(12)	Accumulative MEDCASE	(13) E	st A	ccumi	ılat v	/e (14)	Per	iodic (continue	
	Cost:	0	MA C	os t:			Rev	iew Res	sults: 6,	<u> </u>
(15)	*Study Objective:									
	To determine to what deg	gree tl	he re	eacti	vity	of comme	rci	al hous	e dust	
	extract is related to it	s con	tent	of 1	ecogn	ized all	erg	ens suc	h as	
	animal dander and mite r	roduct	ts.		_					

- animal dander and mite products.
- (16) *Technical Approach:
 Use of pooled house dust allergic serum and RAST inhibition employing allergen disks manufactured in the allergy research laboratory.
- Additional studies were done during this period expanding the number of known allergens tested against house dust. Further studies will be required during the ensuing year.

FAMC WU No (Prot No)

73/135

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary

Sheet.)

SERVICE Allergy-Immunology

DEPARTMENT Medicine

(1) Mansfield, L.E., Nelson, H.S., Allergens of Commercial House Dust Extracts (Abstract), Journal of Allergy and Clinical Immunology, 63:212; 1979

FAMC WU No (Prot No) 73/135

PRESENTATIONS for FY 80 Annual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE Allergy-Immunology

DEPARTMENT Medicine

- (1) Mansfield, L.E., Allergens of Commercial House Dust Extracts, Annual Meeting Academy of Allergy, New Orleans, Louisiana, 25 March 1979.
- (2) Martin, Bruce, Analysis of the Allergens of Commercial House Dust, Annual Allergy-Immunology Pulmonary Symposium, Fitzsimons Army Medical Center, 21 January 1981.

DEPARTMENT OF CLINICAL INVESTIGATION FITZSIMONS ARMY MEDICAL CENTER Aurora, Colorado 80045

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

30.050.05					
)	101	(3) Status: Ongoing		
		Myelopro	oliferative and Plasma-		
<pre>proliferative Disease</pre>	s.				
Start Date: 1 Jul 74		(6) Est	Comp Date: Oct 81		
Principal Investigator	•	(8) Fac	ility: FAMC		
Nicholas J. DiBella,	COL, MC		•		
Dept/Sec: Medicine/Hem	atology Svc	(10) A	ssoc Investigators:		
Key Words:		George L. Brown, Ph.D., COL, MSC			
Immunodiagnosis		R. Stephen Whiteaker, Ph.D., CPT,			
Myeloproliferative		MSC			
Plasmaproliferative					
Accumulative MEDCASE	(13) Est Accum	ulative	(14) Periodic continue		
Cost:	OMA Cost:		Review Results: 1/80		
*Study Objective:			1/00		
To determine whether	there are any al	teration	ns of serum protein profiles		
in myeloproliferative	and plasmaproli	ferative	e disease.		
To determine whether	there are any al	teration	ns of serum protein profiles		
and lymphocyte transf	ormation in mye	oprolife	erative and plasmaprolifer-		
	Title: Immuno-chemica proliferative Disease Start Date: 1 Jul 74 Principal Investigator Nicholas J. DiBella, Dept/Sec: Medicine/Hem Key Words: Immunodiagnosis Myeloproliferative Plasmaproliferative Accumulative MEDCASE Cost: Study Objective: To determine whether in myeloproliferative To determine whether	Title: Immuno-chemical Evaluation of proliferative Diseases. Start Date: 1 Jul 74 Principal Investigator Nicholas J. DiBella, COL, MC Dept/Sec: Medicine/Hematology Svc Key Words: Immunodiagnosis Myeloproliferative Plasmaproliferative Accumulative MEDCASE (13) Est Accumula	Title: Immuno-chemical Evaluation of Myelopro proliferative Diseases. Start Date: 1 Jul 74 (6) Est Principal Investigator (8) Fac Nicholas J. DiBella, COL, MC Dept/Sec: Medicine/Hematology Svc (10) A Key Words: Immunodiagnosis R. St Myeloproliferative Plasmaproliferative Accumulative MEDCASE (13) Est Accumulative Cost: OMA Cost:		

- (16) *Technical Approach: This is in-depth immunologic evaluation of patients with myeloproliferative and plasmaproliferative disorders.
- Three patients with myeloproliferative and forty-three with plasmaproliferative disorders were studied immunologically. 1. Myeloproliferative Disorders: Results recorded were as follows: No monoclonal
 gammopathies, serum immunoglobulin levels were recorded within normal
 limits, Lymphocyte blast transformation to PHA was suppressed.
 11. Plasmaproliferative Disorders: Results recorded were as follows:
 Fifteen subjects studied had 1gG monoclonal gammopathies with evidence

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 74/101

(17) continued-

of free light chains in the serum. Seven patients were found to have elevated serum IgM levels with monoclonal gammopathies, differentiated as IgM type. One patient each with IgA and IgD monoclonal gammopathy was studied. One case denoting immunoglobulin light chain disorder was recorded.

PUBLICATIONS for FY &O Annual Progress Report

(2nd Part of Detail Summary Sheet.)

SERVICE Hematology-Oncology

DEPARTMENT of Medicine

- (1) Brown, G.L., DiBella, N.J., and Corby, D.G.: IgE-IgM Kappa Gammopathy Associated with Lymphocytic Lymphoma. Federation Proceedings 35:438, 1976.
- (2) Brown, G.L., Corby, D.G., DiBella, N., and Lima, J.: IgE-IgM Gammopathy Associated with Lymphocytic Lymphoma: Immunologic Considerations. Mil Med, 142:921, 1977.
- (3) DiBella, N.J., and Brown, G.L.: Immunologic Dysfunction in the Myeloproliferative Disorders. Cancer 42:149, 1978.

PRESENTATIONS:

- (1) DiBella, N.J., and Brown, G.L.: Cellular and Humoral Immunity in the Myeloproliferative Disorders. Presented: Annual Joint Meeting of the American College of Physicians and American Society of Internal Medicine, Colorado Regional Meeting, Colorado Springs, CO, January 15, 1976.
- (2) Brown, G.L., DiBella, N.J., and Corby, D.G.: IgE-IgM Kappa Gammopathy Associated with Lymphocytic Lymphoma. Presented: FASER Anaheim, CA, April 12, 1976.

DEPARTMENT OF CLINICAL INVESTIGATION FITZSIMONS ARMY MEDICAL CENTER Aurora, Colorado 80045

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2)	Prot No.: 7	4/110	(3) Sta	tus: On	going	
(4) Title: Reactive Hypogl				lin-Gluc	agon	
Interrelationships and Coun	ter Hormonal Rea	rulatory	Factors.			
(5) Start Date: FY71		(6) Est	Comp Date:		<u>ite</u>	
(7) Principal Investigator	•	(8) Fac	ility: FAMC			
Fred D. Hofeldt. COL. MC		l				
(9) Dept/Sec:		(10) As	soc Investi	gators:		
(11) Key Words:	Gerald C. Kidd, LTC, MC					
reactive hyperlycemia	,	David Molock, MAJ, MC Leonard F				
glucose tolerance		T.P. O'Barr, Ph.D., DAC Lodgen,				
counter-regulartory h	ormones	A. Sh	ackelford, N	MT, DAC	MAJ, MC	
(12) Accumulative MEDCASE	(13) Est Accum	ulative	(14) Period	ic con	tinue	
Cost:	OMA Cost:		Review	Results	i: 11/79	
(15) Study Objective: Th	e objectives of	the hypo	glycemic stu	udy is t	o continue	
to investigate in our large clinic population the glucose-insulin-glucagen and						
prolactin interrelationships and the response of counter-regulatory hormones to						
hyporlycemic stress. This project is a continuation of the previous project					roject	
initiated in 1969 at the University of California Medical Center, Moffatt						
Hospital, San Francisco, Ca						
Hopping - run Transferd - Adria Alima						

(16) *Technical Approach: The clinical research protocol involves evaluation of control subjects and hypoglycemic patients to assess the interrelationships of beta cell and alpha cell responsiveness to oral and intravenous glucose administration. Based upon findings in controls and patients with disease states, a classification system has been proposed. The data have allowed for an understanding of the basic pathophysiology of reactive hypoglycemia listorders. The clinical studies are being conducted in the Department of Medicine, 17) *Progress:

This study continues to be an active protocol with recruitment of patients with bona fide reactive hypoglycemia. The total number of patients started since the beginning of this protocol numbers approximately 500. The data on these patients is being stored on MTSO computers and is currently undergoing a data analysis by Dr. Leonard Sanders. The project is to be continued as an ongoing Endocrine project with the assignment of new associate investigators

Proto No: 74/110

(16) Technical Approach (cont)

Endocrine Clinic, with the assistance of an assigned 35-5 to perform blood sampling and assist during the testing. During the plucose tolerance test, the patient has an indwelling catheter for frequent sampling of blood glucose, is continually monitored by a cardiac monitor system and blood glucoses are assessed immediately after sampling by the Ames Beflectance Meter. After glucose administration, blood insulins, glucagons, growth hormones, prolactins and cortisols are sampled and values are determined by a sensitive radioimmunoassay. The procedure is designed to provide a minimum of patient inconvenience in the performance of these well standardized procedures. Many normal individuals experience a low blood sugar state sometime after glasses administration, the clinical significance of a low blood glucose state is observed by recording appropriate adrenergic symptoms at the nadir of the glucose and determining if there is a counter hormonal responsiveness to defend the stress of a low blood glucose state. This approach allows corist definition of bona fide reactive hypoglycomia and clearly distinguishes it from the benign low blood glucose states.

(17) Trogress (cont,

to replace those individuals who are currently not at Fitzsimons Army Medical Center. New interests will be directed towards to gastrointestinal factors important in the entereinsular axis as possible pathophysiological alterations causal in this disease.

FAMC WL	No (Prot No)	74/110
---------	--------------	--------

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE Endocrine	DEPARTMENT Medicine

- (1) Abrams, R., Hofeldt, F.D., Adler, R., O'Barr, T.P., and Morse, F.: Late Reactive Hypoglycemia in Hypothyroidism. (Submitted for review to American Journal of Medical Sciences.)
- (2) Charles, M.A., Hofeldt, F.D., Dodson, L.E., Shæckelford, A., Waldeck, N., Bunker, D., Cogsins, J.T., and Eighner, H.: Comparison of Glucose Tolerance Tests and Mixed Meals in Patients With Idiopathic Reactive Hypoglycemia: Absence of Hypoglycemia After Mixed Meals. (Submitted for review Annals of Internal Medicine.)
- (3) Sanders, L.E., Hofelct, F.D., Kirk, M., and Levin, J.: Food Abuse as a Cause of Reactive Hypoglycemia. American Journal of Clinical Nutrition (in press).
- (4) Hofeldt, F.D.: Transitional Low Blood Glucose States. Rocky Mountain Medical Journal, 76:30-34, 1079.
- (5) McCowen, K.D., Adler, R.A., O'Barr, T.P., and Hofeldt, F.D.: Clinical implications of Flat Oral Glucose Tolerance Test. Military Medicine, 144:177-179, 1979.

FAMC WU No (Prot No) 74/110

PRESENTATIONS for FY 80 Annual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE Endocrine Service DEPARTMENT Medicine

- (1) Hofeldt, F.D.: Reactive Hypoglycemia: Update 1980. Presented: Endocrine Grand Rounds, University of Colorado Health Sciences Center, Denver, CO, 16 January 1980.
- (2) Sanders, L.R.: Reactive Hypoglycemia. Presented: Grand Rounds, University of Colorado Medical Center, Denver, CO, 13 March 1979.
- (3) Sanders, L.R.: Reactive Hypoglycomia. Presented: Medical Grand Rounds, Denver General Hospital, Denver, CO, 15 March 1979.
- (4) Sanders, L.R.: Reactive Hypoglycemia. Presented: Endocrine Grand Rounds, University of Colorado Medical Center, Denver, CO, 11 April 1979.

DEPARTMENT OF CLINICAL INVESTIGATION FITZSIMONS ARMY MEDICAL CENTER Aurora, Colorado 80045

ANNUAL PROGRESS REPORT (HSSF 40-23, App. C.) (Detail Summary Sheet)

(1 Date: 30 SEP 80 (2) Prot No.: 75	/107 (3) Status: on-going
Title: A Comparison of the Results o	f Hyposensitization with Aqueous
Griss Extract and Aluminum Precipitated A	queous Extracted Grass Extract
VSI Start Cate: 1975	(6) Est Comp Sate: 1980
(M. Pri : 3) investigator	(8) Facility: FAMC
Harold S. Nelson, MD, COL, MC	1
(5) Deur Sec: Medicine/Allergy-Immunol.	(10) Assor Investigators:
(II) Key Lands:	
Allerm Immunotherapy	None.
(T2) Total Ot of PadCASE (13) Est Accordance OMA Cost	
(The Assume Superctive:	

The state of the s

is a small and an initial precipitated allergy extracts.

the content of a content Magnifering the limited tolerants for the extracts drawing blood twice ancestly of a period of four years and measuring the immune response by both appoint table and IgG antibody assists.

(Fig. 1980) the first part (Phiring these fiscal year blocking antibody studies were performed on some which had been collected over the period 1975 to 1978 with the scheme, 1 publication of the results in the Annals of Allergy in December, 1980, the protocol will be completed.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 75/107

(4) Title: in the Treatment of Patients with Allergic Symptoms Due to Grass Allergy

FAMC WU No (Prot No)

75/107

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE Allergy-Immunology

DEPARTMENT Medicine

- (1) Nelson, H.S., A Three-Year Comparison of Immunotherapy with Alum Precipitated and Glycero-Saline Grass Extracts (Abstract) Annals of Allergy, 42:123;1979
- (2) Nelson, H.S., A Comparison of Long-Term Immunotherapy with Aqueous and Alum Precipitated Grass Extracts, Annals of Allergy, Dec, 1980.

FAMC WU No (Pret No) 75/107

PRESENTATIONS for FY 80 Annual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE Allergy-Immunclogy

DEPARTMENT Medicine

(1) Nelson, H.S., A Three-Year Comparison of Immunotherapy with Alum Precipated and Glycero-Saline Grass Extracts presented at the Annual Meeting of American College of Allergist, San Francisco, California, 29 Jan 79.

DEPARTMENT OF CLINICAL INVESTIGATION FITZSIMONS ARMY MEDICAL CENTER Aurora, Colorado 80045

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.: 75/	116	(3) Status: Ongoing
(4)	Title: Fractionation of	Kochia Pollen	with Isc	lation of Kochia Pollen
	Allergens			
(5)	Start Date: 1975			Comp Date: unknown
(7)	Principal Investigator		(8) Fac	lity: FAMC
	Harold S. Nelson, MD, (
(9)	Dept/Sec Medicine/Allers	gy-Immunol.	(10) As	soc Investigators:
(11)	Key Words: Purified Kochia Allerge	ens	Т.Р.	O'Barr, Ph.D., DAC
(12)	Accumulative MEDCASE Cost:	(13) Est Accum OMA Cost:	l ulative	(14) Periodic continue Review Results: 12/79
(15)	*Study Objective:			

15) *Study Objective:
To extract raw Kochia pollen and purify the principle allergens through chemical fractionation.

- (16) *Technical Approach:
 The study will employ multiple methods of separation of proteins with investigation of allergenic activity of the fractions by RAST assay.
- This project has been inactive since the original principle investigator was transferred. However, It will be resumed in the near future.

Publications and Presentations: None

DEPARTMENT OF CLINICAL INVESTIGATION FITZSIMONS ARMY MEDICAL CENTER Aurora, Colorado 80045

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2) Prot No.: 75/	118 (3) Status: Completed
74)	Title: A Study of the Stability of Al	lergy Extracts under Varying
	Conditions	
(5)	Start Date: 1975	(6) Est Comp Date: 1980
(7)	Principal Investigator	(E) Facility: FAMC
	Harold S. Nelson, MD, COL, MC	
(9)	Dept/Sec: Medicine/Allergy-Immunol.	(10) Assoc Investigators:
(11)	Key Words:	
	Extracts Stability	None
(12)	Accumulative MEDCASE (13) Est Accum	ulative ((14) Periodic continue
	Cost: OMA Cost:	Review Results:10/79
(15)	<pre>#Study Objective:</pre>	
	To systematically explore the effects	of several stabilizers on the
	loss of potency of allergy extracts a	it different concentrations,
	volumes and time intervals.	

(16) *Technical Approaca:

Allergy extracts were reconstituted from lyophilized sources at various time intervals prior to testing. Residual potency was compared with that of freshly reconstituted dilutions employing pooled allergic serum and RAST inhibition.

(17) Progress:

Studies have been completed, and with the publication of the second paper on the subject currently in press in the <u>Journal of Allergy</u> and Clinical Immunology, this study is effectively finished.

FAMC	WU	No	(Prot	No)	
------	----	----	-------	-----	--

75/118

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE Allergy-Immunology DEPARTMENT Medicine

- (1) Nelson, H.S., Effect of Diluent and Conditions of Storage on Allergy Extract Potency (abstract), Journal of Allergy and Clinical Immunology, 63:195; 1979.
- (2) Nelson, H.S., The Effect of Preservatives and Dilutions on the Deterioration of Russian Thistle (Salsola pestifer) A Pollen Extract, Journal of Allergy and Clinical Immunology, 63:447; 1979.
- (3) Nelson, H.S., The Effect of Dilution and Conditions of Storage on Allergy Extract Potency, Journal of Allergy and Clinical Immunology (in press).

FAMC WU No (Prot No) 75/118

PRESENTATIONS for FY 80 Annual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE Allergy-Immunology

DEPARTMENT Medicine

- (1) Nelson, H.S., The Effect of Preservatives and Dilution on the Deterioration of a Pollen Extract--Russian Thistle (Salsola pestifer), Annual Meeting of the Academy of Allergy, Phoenix, Arizona, March, 1978.
- (2) Nelson, H.S., Effect of Diluent and Conditions of Storage on Allergy Extract Potency, Annual Meeting Academy of Allergy, New Orleans, Louisiana, 24 March 1979.

DEPARTMENT OF CLINICAL INVESTIGATION FITZSHONS ARMY MEDICAL CENTER Aurora, Colorado 80045

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

75Y -	Chloroethyl)-3-(4-Methyl Cyclohexyl) Start Date: 1976		Comp Date: 1982
	Principal Investigator N. J. DIBELLA, MD, COL, MC		ility: FAMC
(9) (11)	Dept/Sec: Hematology=Oncology Key Words: Chemotherapy, CA of colon	7	soc Investigators:
(12)	Accumulative MEDCASE (13) Est Accum Cost: OMA Cost		(14) Periodic continue Review Results: 10/80
	*Study Objective:		· · · · · · · · · · · · · · · · · · ·

- (16) *Technical Approach: Clinical study.
- four patients have been entered on this protocol. One patient is too early to evaluate, but the other three patients have failed to respond. No serious toxicities have been observed.

Publications and Presentations: None

DEPARTMENT OF CLINICAL INVESTIGATION FITZSIMONS ARMY MEDICAL CENTER Aurora, Colorado 80045

ANNUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sheet)

	76/103 (3) Status: Terminated			
(4) Title: An Objective Measure of CNS De	velopment in Children			
(5) Start Date: 1 Jul 76 (7) Principal Investigator	(6) Est Comp Date: Terminated (8) Facility: FAMC			
R. John Morgan, Jon H. Buscemi	Colorado State University			
(1) Dept/Sec:Dept of Med., Neurology Svc (11) Key Words: Central Nervous System Development in	John W. Steadman, Ph.D. (CSU, CO) C. Norman Rhodine, Ph.D. (CSU, CO) Paul W. Daugherty, B.S. (CSU, CO)			
Children	James W. Howell, B.S. (CSU, CO)			
(12) Accumulative McDCASE (13) Est Accum Cost: OMA Cost:	Review Results: 2/80			
(15) *Stul Objective: A long term goal of a clinical method of assessing central ner children too young to be tested using behalphormal CNS development is of paramount if therapy which influences the prognosis. S	vous system (CNS) development in vioral methods. Early diagnosis of mportance in early institution of			
using testing methods which require verbal				

(16) *Technical Approach: The proposed research will develop a quantitative method of assessing CNS development and the data base for normal subjects. Abnormal development of the CNS, such as mental retardation, will be the subject of a later research. This study is designed to find parameters of the Electroencephalogram (EEC) which will be reliable quantitative measures of CNS development and establish the normal range of these parameters. The variation of these parameters with age in normal children will be established and (17) *Progress: statistically tested for significance.

This protocol was terminated due to lack of sufficient number of patients and transfer of the investigator.

Publications and Presentations: None

DEPARTMENT OF CLINICAL INVESTIGATION FITZSIMONS ARMY MEDICAL CENTER Aurora, Colorado 80045

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

	Jate: 30 SEP 80 (?) Prot No.: 76	5/105	(3) Status: Terminated
(4)	Title: Evaluation of Testicular Funct	cion in Pa	atients Receiving
	Cytoloxic Cherspy	, , , , , , , , , , , , , , , , , , , 	
(5)	Start Date: wy R		Comp Date: Terminated
(7)	Principal Divestigator	(8) Faci	Hity: FAMC
	MARY L. TREE M. DD. LTD. MC		
(9)	Dept/Sec: Englishine Mervice	(10) As	soc Investigators:
(11)	Key Words:	Nich	olas J. DiFella, COL, MC
	testiquar tar ion	1	
	cytotexic therem	ļ	

(12)	Accumulative He Choc (13) Est Accume	ulative	
	Cost: OMA Cost:	i	Review Results: 5/80
(15)	*Study receive: "b determine if t	there are	abnormalities in testicular
fum.	ilm results to the most otoxic therapy.		
nusi Turkai	hermone term tension to teneficial to	the rati	ents, particularly by
3	wing the letter of the function or oth	her testo	sterone related parameters
	as prosede a readth, weight gain, etc.		•
	The first of the same of the s		

(16) *Technical Application outpatients undergoing cancer chemotherapy were nationed a liberal for all study, if the expected survival was at least a mention. For we arrange expeciment, the patients would be studied with the Patients will be studied with the Patients will be blained and a military by a questionnaire. Patients with decreased test extende or increased like will be treated with 200 mg of testosterone applicable to the continue to have enjoying

No patients fewe feet of Hed under this protocol. The principal investigator was left "Monatore Amp Medical Center and the studied will not be continue;. The study is to be continue;.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (8locks 1 through 17)

Proto No: 76/105

Technical Approach, continued:

studies drawn and questionnaires filled out during the course of cancer chemotherapy.

Publications and Presentations: None

DEPARTMENT OF CLINICAL INVESTIGATION FITZSIMONS ARMY MEDICAL CENTER Aurora, Colorado 80045

ANNUAL PROGRESS REPORT (HSCR 40-23, App. +.) (Latail Summary Sheet)

$\overline{(1)}$	Date: 30 SEP 80 (2) Prot No.: 76/	112 (3) Status: Completed
4)	Title Study of the Effect of Tetracycl on Pleural Effusion in Cancer P	
(5)	Start Date: 1976	(6) Est Comp Date: July 1980
(7)	Principal Investigator A. J. ZALOZNIK, MD, CPT, MC	(8) Facility: FAMC
(9)	Dept/Sec: Hematology-Oncology	(10) Assoc Investigators:
(11)	Key Words: Pleural efficiens, chest tube drain- age.	STEPHEN G. OSWALD, DO, CPT, MC
(12)	Cost: (13) Est Accumi	ulative (14) Periodic continue Review Results: 10/79
(15)	*Stude Objective: to determine in a prospective, random pleural distrage and tetracycline are alone in the treatment of pleural eff	e better than pleural drainage

The state of the s

(16) *Technical Appro whi

Patients with biopsysproven malignancy with malignant infusion are being randomized to closed chest tube drainage alone or closed chest tube drainage with retracycline. This is being done in a double-blind manner by the Pharmacy Service so ward physicians do not know if the patient is given tetracycline or the vitamin solution which looks the same as tetracycline.

(17) *Progress: A complete resolution of the effusion was seen in 1 of 9 (11%) controls and 9 of 13 (69%) TCM patients; partial responses occurred in 1 of 9 particls and 1 of 13 patients; stabilization occurred in 2 of 5 controls and 2 of 13 TCN patients. Some particles are particles are particles are particles and 2 of 13 TCN patients. tients treated with TCN experienced local discomfort and one patient developed a pleurocutaneous fistula.

Publications and Presentations: None

DEPARTMENT OF CLINICAL INVESTIGATION FITZSIMONS ARMY MEDICAL CENTER Aurors, Colorado 80045

A MURL PROGRESS REPORT (HSCR 40-23, App. U.) (Detail Summary Sheet)

$\sqrt{1}$	Date: 30 SEP 80 (2) Prot No.: 76,	/116 (3) Status: ngoing
(4)	Title:	
	the Cirect of Lexandlescone on Gonadot	ropins in Fost-menopausal Women
5)	Start Jate: 6 6	(6) Est Comp Date: 1981
(7)	Principal lavestigator	(8) Facility: FAMC
	Jary J. Treens, M., NO	
(9)	Sept/feet It define/our minology	(10) Assoc Investigators:
(11)	Ker words:	William J. Georgitis, MD, CPT, MC
	Dexame thase: work n	
	ronadebroping	
	1001-menoteus	
.121	real-menobalis (5) Est Accum	ulative (14) Periodic continue
	Cost: OMA Cost:	Review Results: 12/79
(15)	Stud miles in clarify the me	echanisms whereby glusocorticoid.
may	interfer with a pad to pin secretion of	or release in jost-menopausal
	a. This is a filler but for the	
	braningstierth. Seie withtemale, with	
	ing to the first of the second	• • • • • • • • • • • • • • • • • • • •
• • • • •	eren i de la gradita de la companya	

- (16) *Technical operation in the population to be studied are healthy, post-semplement when it is reflection. A post-menopausal woman will be indicated as an initial element plasma goradotropin levels as a result of plant decimal wherein allower or prior surgical extirpation of the openion. A baseline of the page as a prior to the subjects taking 2 mg qid po of became that one on these contributed days. A.M. FSH, LH, cortisol and prolactin (Cont)
- (17) *Progress: As reported in the Research Project Resume of 30 Sep 77, seven post memory soft tracks have been studied. Saline placebo injections prior to the office injection foiled to after hormone levels in three subjects. The basis levels and the recepts of to GNRH for prolactin, FSH and LH was not significantly officed by the methasone in five patients. An unanticipated new observation was what GNRH of implated prolactin release in post-menopausal subjects with the time of the peak response being delayed by Dexamethasone. (Cont.)

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

(16) Technical Approach - continued: levels will be obtained daily during the Dexamethasone treatment. In order to define the site of the anticipated Dexamethasone suppression of the gonadotropins a GURH infusion test will be performed by giving a single IV bolus of 100 ug of GURH on the day prior to and on the third Dexamethasone treatment day. Blood for FSH, LH, cortisol and prolactin will be drawn at -15, 0, 15, 30, 45, 60, 90 and 120 minutes after GURH injection.

Proto No: 76/116

(17) Progress - continued: Such a response by prolactin to GNRH has been reported recently in premenopausal women with secondary amenorrhea, but heretofore has not been reported for post-meropausal women.

FAMC	UW	No	(Prot	No)	76	/116	
IMIN	*** •	1 10	1. 101	. 10/_	10	/ 110	_

PUBLICATIONS	for	FΥ	80	Annual	Progress	Report	(2nd	Part	of	Detail	Summary
					- -						Sheet.)

SERVICE Endocrinology

l Hofeldt, F.D.: Effect of GNRH on

DEPARTMENT Medicine

(1). Treece, G., Podson, L.E., and Hofeldt, F.D.: Effect of GNRH on Post-Menopausal Gonadotropins and Prolactin Levels: Influence of Short-term Glusdcorticoid Administration. Program and Abstracts, 61st Annual Meeting of the Endocrine Society, Anaheim, PA 1979.

FAMC V	W No	(Prot No	<u> 76/116</u>
--------	------	----------	----------------

PRESENTATIONS for FY 80 Annual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE Endocrinology DEPARTMENT Medicine

(1) Treece, G., Dodson, L.E., and Hofeldt, F.D.: Effect of GNRH on Post-Menogausal Gonadotropins and Prolactin Levels: Influence of Short-term Glucocorticoid Administration. Presented: 61ct Annual Meeting of the Endocrine Society, Anaheim, CA, 1979.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.: 77/	
(4) Title: Comparison of the Clinical and	d Immunological Response of Pre-
seasonal and Co-seasonal Versus Post Seasonal	onal Initiation of Allergy Immunother
(5) Start Date: 1977	(6) Est Comp Date: 1980 apy
(7) Principal Investigator	(8) Facility: FAMC
Brian Fortner, MAJ, MC	
(9) Dept/SecMedicine/Allergy-Immunolog.	(10) Assoc Investigators:
(11) Key Words:	William R. Tipton, COL, MC
Frequency of immunotherapy	• • •
(12) Accumulative MEDCASE (13) Est Accum	ulative (14) Periodic continue
Cost: OMA Cost:	Review Results: 1/80
(15) Study Objective:	
This study was altered somewhat in the pro-	otocol in order to gain more
clinically meaningful data. In a double I	
received immunotherapy to ragweed either of	
schedule with a cross over at two months.	· · · · · · · · · · · · · · · · · · ·

(16) *Technical Approach: Immunological approaches including specific IgE (RAST), titrated skin test, blocking antibody (IgG), nasal provocation titrations, and conjunctival challenge were done on patients during a double blind cross over during four months of nonpollenating season to determine the effecacy of the immunotherapy related to the frequency of the injections. Weekly injections were compared with monthly injections.

(17) *Progress:
This data is now being accumulated for presentation in the next few months and possible publication.

Publications and Presentations: None

the nonpollen season.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2) Prot No.: 77	
(4)	Title: Evaluation of Immunoglobulins	and Immunoglobulin-Bearing Lympho-
	cytes in Asthma	
(5)	Start Cate: 1907	(6) Est Comp Date: 1980
(7)	Principal Investigator	(8) Facility: FAMC
	Harold S. Nelson, MC. COL, MC	
(9)	Dept/Sec: Medicine/ Nilergy-Immunol.	(10) Assoc Investigators:
(11)	Key Words:	Lyndon E. Mansfield, MD,LTC, MC
	Immunoclobulin levels in asthmatics	
(12)	Accume 11 - MEDMARCH (13) Est Accu	mulative (14) Periodic continue
	Cost: OMA Cost	
(15)	& Study Spine + ive .	

To determine whether patient's with bronchial asthma have mean immuno-globelin levels which are lower than normal for their age or have abnormalities of tymphocytes as determined by surface markers.

(16) *Technical Approach:
Blood was drawn, and a survey sheet completed on approximately 150 patients with bronchial asthma seen in the Allergy Clinic at Fitzsimens Army Medical Center. Immunoglobulin levels were performed on these blood samples.

(17) *Progress:
The data has been analyzed, and a previously unsuspected correlation between low *mmunoglobulin levels and beta adrenergic therapy was demonstrated. The data is currently in the final stages of preparation for machinetion. Upon publication this study will be completed.

ANRUAL PROGRESS REPORT (HSCR 40-23, Mp. C.) (Detail Summary Sheet)

\mathbb{C}	Date: 30 SEP 90 (2) Prot No.: 7	7/105 (3) Status: Completed
4)	Title: An Evaluation of Cross Allers	enicity among Pollen Extracts of
lembe	rs of Chenopodiaccae and Amaranthacea	e
-(5)	Start late: 1977	(6) Est (omp Date: unknown
(7)	Principal Investigator	(8) Facility: FAMC
	Harold S. Nelson, MD, COL, MC	
$\langle \alpha \rangle$	Dept/Sec: Medicine/Allergy-Immunol.	(10) Assoc Investigators:
(11)	Key Words:	
	Chenopod cross allergenicity	Richard W. Weber, LTC, MC
7137	Vicumulative Mar 1991 (13) Est Accu	mulative 104) Periodic continue
	Cost: CMA Cost	: Review Results: 5/80
(15)	AStudy Objective:	
	To evaluate the cross allergenicity a	mong pollens of the weed families,
	Chenopodiaceae and Amaranthaceae.	- ·

(16) *Technical A promen:

Twelve members of the Chenopod-Amaranth families were studied. Rabbit antisera were prepared and Ouchterlony immunodiffusion and inhibition of passive hemagglatination was performed. RAST inhibition was also performed employing pooled allergic serum and extracts of the 12 weeds.

173 Progress:

No further study has been performed on this protocol since the transfer of Dr. Weber to Europe two years ago.

FAMC WU	No (Prot No)	
---------	--------------	--

77/105

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE Allergy-Immunology

DEPARTMENT Medicine

- (1) Weber, R.W., Nelson, H.S., An Evaluation of Cross Allergenicity Among Pollen Extracts of Members of the Chenopodiaceae and Amaranthaceae submitted to the 1978 Hugh-Mahon Lectureship Award Competition, awarded second prize.
- (2) Weber, R.W., Mansfield, L.E., Nelson, H.S., Cross Reactivity among Weeds of the Amaranth and Chenopod Families (&bstract), Journal of Allergy and Clinical Immunology, 61:172;1978.

FAMC WU No (Fret No) 77/105

PRESENTATIONS for FY 80 Annual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE_Allergy-Immunology

DEPARTMENT Medicine

(1) Weber, R.W., Cross Reactivity among Weeds of the Amaranth and Chenopod Families, Annual Meeting Academy of Allergy, Phoenix, Arizona, 28 Feb 78.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.: 77	/106	(3) Status: on-going
(4)	Title: The Effect of (lly Mediated Bronchial
	Constriction of Bronchi	al Smooth Musc	le	
(5)	Start Date: 1977		(6) Est	Comp Date: 1981
(7)	Principal Investigator		(8) Fac	ility: FAMC
	David Pitman			
(9)	Dept/Sec: Medicine/Allo	rgy-Imm/Pathol	, (10) A	ssoc Investigators:
$\overline{(11)}$	Key Words:		7 ' '	3
	Bronchial smooth muscle	<u>!</u>	L.E.	Mansfield, MD, LTC
			1	, , , , , , , , , , , , , , , , , , , ,
			[
(12)	Accumulative MEDCASL	(13) Est Accus	nulative	(14) Periodic continue
	Cost:	OMA Cost		Review Results: 7/80
(15)	*Study Objective:		\ 	7700

To determine if the hyperactivity or constriction of the bronchial smooth muscle in asthmatic patients is the cause of the bronchial smooth muscle hypertrophy found in the asthmatic lung, and secondly, to determine if bronchodilators as presently used have any protective effect against this hypertrophy.

(16) *Technical Approach:
Guinea pigs were subjected to nonantigen mediated bronchoconstriction from the age of weaning to sexual maturity. The animals were then sacrificed, and bronchiel muscle examined.

(17) *Progress:

All of the animals have been sacrificed. The histologic material is awaiting examination by Dr. Fitman.

(HSCR 40-2), App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

compared to normal weighted controls.

?1)	Date: 30 SEP 30 (2) Prot No.: 77/	107	(3)	Status:	Terminate
111	Title				
	L-Dopa Stimulation of Glucagon in Obe				
(6)	Start Jate: 1977			10: 1980	
(7)	Principal Investigator	(8) Fac	lity:	FAMC	
	Gary L. Treece, MD, LTC, MC				
(9)	Dept/fec: Endocrinology Service	(10) As	soc In.	estigator	:
11)	Ker words:	, Wil:	liam J.	Georgiti:	s, MD, CPT, MC
	L-Dopa				
	glucagon				
. ,	obesity				
1121	Concumulative MEDDASE (13) Est Accum	ulative	(iii) Pe	riodic c	continue
	Co::: OMA Cost:		Re	view Ress	<u>1) 15: 4/80</u>
	-Study objective: It has been sugges				
def	iciency of glucaron reserve. L-Dopa h	as been	reported	l to caus	e a rise
in	serum glucagon levels in normal weight	subject	s. This	s study w	as designed
to	observe the effect of L-Dopa on serum	glucagon	levels	and obes	e subjects

normal weight, non-diabetic subjects; 10 obese, non-diabetic subjects; and 13 obese diabetic subjects. In the latter group, subjects taking insulin and/or oral hypoglycemic agents will be excluded from the study. Diabetic subjects will be defined on the basis of standard 3-hour glucose tolerance tests. Subjects with a history of cardiovascular disease, glaucoma, melanoma, peptic ulcer disease, psychosis, and patients taking MAO inhibitors will be excluded (cont)

Concern that normal weighted and obese subjects might not receive an equivalent stimulus from a fixed dose of L-Dopa prompted an attempt to assess the dose response relationship of L-Dopa and serum glucaton. Oral doses of 500, 750 and 1000 mg of L-Dopa were tested in a single subject. Basal levels were very reproducible (coefficient of variation 5%). The lower dose produced no nausea, but severe, transient nausea was encountered at the higher doses about 30 minutes after ingestion of the drug. The well known (cont.)

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

(16) Technical Approach - continued: from the study. All subjects will be on a weight maintaining 150 gm carbohydrate diet three days prior to the study. If not previously documented in the subject's medical records, a 3-hour GTT will be performed on a day prior to L-Dopa administration. Subsequently, after an overnight fast, all will be given a 7.5 mg/kl dose of L-Dopa by mouth at 0800 hours. In the supine position, venous blood samples will be obtained from an indwelling scalp vein catheter at -15, 0, 15, 30, 45, 60, 90, 120 and 180 minutes for determinations of plasma glucose, growth hormone, insulin, glucagon and prolactin.

Proto No: 77/107

(17) Progress - continued; suppression of prolactin and elevation of serum growth hormone levels was observed consistantly but glucagon did not show a consistant or even graded response.

Three additional studies of normal weighted subjects were done with a 500 mg done of L-Dopa. Nausea occurred in one subject again at 30 minutes. Of the 4 tests done in normal weighted subjects with a 500 mg dose, 2 show. A rise in serum glucagon with peak values at 45 and 60 minutes of roughly 60% basal. One subject had a flat response and another a 25% fall from basal at 60 minutes. Again, prolactin and growth hormone responses were present in all subjects except for one who failed to show a growth hormone response. This implies that the L-Dopa had been taken and was active in all subjects.

Statistical imalysis of the 4 normal weighted subjects' response by paired-t test analyzing absolute peak levels in pg/ml, peak percentage change from basai, or the areas under the curves by a method of intergrated rectangles failed to achieve a significant t value for p <.05 (the p value for areas under the curve was >.20). Although this represents a small sample it seems reasonable to conclude that it would hazardous to continue the study further since a dose response in serum glucagen to oral belopa was not demonstrated even though reasonable prolactin growth hormone responses were seen. The mean peak response of 4 normal weighted subjects was positive but small with a green dead of variability (near = 38 pg/ml at both 30 and 60 minuter with standard leviations of 67 and 69, and standard errors of 33 and 34 of 30 and 60 minutes, respectively). This suggests that the assessment of clacaton reserve in obese subjects compared to normal weighted subjects it beyond the we uitivity of this method. This may be a result of the measurement of peripheral rather than portal venous levels of glucagon, poor sensitivity of the glucagon assay in the lower range, inadequate glucagon stimulation by L-Popa, or some other undetermined factors. The hypothesic that gluckers reserve is diminished in obesity might be tested in peripheral blood by a more potent secretagogue if one is found in the future. It is possible that higher doses might provide an accurate assessment of slucagon reserve in peripheral blood, but the severe nauses encountered with himer doser makes this approach unreasonable.

Publications and freshnts lons: none

ANGUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sneet)

(1) Date: 30 SEP 80 (2) Prot No.: 77/108 (3) States: completed (4) Title: A Comparison of the Clinical and Lemanologic Responses to Grass Pollen Extract with or without the Addition of Governments (5) Start Date: 1977
(7) Principal Investigator (2004) Fire Control William R. Tipton, COL, MC (9) Dept/Sec: Medicine/Allergy-Immunol. (27) A Fig. (11) Key Words: (27) A Cott. AC Immunotherapy Grass pollen extract (12) Accumulative McMASS (13) Est Accumulative Mar die continue

Cost: Style Cost: General Cost: General Cost (15) GStudy Objective: To determine whether there is a difference in the scalar approximation to allergy injection therapy if the entirely to a more or extract contains glyceria as opposed to sall as

(16) Alechnical Appropria

Alternate patients beginning themselve, as the second of the two types of grantes and a second immunotherapy with this extract through two or less and blocking untiledy to all before the second of t

(27) #Progress:

This data has been acquestated forthering the second of the data between the aqueous extrace as the first and the ligh between the aqueous extracr as (RAST) levels. Involved to the contract of the Service and the to the mobile population of the

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(5)	Start Date: pv78	(6) Est Comp Date: 1, 11 togge
	Principal Investigator L. Preece, M., 1995, MC	(8) Facility: FAMO
(\cdot)	Dupt/Sec: Engernine Pervice	(10 Acsoc Investigators:
(11)	Key Words:	
	Proprancial diabetes	None.
	Cost: OHA (Accumulative (14) Periodic continue Cost: Review Results: 6/
(15)	#Study or a vet to a patrimer.	ne what effect a normande, siven sme.

(16) *Teannical as awards the penth with hypertonsion telms attented in temporal deliberary with our theory the tells attent. A readline PMIN and Serve PMI wish to obtained period that map. The initial pure of programs will to 50 min girp. A report of DM and Serve PMI will be intained at 2 and 6 weeks of therapy, and approximately approach attained few lifts are to the programs of the therapy. The street of programs is an electrical trained after 1 menth of cemilled therapy. The street of programs is an electrical form.

To patient, have been coupled on this pass ont. The pointing from tixe that has left bitchis at Amp to I also on all the straights to be ferminated.

. . Black w

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: __77/110

Technical Approach, continued.

disappearance rate (K value) and glucose tolerance will be examined. The effect of propranciol on insulin and glucagon levels will also be examined.

ANNUAL PROGRESS REPORT (MSC: 40-23, App. 1.) (Detail Summary Sheet)

(1) water 72 CEP FO (2) From No.: 77/113 (3) States: completed (4) 1-10-1. A Study of Terbutaline Aerosol in the Treatment of Patients with Bronchial Asthma 1980 Carling Care 1980 (a) Start True 1977 (a) Fritzion live de ter Harold S. Nelson , MD, Cot. MC

W Dentile Medicine/Allery - Tamaunol.

Key Words: .A. Smith, LTC, USAF, MC Terbutaline bestchodilater sub-R.W. Weber, LTC, MC tivity / / Fig. accommodative [ria: North die continue fost. (S) Study (177A Courts 12/79 To deter the offerfiveness of from propelled metered dose acrosolized forms along as a broadball lator administered on a regular, four times leady to a

Secondary considerations were to determine the development of subsensitivity and to compare the infectiveness of Terbutaline with that of the Thepphylitims.

Fifteen patients recommended that the appeared of 12 weeks four times daily. These more than a partial was meaned initially and at the end of the property well as at two week intervals while receiving the arms. The first of last studies were performed double blind. Following completes a property form and entered a double blind-cont.

This study was completed. The square notween acrossized terbataline and Theophylline is correctly in press in the journal, Chest, while the 12-week subsensitivity only he best submitted for possible publication in the American Review of a street liseases with completion of these results. This study is explain.

CONTINUATION SHEET FOR FY 30 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 77/113

16. cross over study in which a placebo was substituted for either the inhaled Terbutaline or the oral Theophylline. Response was monitored by four times daily measurement of pulmonary function.

TAINE NO 190 MITTING

77/113

PUBLICATIONS for FY 80 Annual Progress Report (2nd fail of Detail Some and Digetty

SERVICE Allergy-Immunology

DEPARTMENT Medicine

- (1) Smith, J.A., Weber, R.W., Nelson, H.S., Comparison of Aerosolized Terbutaline and Optimal Dose Theophylline in the Management of Bronchial Asthma (abstract), Annals of Allergy, 42:121;1979.
- (2) Smith, J.A., Weber, R.W., Nelson, H.S., Long-Term Use of Aerosolized Terbutaline in the Treatment of Bronchial Asthma--The Development of Subsensitivity (abstract), American Review of Respiratory Disease, 119:1708;1979.

i or the

PRESENTATIONS for FY 80 Annual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE Allergy-Immunology

DEPARTMENT Medicine

- (1) Smith, J.A., Comparison of Aersolized Terbutaline and Optimal Dose Theophylline in the Management of Bronchial Asthma, presented at the Annual Meeting American College of Allergist, San Francisco, California, 29 Jan 1979.
- (2) Smith, J.A., Long Term Use of Aerosolized Terbutaline in the Management of Bronchial Asthma--The Development of Subscittivity, presented at the Annual Meeting of American Thoracic Society, Las Vegas, Nevada, 14 May 1979.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Uetail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.: 77 (4) Title: Effect of Propranolol in Page 1	
Hypoglycemia	
(5) Start Date: PY78	(6) Est Comp Date: 548
(7) Principal Investigator	(8) Facility: FAMC
Gary L. Treece, MD, UTC, MC	
(9) Dept/Sec: Endocrine Service	(18) Assoc Investigators:
(11) Key Words:	To so a D. Hofferdt, Mr. 77, Mr.
Propranolol	Achellie Shackelt rd, MT, IA
reactive hypoclycemia	
(12) Accumulative MEDCALL (13) Est Accum Cost: OMA Cost	mulative (14) Periodic continue : Review Results: 4/80
(15) "Study Objective: To investigate the oral proposed of Thieral) administration defects of patients with posteborostive (r	in the symptomic manner of the list

(16) **Fechnical Approach: the subjects will restrict with jets the computer at slow implies prior true or dictary thereby the and of the term of mention spirity series. A true include case case a context approach to the context of the context of

Additional patient chare not town studies are sense of the constant and analysis and an appropriate and are present and affire year FVO. The constant in the tree to a will be exampled in the next report for all or pears.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 77/114

Technical Approach, continued:

second questionnaire obtained at the end of the month. For a second month the alternate drug is administered and another 5-hr GTT and questionnaire obtained. The effect of glucose, insulin, glucagon, growth hormone, cortisul and prolactin levels during the 5-hr GTT will be compared.

ANNUAL PROGRESS RE (HSÇR 40-23, App. C.) (Detail Summary Sh	
(Historian 25, App. C.) (Detail Summary 3h	eet;
, second	
(1) Date: 30 SEP 80 (2) Prot No.: 78	/102 (3) Status: on-going
(4) Title: The Development of Specific as	nd Cross Sensitivity in the Tracheal
Fissue of Guinea Pigs Treated with Isoprote (5) Start Date: 1978 (7) Principal Investigator	erenol and Aminophylline
(5) Start Date. 1978	(6) Est Gume Partet 1981
(7) Principal Investigator	(8) Facility: CAME
William Ronald Tipton, MD, COL, MC	
(9) Dept/Se/ Medicine/Allergy-Immunol.	(10) As as Investigators:
(11) Key Words:	1 1 Hows, Allergy-Immunology Svc.
Sub≸ensitivity	FAMC
cyclic nucleotides	, ,
Beta adrenergic agomist	
(12) Accomulative Research (13) Est Accum	unative (14) Periodic continue
Cost: OMA Cost:	Review Results:4/80
(15): AStudy Objective:	
This study is designed to measure the devi	elopment of the subsensitivity to
two drugs, Isoproterenol and Theophylline	, by examining both their dilating -
response on histamine contracted tracheal	tissue and ability to increase
levels of cyclic-AMP in tracheal tissue as	nd parenchymal lung tissue.

stop sets berical man asmi

Guinea pig tracheal and peripheral lung strops will be analyzed for cyclic nucleotide levels as well as physiological responsive priors mediators as previously described. Modifications to existing equipment will enable the investigators to do the tension studies at fitnessmen. Army Medical Center. Manpower (in professional man year.) 2.5/ve.

Funding (in thousands) FY 80° ~ 8.6

This study has been completed in the initial phase an lading precentation at the Pulmonary Symposium in 1979, presentation at the Pulmonary Symposium in 1979, presentation at the American Thoracic in May, 1979. The equipment is now available for the entire experiment to be performed here at FAMC, and currently we are ewaiting the arrival of an additional polygraph in order to facilitate forther study.

FAMC	WU	No	(r'roi	No)

78/102

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE Allergy-Immunology DEPARTMENT Medicine

(1) Tipton, W.R.: The Development of Specific and Cross Sensitivity in The Tracheal Tissue of Guinea Pigs Treated with Isoproterenol and Amino-phylline. (Accepted for Publication in Lung.)

FAMC WU No (Prot No) 78/102

PRESENTATIONS for FY 80 Annual Progress Report

SERVIC	E Al	lergy-	Immuno	logy
--------	------	--------	--------	------

DEPARTMENT Medicine

- (1) Tipton, W.R., Jacobson, K., Nelson, H.S., Morris, H., Souhrada, J.: Dynamics and Mechanism of Guinea Pig Trachea Subsensitivity to Isoproterenol. Present: 31st Annual Pulmonary Disease Symposium, Fitzsimons Army Medical Center, Aurora, CO, Sept, 1978
- (2) Tipton, W.R., Jacobson, K., Nelson, H.S., Morris, H., Souhrada, J.: Dynamics and Mechanism of Guinea Pig Trachea Subsensitivity to Isoproterenol. Presented: American Thoracic Society, Las Vegas, Nevada, May, 1979,

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.: 78/	104	(3)	Status: Terminated
(4)	Title: Study of Coagul	ation Parameters	in Pati	ents wit	h Suspected
	Deep Vein Throm	bophlebitis Befo	re and A	fter Ven	ography
(5)	Start Date: 1978		(6) Est	Comp Da	te: 1980
(7)	Principal Investigator	•	(8) Fac	ility:	FAMC
	Joseph R. Haskett, Jr.	CPT, MC			
$\overline{(9)}$	Dept/Sec: Congt Caps/De	ncology Clinic pt Pathology	(10) As	soc Inve	estigators:
(11)	Key Words:		1-1-0	Wint al	al. I'DO MO
	clotting, coagulation	n parameters,	John C	. Michai	ak, LTC, MC
	thrombophlebitis				
$\overline{(12)}$	Accumulative MEDCASE	(13) Est Accum	lative	(14) Per	riodic continue
	Cost:	OMA Cost:		Res	view Results: 4/80
(15)	*Study Objective:				· · · · · · · · · · · · · · · · · · ·
	To determine if coagu	lation parameter	s which	have bee	n associated
	with hypercoagulable	states are alter	ed by lo	wer extr	emity venography.

(16) *Technical Approach:
Following informed consent all adult patients who are referred to the
Department of Radiology for venography are screened with a variety of
clotting studies to include: fibrinogen and fibrin degradation products,
protamine sulfate paracoagulation test, thrombin generation index, and
serum anti-thrombin 3 before venography and 24 hours after to determine
if there is a change in the patients coagulation parameters from the
procedure and dye. Funding (in thousands) FY 80: 0
*Progress:

Study was revised prior to initiation; essentially it has been replaced by 80/102

.74

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheel)

(1) Date: 30 SEP 80 (2) Prot No.: 78	/106 (3) Status: Completed
(4) Title: Effects of the Evaluation	n of the Frequency of Pollen
Allergen Injections During t	he Pollen Season.
Allergen Injections During to Start Date: February 1980	(c) Let let laster: July 1980
(/) Principal Investigator	(8) Facility: TAMC
Bryant R. Fortner, Jr., Maj.MC	
(9) Dept/Sec: Medicine/Allergy	((0) Assis Envertigators:
(11) Key Words!	william R. Tipton, Col MC
Pollen	Harold S. Nelson, Col MC
Hyposensitization injections	Brian S. Dantzler, Maj MC
ragweed immunotherapy_	
(12) Accomulative (LDCASE) (13) Est Accum	nulative (4) Periodic continue
Cost: OMA Cost:	Review Results: 6/80
(15) *Study Objective:	
To establish if the more freque	
injections during the specific	
patients are receiving immunoth	
or clinically better than a les	s frequent schedule.

- blinded crossover study. All were on maintenence ragweed immunotherapy and were evaluated monthly for four months, measuring tissue threshhold sensitivity to ragweed (titrated skin tests, conjunctival sensitivity, nasal airway resistance). For two months, the patients received ragweed injections at weekly intervals and for two months at monthly intervals.
 - This study has been completed and is being written for presentation and publication.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 78/106

16 cont. Blood was drawn at each visit and stored until completion of the study at which time specific serum IgG and IgE antibody to ragweed was measured.

Publications: none

Presentations: none

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)


(1) Date: 30 SEP 80 (2) Prot No.: 78	/107 (3) Status: Ongoing
(4) Title: AN EVALUATION OF THE EFFICACY	OF ANIMAL DANDER ALLERGY
IH-UNOTHERAPY IN PERENNIAL RH	
	10 Est Gent Patet 1 June 1981
(7) Principal Investigator	(8) Facility: Test
Bryant R. Fortner, J., Maj, MC	
(9) Dept/Sec: Medicine/Allergy	(for 7) westigators:
(11) Key Words:	7
Animal dander	Harold S. Helson, Col. MC
skin test	Alvin J. Aubry, Ltc MC
antibody titers	Gary P. Carpenter, Maj MC
(12) Accumulative Mebanaa (13) Est Accum	ulative Feriodic continue
Cost: None OMA Cost:	None As Alex Results: 6/80
(15) *Study Objective:	and the second s

To evaluate the response to immunotherapy with commercial cat and dog extracts in patients with marked skin test reactivity to these antigens and their response in their perennial symptoms.

(a) feethical Approach:

Patients markedly sensitive to dog or cat danger extract and having perennial symptoms are randomly places on each og or dat dander or placebo extracts for a period of at least megical During this period of time the tissue threshhold is measured by periodic titrated skin tests and titrated masal challenges and the ammunologic response is measured by specific RAST and blocking antibody titers.

study, with seven having completed the study and the remainder are at maintenence and require one further visit for measurement of tissue threshold to cat and dog dander allergens. At the same time blood will be obtained and stored until completion of this study at which time the antibody levels will be determined.



(HSCR 40~23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 8C (2)	Prot No.: 78/1	08	(3) S	tatus:	terminate
(4) Title: Investigation is	nto the Generati	on of Antig	en Spec	ific :	Suppressor
Cells during Allergy Imm	unotherapy				
(5) Start Date:		(6) LSE Con	p Date	:	
(7) Principal Investigator		(8) Facilit	y: FA!	1C	
L.E. Mansfield, MD,	G.L.Brown				
(9) Dept/Sec: Medicine/All	ergy-Imm./CI	(10) Assoc	. Invest	tigato	rs:
(11) Key Words:					
Suppressor cells		none			
(12) Accumulative MEDCASE Cost:	(13) Est Accumi OMA Cost:	lative (14			continue ults: 6/80
(15) *Study Objective: To evaluate the development allergy immunotherapy and formation of IgE.					

- (16) *Technical Approach:
 NA since no work was done on this study.
- (17) *Progress:
 Both of the principal investigators have departed Fitzsimons, and this protocol is consequently terminated. A similar study was conducted by a group of investigators from Italy and reported in the Journal of Immunology in 1980.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

711	Date: 30 SEP 80 (2)	Prot No.	: 78/	109	(3)	Status	: Terminate
(4)	Title: Are Chirrhotic P. Following UG End	atients a					
(5)	Start Date: 30 Sep 79	озсору.	1	(6) Est	Comp Da	te:	1980
_\	Principal Investigator Hugh P. McElwee, MAJ, M	C (cont'	d)	(8) Fac:	lity:	FAMC	
(9)	Dept/Sec: Dept. of Med/	Gastro		(10) As	soc Inv	est igat	ors:
(11)	Key Words: bacteremia, cirrhosis			No	one		
(12)	Accumulative MEDCASE Cost:		Accumu Cost:	lative			Terminate sults:8/80
(15)	*Study Objective: To do higher incidence of barpatients.						

- (16) *Technical Approach: Control patients and patients with cirrhosis have baseline and serial post procedural blood cultures drawn. Blood cultures are collected for both aerobic and anaerobic organisms. Positive results are recorded and if necessary patients are notified and treated.
- (17) *Progress: This protocol was terminated due to Dr. McElwee's leaving FAMC.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 78/109

· 7. continued -

James J. Damato, MAJ, MSC

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2) Prot No.: 78,	/113 (3) Status: Ongoing
(4)	Title: Effects of Salicylic Acid on	Fatty Acid Oxidation in Rat
	Skeletal Muscle Mitochondria	
(5)	Start Date: 4 January 1979	(6) Est Comp Date: June 1982
(7)	Principal Investigator	(8) Facility: FAMC
	Robert F. Jones CFT MC	
(9)	Dept/Sec: Endocrinology Service, DOM	(10) Assoc Investigators:
(Π)	Key Words:	Gerald S. Kidd, LTC, MC
	mitochondrial fatty acid metabolism	David T. Zolock, CPT, MC
	long chain fatty acid: CoASH ligase (A	MP) Fred D. Hofeldt, COL, MC
	salicylic acid	
(12)	Accumulative MEDCASE (13) Est Accum	ulative ((14) Periodic continue
	Cost: OMA Cost:	Review Results: 10/80
(15)	*Study Objective: The principal object	ctive of this protocol is to
dete	rmine the mechanism of salicylate-indu	
oxid	ation by studying the effects of salid	cylic acid and other compounds
on t	he activation step of fatty acid oxide	ation, fatty acid:CoASH ligase
	P)(E.C.6.2.1.3).	
•	•	

(16) *Technical Approach: Rat skeletal muscle mitochondria are isolated from the quadriceps femoris muscle group. Lipase activity is determined using a radio-lipand millipore filter procedure. Calicylic acid, phosphate and NaF are co-incubated with substrates for the lipase reaction. Statistical analysis is performed with a paired t test on individual data points or an unpaired t test on the slopes of the lines generated by double-reciporical plots.

Salicylic acid enhances the rate of fatty acid:CoANH ligade by lowering the Michaelic constant (Km) of palmitic acid from 0.0030 mM in controls to 0.0019 mM (p < 0.001) without effecting the maximal velocity of the reaction. Bose response curves for salicylate are hyperbolic with maximal stimulation (40% over controls) occurring at concentrations of 0.05 mM or greater. At half saturating concentrations of palmitate (preliminary studies), phosphate (5 mM) and NaF (25 mM) both stimulate the ligase

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 78/113

reaction by approximately 50% (p<0.005). The effects of salicylic acid and phosphate are not additive which suggests a possible common mechanism of action whereas the trend of the salicylate and fluoride data suggest that fluoride inhibits ligase stimulation by salicylate. These observations are compatible with the possibility that salicylic acid may indirectly enhance the ligase reaction by facilitating the rate of pyrophosphorolysis (e.g., inorganic pyrophosphatase). Additionally, the fluoride enhancement of the ligase enzyme may imply the presence of an additional controlling factor for mitochondrial fatty acid activation such as a fluoride-sensitve protein kinase. Further studies aimed at clarifying these interactions are being planned.

FAMC WU No (Prot No) 78/333

PRESENTATIONS for FY 80 Annual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE Endocrine DEPARTMENT Medicine

(1) Jones, S.E.: Saticylic Acid Stimulation of Pulmitic Acid Exidation by Bat Skeletal Muscle Mitochondria. Presented: Hugh Mahon Lectureship Award, FAMC, June 1980.

FAMC	WU	No	(Prot	No)	78/113	
-------------	----	----	-------	-----	--------	--

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE <u>Endocrine</u>	DEPARTMENT <u>Medicine</u>
--------------------------	----------------------------

- (1) Jones, R.E., Askew, E.W., Hecker, A.L., and Hofeldt, F.D.: Salicylic Acid Stimulation of Palmitic Acid Oxidation by Rat. Skeletal Muscle Mitochondria. Submitted to Biochim. Biophys. Acta.
- (2) Jones, R.E., and Hofeldt, F.D.: Stimulation of Mitochondrial Long Chain Fatty Acid: CoASH Ligase (AMP) by Salicylic Acid. J. Colorade-Wyoming Acad. Sci. (In press).

AMRUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Just 30 SEr 50 (2) Prot No.:	78/114 (3) Status ongoing
Title: Treatment of Systemic Scler	oderma with Minoxidil (U-1858)
15) Start Date: Jun 79	(6) is tem, Date Feb 81
.,, Principal Investigator	(8) Facility: Felt.
JAMES A. MCCOY, M.D., LTC, MC	
(0) Dept. Sec: Dermatology, DOM	10 % Assoc investigators:
17) ter Words.	JOHN L. AELING, M.D., COL.,MC ROBERT G. CLAYPOOL, M.D.,COL,MC
Systemic Scleroderma/Minoxidil	STEVEN R. BAILEY, M.D., CPT, MC
(12) A amulative MEDOASE (13) Est Acc	complative ((4) feriodic continue
(Costs OMA Costs) OMA Cos	st: Levieu Results: 10/79
A 15 to the Silver Carlot Carlot Enver	

To determine if Minoxidil is a useful, vasoactive drug for the control of systemic scleroderma and the associated Raynaud's phenomena.

n chinical hyphoden:

Patients with systemic scleroderma are entered into this double-blind cross-over study, using Minoxidil in low doses and followed at bi-weekly and monthly intervals. Hospital admissions as indicated for dosage increase and the performance of laboratory studies.

Programme

In June 1979 the first patient was admitted to the protocol; since then a total of 8 patients have entered; five patients have completed the study to date. Computer analysis of objective data is pending; no significant side effects necessitating withdrawal from the study have occured to date. All patients completing the study felt they experienced subjective improvement during the six months they received Minoxidil.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Pate: 30 SEP 80 (2) Prot No.:	78/116 (3) State:on-going
(4) Title: The Effect of Positive an	d Negative Alr lons on Pulmonary
Functions in Patients with Bronchial	Asthma
(5) Start Pate: 1978	(B) the day Dayer indefinite
(7) Principal Investigator	[83] Facility: 1000
Harold S. Nelson, MD, COL, MC	
(a) Dept/Sec: Medicine/Allergy-Immunol	. the accessoring tons:
(11) Key Words:	general community
Small air ions	Farian Dantzler
	Bruce Martin
(12) Accumulative Messall (13) Est Accomplative Messall (13) Est A	ost: Review Results: 10/79
(b) Astudy Dejective: To evaluate the short-term response to an increase in the ambient concentions.	of patients with bronchial asthma

(lo) - feehnical Approach:

Patients with bronchial asthma whose clinical condition was stable will be exposed on two consecutive days for periods of all hours to either an increased concentration of positive or negative scall air ions. The response will be monitored by pulmonary function stables.

(c) Crogress:

Nine patients were studied in the room with manipolistion of small air ion concentration. The results of this first preliminary study are being analyzed and will be presented at the Pulmonary Symposium at Fitzsimons in Japuary, 1981.

ANNUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2)	Prot No.: 78/	117	(3) Status: on-going	
(4) Title: The Effect of P.	arasitic Infesta	tion on	Immediate Skin Test	
Reactions				
(5) Start Date: 1980		(6) Est	Comp Date: 1981	
(7) Principal Investigator			ility: FAMC	
Harold S. Nelson, MD. CO	L. MC			
(9) Dept/Sec: Allergy, DOI	1	(10) A:	soc Investigators:	
(11) Key Words:		L.E. Mansfield, MD, LTC		
IgE parasites	:		n Phanupahak, MD, PhD	
(12) Accumulative MEDCASE Cost:	(13) Est Accum OMA Cost:	ulative	(14) Periodic continue Review Resuits: 10/80	
(15) *Study Objective:				
To determine whether ant high concentrations in n			the IgE class present in	

receptors in the mast cells and in so doing block mast cell sensitization

by IgE antibody directed toward inhaled allergen.

(16) *Technical Approach:

Evidence for mast cell IgE receptor saturation will be sought by comparing the direct immediate wheal and flare skin test to circulating levels of IgE specific for the same allergen. The clinical portion of this study will be performed in Thailand by Dr. Phanuphak. The laboratory portion will be performed at Fitzsimons.

The clinical portion of this study is currently being performed in Thailand.

ANNUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sheet)

(1) Date: 30 SEP 86 (2) Prot No.: 78/ (4) Title: A Precision Measurement of Analysis, Comparison with Fowle	(3) Status: Ongoing atomic Deadspace Using Multiple er's Technique and Application
(5) Start Date: September, 1978	(6) Est Comp Date: 1982
(7) Principal Investigator Michael E. Perry, LTC, MC	(8) Facility: FAMC
(9) Dept/Sec: Medicine/Pulmonary	(10) Assoc Investigators:
(11) Key Words: Deadspace Steady state diffusion	Meal B. Kindig, PhD
(12) Accumulative MEDCASE (13) Est Accum Cost: OMA Cost:	ulative (14) Periodic continue Keview Results: 10/79
(15) *Study Objective: To experimentally procedure for anatomic deadspace measurement over conventional techniques.	confirm a proposed new entswhich has important advantages

(16) *Technical Approach: Deadspace measurements are first performed using the technique of Fowler, with careful attention to insure a constant inspiratory volume and exporatory air flow. This is followed by the multiple inert gas technique whereby two breaths of specific mixtures of argon, neon, and nitrogen are inhaled in a two breath sequence and the exhaled gas from each sequence analyzed on a gas chromatograph. From changes in concentration of the inert gases deadspace is deduced. Extensive modification was made concerning recording

techniques of both methods of deadspace determination. Data on normal individuals has been collected and very precise measurements were made by both techniques. Consistent differences between the two techniques were noted however. A theoretical explanation of these differences was worked out and will be tested using a different sequence of the inert gas mixtures,

using the same inert gases.

Proto No: 78/118

(4) to Steady State Diffusion Estimates.

Publications:

- (1) Kinding, N.B., Martin, B., MOrgan, E. Filley, G.F.: Ventilation Variations at Constant Load Exercise. Federation Proceedings 38:1050, 1979.
- (2) Kindig, N.B., Zimmerer, R.W., Hazlett, D.R.: Automation and Profile; Computer Simulation. Clinical Engineering, 6:68-63, 1978.
- (3) Hazeltt, D.R., Zimmerer, R.W., Kindig, N.B.: Ultrascond of Tissue Characterization. Medical Instrumentation 11:74 379.
- (4) Kindig, N.B., Editor: Proceedings of the 16th enhalt Booky Mountain Bioengineering Symposium and the attendational ISA Biomedical Sciences Instrumentation (ymposium, Biomedical Sciences Instrumentation, 15, Instrument Society of America, Pittsburg, 1979
- (5) Kindig, N.B., Perry, M.E., Filley, G.F.: Gas-Mixing Deadspace: Measurement with Tracer Gases Unbound. (Abst)Max Planck Institute for Experimental Medicine, July 1980.

Presentations:

- (1) Kindig, N.B.: Physiologic Deadspace; Influence of Pattern of Breathing. Presented: 32nd Annual Pulaonary Evaposium, FAMC, Aurora, CO, September 1979.
- (2) Kindig, N.B., Perry, M.E., Filley, 3 % of North Agricultus of Anadspace: Measurement with Tracer Gases. Presented: 190 to ensium on Gas Exchange Function of Normal and Disease rungs, Max Planck Institute for Experimental Medicine, Goettingen, Germany, July 9 11, 1980.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.:	: 78/119 (3) Status: on-going
(4) Title: The Effect of Aspirin on P	Platelet Aggregation in Aspirin
Sensitive Asthmatics	
(5) Start Date: 1578	(6) Est Comp Date: indefinite
(7) Principal Investigator	(8) Facility: FratC
H.S. Nelson, MD, COL, MC	
(9) Dept/Sec Medicine/Allergy-Immun.	Compared to the second of the
(11) Key Words:	
Aspirin sensitivity platelet aggre-	R. E. Danziger, CDR, USN, MC
gation	P.T. O'garr, PhD, DAC
(12) Accumulative MEDCASE (13) Est A	}
Cost: OMA (Cost: Geview Results: 10/79
(15) *Study Objective:	
To determine that has the intellegent	sa ta againin and ather palated sub

To determine whether the intolerance to aspirin and other related substances manifested by some patients with bronchial asthra could be diagnosed by an in vitro test.

(16) *Technical Approach:
The plan is to utilize the platelet aggregation assumend the thromboxane assay to compare the response of platelets from pathods with aspirin sensitivity and control patients.

(17) *Progress:
The patient study portion of the protocol is completed. The results are presently being analyzed and prepared for submission.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.: 7	
(4) Title: Diabetic Treatment Study: Asse	ssment of Metabolic Control and Change
in Quality of Life Following Short Term Trea	tment of Diabetic Patients with Tolaza-
(5) Start Date: pv-8	(6) Est Comp Date: Terminated mide
(7) Principal Investigator	(8) Facility: FAMC
Fred D. Hofeldt, COL, MC	
(9) Dept/Sec: Endocrire Service	(10) Asso. Investigators:
(11) Key Words:	Gary L. Treece, LTC, MC
diabetic treatment oral agents	Francis G. Henderson, MD, Upjohn Moni-
Tolinere	J.T. Keene, Upjohn Medical Assoc. tor
Tolazamide	Annie Shackelford, MT, DAC
(12) Accumulative MEDCASE (13) Est Accum	hulaquaed R: 43amderad (PT, MC continue
Cost: OMA Cost:	Review Results: 1/79
(15) *Study Objective: The objective of t	his double blind pilot study is to
determine if the methodology employed will a	dequarely determine whether maturity-
onset non-ketotic diabetic patients feel and	
blood sugars are controlled.	•
, and the second se	

(16) *Technica! Approach: Patients with moderate diabetes mellitus are introduced into a double blind study where they will be treated with placebo or with Tolazamide tablets. The dose of the piacebo and the foinase is regulated according to blood sugar determinations on frequent follow-up of patients. In addition to controlling the metabolic parameters of the disease as measured by hemoglobin AIC, fasting blood glucose determinations and symptomatic state of the patient, the patient will complete a questionnaire which will assess his quality of life.

Seven patients have entered the study and have completed their long-term follow-up and termination of the study. The study has been terminated as patient recruitment has been determined to be sufficient to merit that data analysis by the Upjohn Company.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(3) Status: on going	
lergenicity between Western Grass	
ns	
(6) Est Comp Date: 1981	
(8) Facility: FAMC	
(10) Assoc Investigators:	
B.G. Martin, MAJ, USAF, MC	
ulative (14) Periodic continue	
Review Results: 12/79	
racts of common western prairie	

To study the cross allergenicity of extracts of common western prairie grasses and to compare them to the already well-studied northern pasture grasses and Bermuda grass.

(16) *Technical Approach:

The approach is to employ a pooled allergic serum and RAST inhibitions with allergen disks manufactured in the allergy research laboratory at Fitzsimons and a variety of commercial allergy extracts.

(17) *Progress:
Extensive studies were performed under this protocol during the preceding year. The data is currently being analyzed and prepared for publication.

(a. a.a.)	FAMC	wυ	No	(Prot	No)		_
						78/12	1	
oress	Report	(:	Ind	Part	οf	Detail	Summary	

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE Allergy-Immurology DEPARTMENT Medicine

(1) Martin, B.G., Mansfield, L.E., Nelson, H.S., Patterns of Cross Allergenicity among Grasses (abstract), Journal Allergy-Clinical Immunology, 65:229;1980.

FAMC WU No (Prot No) 78/121

PRESENTATIONS for FY 80 Annual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE Allergy-Immunology

DEPARTMENT Medicine

(1) Martin, B.G., Patterns of Cross Allergenicity among Grasses, presented at the annual meeting of the American Academy of Allergy, Atlanta, Georgia, 20 Feb 1980

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.:	(2) (4.4.6.
	78/122 (3) Status: Ongoing
(4) Title: Effects of Dietary Fructose	in Diabetes Mellitus.
·	
(5) Start Date: FY78	(6) Est Comp Date: FY81
(7) Principal Investigator	(8) Facility: FAMC
Fred D. Hofeldt COL MC	
Ered D. Hofeldt, COL, MC (9) Dept/Sec: Endocrine	(in) Assoc Investigators:
(11) Key Words:	Phyllis A. Crapo, UCHSC, Denver, co
fructose	Jarrold M. Olefsky, MD, UCHSC, Denver,
diabetes mellitus	Orville G. Kolterman, MD, UCHSC, Denver
diabetes merritus	Jon Insel, MD, UCHSC, Denver, CO
(12) Accumulative MEDCASE (13) Est Acc	
	Review Results: 12/79
	st prandial response of simple carbo-
hydrates (fructose, glucose and sucrose)	and ratural cooked foods (cake and ice
cream) which are prepared with either su	
study is to determine if fructose, a nat	
as an artificial sweetener in diabetic p	
responses to the various test meals will	
stance is the most diabetogenic. Fructo	ose plays an unimportant role in (cont)

Three groups of subjects will be studied to include 1) chemical diabetics, 2) adult onset, non-ketotic diabetics with significant fasting hyperglycemia (plasma glucose levels greater than 140 mg% on three different occasions) and 3) age and weight matched diabetic control patients. These patients will undergo acute studies where their hormonal responses will be determined to glucose, sucrose and fructose and chronic studies where the patient will be fed (17) *Progress:

Only 2 patients have been referred to the medical school for this study. A number of cases have been studied at the medical school and preliminary data suggests that fructose is not diabetogenic and can serve an important role as an artificial sweetener for diabetic patients. The study is ongoing.

Proto No: 78/122

- (15) Study Objective (continued): carbohydrate metabolism; its use as a food sweetener might have therapeutic value in the management of the large diabetic population.
- (16) Technical Approach (continued):
 diets containing mixed test meals of various starches containing calories of
 fructose or sucrose and glucose. Postprandial hormonal responsiveness again
 will be measured. Each of the diets will be fed for a period of 3 weeks.
 At the end of this time the postprandial plasma glucose, insulin and glucagon
 responses will be determined following the ingestion of 50 grams of glucose,
 sucrose and fructose. (As described above.) Likewise, each patient's
 tolerance will be tested with a standard glucose to tolerance test before and
 after the 3 weeks of the chronic dietary period. The influence of diet on
 triglyceride metabolism will be determined by the measurement of VLDL-TG
 production rate and fasting triglyceride levels, before and after the
 dietary period.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.: 78,	
(4) Title: A Comparison of the Zimmerer	and Dubois Techniques of Airway
Resistant Measurements by Body Plethysmogram (5) Start Date: January 1979	phy.
	(6) Est Comp Date: 1982
(7) Principal Investigator	(8) Facility: TAM
Michael E. Perry, LTC, MC	
(9) Dept/Sec: Medicine/Pulmonary	(10) Assum Investigators:
(11) Key Words:	Robert W. Zimmerer, PhD
Alveolar Pressure	Robert J. Browning, BS
Airway Resistance	-
Body Plethysmography	
(12) Accumulative MEDCASE (13) Est Accum	lative (14) Periodic continue
Cost: OMA Cost:	Review Results:1/79
(15) #Study Objective: To compare a clim	cally untried measurement of
airway resistance with a standard technique	

(16) *Technical Approach: Forced expiratory manuevers are performed with the subject seated in a constant volume body alethysmograph, while plethysmograph pressure and airflow are monitored and recorded with a DEC PDP11/10 computer. With this information and the previously determined FRC of the patient, alveolar pressure is calculated throughout the expiratory manuever. Pressure flow relationships are then related to the patient's maximal expiratory flow volume loop.

(17) *Progress: A heated screen pneumotach was selected to reduce uneven heat flux as much as possible. Valving arrangements were adopted to allow venting just prior to forced manuevers, which further induced leak artifact. The computer program was modified to allow for box drift and to account for pneumotach back pressure and to account for non-linear pneumotach airflow response. The computer program was altered and the numerical integration procedure discontinued because of problems with cumulative error. A significant relationship was found between great fluctuations in

Proto No: 78/123

(17) alveolar pressure at constant flow rates when flow maximums have been reached on the flow volume envelope.

FAMC WU	No	(Prot	No)	78	/123
---------	----	-------	-----	----	------

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE Medicine DEPARTMENT Pulmonary

- (1) Perry, M.E., Zimmerer, R.W., Browning, R.J.: Non-Invasive Alveolar Pressure/Flow Pattern Determination by Computerized Plethysmography (Abstract) Symposium on Computers in Critical Care in Pulmonary Medicine, Page 47, June 1980.
- (2) Parry, M.E., Zimmerer, R.W., Nelson, R.A., Browning, R.J.: Non-Invasive Determination of Alveolar Pressure-Flow Relationship (Abstract) American Review of Respiratory Disease, Volume 121, Page 389, April 1980.
- (3) Zimmerer, R.W., Perry, M.E., Browning, R.J.: Expiratory Pressure/Flow Assessment by Plethysmography (Abstract) AAMI 15th Annual Meeting, Page 246, April 1980.

s in the base supplied in

FAMC WU No (Prot No) 78/123

PRESENTATIONS for FY 80 Annual Progress Report

SERVICE	Medicine	DEPARTMENT_	Pulmonary

- (1) Perry, M.E., Zimmerer, R.W., Browning, R.J.: Non-Invasive Alveolar Pressure/Flow Pattern Determination by Computerized Plethysmography, presented at the annual Computers in Critical Care and Pulmonary Medicine, Lund, Sweden, June 3-6, 1980.
- (2) Zimmerer, R.W., Perry, M.E., Browning, R.J.: Expiratory Pressure/Flow Assessment by Plethysmography, presented at the AAMI 15th Annual Meeting, San Francisco, April 13-17, 1980.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.: 78/	124 (3) Status: Ongoing
(4) Title: A Self Consistent Method of Si	ngle Breath DLCO Measurement
(5) Start Date: September, 1978	(6) Est Comp Date: 1982
(7) Principal Investigator	(8) Facility: Fam.
Michael E. Perry, LTC, MC	
(9) Dept/Sec: Medicine/Pulmonary	(10) % of lovestigators:
(II) Key Words:	Noai B. Kindig, PhĎ
Single breath diffusion	Robert J. Browning, BS
Alveolar gas	
Breathing patterns	
(12) Accumulative MEDCASE (13) Est Accum	alative (14) Periodic continue
Cost: OMA Cost:	Review Results: 1/79
11:	confirm a proposed new method of
TLCO measurement.	a proposed new medical of

(16) *Technical Approach: Data will be sampled during the single breath DLCO determination at various breath holding times and at various exhaled lung volumes. Data will be analyzed offline by computer which will correct for volume averaging and effective breath holding time. If the theoretical approach as outlined in the original protocol is selfconsistent, the calculated diffusion capacity should remain constant regardless of breathing pattern or gas collection timing.

(17) *Progress: Special instrumentation was designed specifically for this protocol by Fogg Systems, Inc. There were many unanticipated difficulties in proper instrumentation design, but over the past year these have all been corrected and the assembled control mechanism is in place in the Pulmonary Function Laboratory. All valving assembly is now complete. At this time the actual computer program is being written by the computer specialist. Much delay was encountered late in the fiscal year because of failure of ADP equipment, which has since been corrected. We anticipate operation of this system

Proto No: 78/124

(17) within sixty days at which time data collection for the protocol itself can begin.

Publications:

(1) Kindig, N.B., Hazlett, D.R., Filley, G.F.: "Timing and Volume Averaging in Single Breath DLCO Measurement". The Physiologist, 21:64, 1978.

Presentations:

(1) Zimmerer, R.W.: Simulated Diffusion Testing. Presented: 32rd Annual Pulmonary Symposium, FAMC, Aurora, CO, September 1979.

ANNUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.: 78	/125 (3) Statuy: Terminated
Title: Adjuvant Therapy of Premenopau	sations with EBH 190 Breast
Cancer with CMF alone versus C	MF plus Tamoxifer and EBP (-) (CONT'D)
	[(6) E 10) 12 March 1930
(7) Principal Investigator	(16) Fax (1) Property
JOHN C. MICHALAK, MD, LTC, MC	
(9) Dept/Sec: HEM-ONC, Medicine	[[[the state of the constant o
(II) Key Words:	1
Breast CA, chemotherapy	S. J. DIBELLA, MD. CGL, MC
(12) Accumulative MEDCASE (13) Est Accum Cost: OMA Cost:	i ulative VII- Pevilseic continue me.les Results: 3/80
(15) *Study Objective: 1. To determine whether therapy with an additive effect to adjuvant chemot with EBP (+) breast cancer who are at	herapy in premenopausal patients

2. To determine whether the results of adjustmat chemotherapy with CMF can be improved by first giving & morths of defocitive chemotherapy with adriamycin and vincristine in promonople sall pellents with EBP (-) creast affectinical Approach cancer.

This is a randomized clinical study of the Galandi decelegy Group.

Aprogress: Six patients have been enter domes take for one to the Pederate myelosuppression has been objected in the particular reguling desc reductions. One patient (Po) superferent my eiter is recetten and had to be taken off the study. Allenge evaluation, a liminarily suggests the reaction was due to Methotrevate. The ends patients continue on study without evidence of disease. The right patient relapsed (FW) after being off CMF for one month, with bony metastasis.

Proto No: 78/125

TITLE: Breast Cancer with CMF alone versus Adriamycin and Vincristine

followed by CMF.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 ((4) Title: The Systemation With Skill. Evaluation with Skills	c Evaluation of U	7126 (3) <u>Status: terminated</u> Urticaria: 1. Response to Therapy
(5) Start Date: 1978		(6) Est Comm Date: terminated
77) Principal Investigat H.S. Nelson, MD, COL,		(8) Facility: 1:40
(9) Dept/Sec: Medicine/Al (11) Key Words: Chronic urticaria Cinet		(10) Assoc Havestigators:
chronic utileatia cine	raine	G.B. Carpenter
(12) Accumulative MEDCAS Cost:	E (13) Est Accum OMA Cost:	nulative (14) Periodic continue Review Results: 3/80
(15) *Study Objective:		

To ascertain the effectiveness of Cimetidine combined with an Hl blocker in the treatment of chronic urticaria, and to examine the histologic features of chronic urticaria.

(16) *Technical Approach:

A double blind evaluation of the effectiveness of combined H1 and H2 blockers together compared to H1 blockers alone was planned. In addition, patients with chronic urticaria were to obtain skin blopsies.

(17) *Progress:

By the time permission had been obtained to complete the study and the appropriate active and placebo drugs had been performed, the several investigators had reported the results of similar studies. Therefore, it did not appear appropriate to continue the protocol.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2) Prot No.:	78/127 (3) Status: Terminated
(4)	Title: Does Neoplastic Disease Pro	oduce a Positive Secretin Test?
(5)	Start Date: 30 Sep 79	(6) Est Comp Date: 1980
(7)	Principal investigator	(8) Facility: FAMC
	Hugh P. McElwee, M.D., MAJ, MC	
(9)	Dept/Sec: Dept of Med/Gastro	(10) Assoc Investigators:
(11)	Key Words: secretin	Nuvia Jarvis, SP5
(12)	Cost: OMA Co	
(15)	*Study Objective: To determine in neoplastic disease.	the secretin test is positive in

- (16) *Technical Approach: The secretin test is tell to be specific for diagnosis of the Zollinger Ellison syndrome. We have an index case of one patient with oat cell carcinoma who had a rositive secretin test and no evidence of Z-E at autopsy. We are the refore testing certain patients with hormonally active cancers to see if they produce positive secretin tests.
- (17) *Progress: This protocol has been terminated due to Dr. McElwee's leaving FAMC.

Proto No: 78/127

7. continued -

Nicholas J. DiPella, LTC, MC Steven Bailey, CPT, MC

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.: 78	/128 (3) Status: Completed					
(4) Title: Assessment of Postprandial Pla	sma Glucose, Insulin and Glucagon					
Response to Different Orally Administered	Complex Carbohydrates in Diabetic Subi.					
Response to Different Orally Administered (5) Start Date: 1778	(6) Est Comp Date: Completed					
(7) Principal Investigator	(8) Facility: FAMC					
Fred D. Hofeldt, COL MC						
(9) Dept/Sec: Endocrine Service	(10) Assoc Investigators:					
(11) Key Words:	Phyllis A. Crapo, RD, UCHSC, Denver,CO					
diabetes	Jerrold M. Olefsky, MD, UCHSC, Denver					
	Orville G. Kolterman, MD, UCHSC, Denver					
complex carbohydrates	, , , , , , , , , , , , , , , , , , ,					
hormonal responses	<u> </u>					
	ulative ((14) Periodic complete					
Cost: OMA Cost:	Review Results: 5/80					
(15) *Study Objective: To establish if fe	eding different simple and complex					
carbohydrates substantially affect plasma glucose and insulin values. This						
project will use mild diabetics, moderately severe diabetics and age and weigt-						
matched, non-diabetic controls in a paired analysis of their response in plasma						
glucose, plasma insulin and plasma glucago	n to 50 grams of carbohydrate					
presented as various meals.						
Francisco en inicon monitor						

(16) *Technical Approach: Selected diabetic patients suitable for the study were studied at the University of Colorado Medical Center, General Clinical Research Unit, where their plasma glucose, insulin and glucagon responses were determined following the ingestion of glucose, potato, rice, corn and wheat (breach starch). The test meals were given in a random order to these diabetic subjects. Statistical analysis on data will be carried out by the use of the paired t test for dependent means.

(17) *Progress:

The study is completed. Approximately 4 of the group of patients studied were from Fitzsimons Army Medical Center. The major findings of the study were that the postprandial glucose response to different starches is quantitatively different. In order of less carbohydrate intolerance to more carbohydrate intolerance, the following ranking of starches was noted: rice, wheat bread, corn, potatoes. Noteworthy, potatoes and glucose were equally diabetogenic in this group of patients.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(4)	Date: 30 SEP 80 (2) Prot No.: 78. Title: Respiration During Sleep in My.							
(5)	Start Date: FY'8	(6) Est Comp Date: FY80						
(7)	Principal Investigator	(8) Facility: FAMC						
Leona	rd R. Sanders, CPT, MC							
(9)	Dept/Sec: Endocrine	(10) Assoc Investigators:						
(11)	Key Words:	Fred D. Hofeldt, COL, MC						
	myxedema	Clifford Zwillich, MD, Consultant						
	respiration							
_	hypothyroidism							
(12)	Accumulative MEDCASE (13) Est Accum	ulative (14) Periodic continue						
	Cost: OMA Cost:	Review Results: 8/80						
(15)	5) *Study Objective: The objective of this study is to determine whether							
sleep	ents with myxedema have abnormalities which in turn might explain the dayt somnolence.	in respiration which occur during ime symptoms of fatigue and						

The second secon

(16) *Technical Approach: At least six uncomplicated, adult myxedema patients will be studied after their myxedema is confirmed by clinical examination and laboratory determinations. After myxedema is determined, the patient will have his ventilatory drives to hypoxia and hypercapnia as well as normal ventilation studies determined. He will then go to the Cardiopulmonary Research Unit at the University of Colorado where a sleep study will be performed. The study will consist of two consecutive nights of sleep where the patient will (17) *Progress:

Eight patients have been studied with varying degrees of hypothyroidism to profound myxedema. These patients have been noted to have a sleep apnea syndrome with marked cardio-pulmonary variations when monitored in the sleep laboratory in the hypothyroid state. These abnormalities are reversed with thyroid hormone.

Proto No: 78/129

(16) Technical Approach (continued): have his EEG monitored, heart monitored with an electrocardiogram, respiratory pattern monitored with a strain gauge attached to the patient's chest wall and oxygen saturation determined by the means of an ear oximeter. The patient will then be replaced with thyroid normone and after there is documentation that the patient is euthyroid both by clinical examination and laboratory values, the above sleep study will be repeated.

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary

Sheet.)

SERVICE Endocrine

DEPARTMENT Medicine

(1) Zwillich, C., Sanders, L., Pickett, C., Hofeldt, F.D., and Weil, J.: Prolonged Apnea and Hypoxemia During Sleep in Myxedema. (Abst.) Clinical Research 28:86A, 1980.

Presentations: None

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.: 7	9/100	(3) Status: Completed		
(4)	Title: Investigation					
` ,	Sodium-L-Ascorbate and	5-FU Chemother		ansplanted B16 Melanoma of		
(5)	Start Date February 19			Comp Date: March 1980 Mice		
(7)	Principal Investigator	•	[(8) Fac	ility: FAMC		
•	N. J. MARTIN, MD, MAJ	, MC				
(9)	Dept/Sec: HEM-ONC, M	edicine	(10) A	ssoc Investigators:		
(11)	Key Words:		1			
	5FU, Ascorbic acid		WILSON	C. BOURG, MD, MAJ, MC		
(12)	Accumulative MEDCASE	(13) Est Accum	nulative	(14) Periodic continue		
, ,	Cost:	OMA Cost:		keview Results: 2/80		
(15)	*Study Objective:					
	To evaluate the possible synergism of 5-fluorouracil and sodium-L-ascorbate against sumor cells in vivo.					

(16) *Technical Approach:
The B16 melanoma was transplanted into the BFD₁ Jackson Laboratory male mouse hosts. An optimal tumor cell number was established to provide and 18-22 day range of mouse death. This was 75,000 cell/cu.mm. In addition to this, the maximum safe dose range for 5FU was established in the BFD₁ hybrid Jackson mouse and this maximum safe dose of 5FU was found to be 20mg/kg. (See Continuation Sheet)

(1/) *Progress:

No additive or synergistic effect was observed with 5-FU and ascorbic acid compared with 5-FU alone.

Proto No: 79/100

16. The mice were divided into five groups; groups 1 through 4 received the Bl6 melanoma. Group 5 was a controlled group which received only sodium chloride injections. Group 1 received only oral vitamin C as therapy in a concentration of 0.1%. Group 2 received no ascorbate but only 5FU given on Days 2 through 10 via intraperitoneal injection. Group 3 received oral vitamin C in the previously mentioned concentration and intraperitoneal 5FU in the previously mentioned dose and concentration. Group 4 received Bl6 melanoma only. Group 5 received no Bl6 melanoma but received vitamin C at 0.1% daily until death and 5 FU at the previously mentioned concentration.

(HSCR 40-23, App. C.) (Detail Summary Sheet)

	Date: 30	SEP 30	(2)	rot N	0.:	79/101	31	Status:	ONGOING	
	Title:									
The	Relationsh	ip of Gra	nuloma	a Annu	lare (GA) To Dia	abetes M	ellitis	(DM).	
(5)	Start Date	: Mar	79			(6) Est	Comp Do	Jun	81	
	Principal					(8) Fac	ility:	FAMC		
GENE	E. GRAFF,	D.O., MA	J, MC							
	∪ept/Sec:					(10) As	500 Inv	estigato	rs:	
	Key Words					BERNAF	RD F. DA	VIES, M.I	O., MAJ. M COL, MC	ſС
Gran	uloma Annu	lare				JOHN I	. AELING	G, M.D.,	COL, MC	
Diab	etes Melli	tis				D.M.	TRONG	M.D. WRA	COĹ, MC	
	Tvping					GEORGE	L. BRO	WN, PhD.,	, COL, MSC	
(1.2)	A-cumulat	ive HEDCA	SE (1	3) Es	t Accun	nulative	(14) Pe	riodic c	ontinue	
	Cost:			011	A Cost:				ilts: 5/80)
(15)	-Study US	inctife:								

To determine if an association exists between GA and DM by special laboratory procedures, including PLA typing.

16) Technical Approach:

Patients with biopsy proven GA are studied for concurrent DM historically, clinically, and following oral and intravencus glucose challenge. HLA typing is also done. Baseline studies include: Complete physical exam, CBC, sedimentation rate, SMA-18, triglycrides, cholesterol, HLDL, two-hour pc blood glucose, TSN, T-3, T-4, Resin uptake T-3, EKG if indicated. Parameters monitored following glucose challenge include: Serum insulin, glucose, glucagon, growth hormone, cortisol.

Since the beginning of this study eleven patients have been identified and included in this study. Ten have been completely studied (except for HLA typing, which will be done terminally). Thus far, two patients have been shown to be diabetic and one has idiopathic reactive hypoglycemia. There has been a paucity of cases identified over this past year.

ANNUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.: 79	0/102 (3) Status: Completed
(4) Title: Mechanism(s) of Insulin Resist	
Fetween Fitzsimons and Endocrine Division,	University of Colorado Medical Center
(5) Start Date: py7g	(6) Est Comp Date: Perminated
(7) Principal Investigator	(8) Facility: FAMC
Tary L. Treece, MD, LTC, MC	
(9) Dept/Sec:	(10) Assoc Investigators:
(11) Key Words:	None.
obesity	
insulin resistance	
(12) Accumulative MEDCASE (13) Est Accur	mulative (14) Periodic continue
Cost: OMA Cost:	Review Results: 7/80
(15) #Study Objective: Insulin resistance	e is a characteristic feature of
Sherity and has been casually implicated i	
of the obese state. However, the mechanis	ams responsible for insulin resistance
In aboutly are not known. The plan is to	develop in vivo insulin dose response
sarved in obese human subjects in order to	delineate the mechanisms of insulin
reclistance in obese humans and to assess t	the relationship between in vitro
to make the time and is vivo inculin action	n
inguling binding and in vivo insulin action (T6) Freehnical Approach:	••
	l

the in vivo insulin-glucose uptake dose response curves in insulin resistant of a patients. Additionally, hepatic glucose production will be simultaneously determined in all studies to quantitate the contribution of this variable to total placose turnover, and to assess the ability of different steady state

(17) #Progress:

me patient in this study was referred to the University of Colorado for study. The study has subsequently been completed by UC using their own subjects from their own patient population. Analysis of data is pending.

Proto No: 79/102

(16) Technical Approach (cont):

plasma insulin levels to suppress the liver's capacity to secrete glucose. Finally, in vitro measurements of adipocyte insulin receptors will performed so that the relationships between overall in vivo insular tivity and insulin receptors can be assessed.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2								
(4) Title: An Evaluation of Combined H1 and H2 Receptor Blocking Agents in								
the Treatment of Seasona	al Allergic Rhini	nitis						
(5) Start Date: 1979		(6) Eut Comp Date: 1981						
(7) Principal Investigato		(8) Facility: FAMC						
Harold S. Nelson, MD, CO								
(9) Dept/Sec: Medicine/All	ergy-Immunol.	(10) Assoc Investigators:						
(11) Key Words:		7						
Histamine receptor block	ing agents	C.B. Carpenter, MAJ, MC						
		A. Bunker-Soler, MAJ, MC						
(12) Accumulative MEDCASE	(13) Est Accum	mulative (14) Periodic continu	ē					
Cost:	OMA Cost:	: Review Results: 7	/8o					
(15) *Study Objective:								

To determine whether the addition of a blocker of the H2 receptor would provide greater symptomatic relief in patients with allergic rhinitis than was provided by an H1 blocking agent alone.

(16) *Technical Approach:
A double blind cross over study was performed during the weed season of 1979. In this study patients continuously received an HI blocker (Chlorpheniramine) and alternately for two week periods received either a placebo or Cimetidine, an H2 blocker. Patients recorded symptoms twice daily throughout the weed season.

(17) *Progress:
The clinical study was performed during the weed season of 1979. The data is still in preparation for final publication.

FAMC	WU	No (Prot	No)
			70/107

79/103

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE Allergy-Immunology DEPARTMENT Medicine

(1) Carpenter, G.B., Bunker, A.L., Nelson, H.S., An Evaluation of Combined H1 and H2 Antagonists in the Treatment of Seasonal Allergic Rhinitis (abstract), Journal of Allergy and Clinical Immunology, 65:187;1980

FAMC WU No (Prot No) 79/103

PRESENTATIONS for FY 80 Annual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE Allergy-Immunology

DEPARTMENT Medicine

(1) Carpenter, G.B., An Evaluation of Combined Hl and H2 Antagonists in the Treatment of Seasonal Allergic Rhinitis, Annual Meeting of American Academy of Allergy, Atlanta, Georgia, 18 Feb 80.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No	.:	79/104	(3	Status:	Ongoing
(4)	Title: Vindesine in th	e Treatme	nt	of Cance	r		
(5)	Start Date: Sep 1979			(6)	Est Comp	Date: 1981	
(7)	N. incipal line stig to	, MC		(8)	Facility:	FAMC	
(9) (11)	Dept/Sec: Hematology- Key Words: Chemotherapy	Oncology		(10)) As soc Tr None	ivest igato	rs:
(12)	Accumulative MEDCASE Cost:			cumulat ost:		Periodic co Review Res	
(15)	*Study Objective:						
	To test the efficacy CA of the breast an			nt in me	lanoma, CA	of the es	ophagus,

(16) *Technical Approach: Clinical study

(17) #Progress:

Four patients have been treated with this agent. One patient with lymphoma has experienced a complete response, but the other three have progression of disease. Neurotoxicity and marrow suppression have been observed.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) (4) Title: Breathing Patte	Prot No.: 79	/105 teady State	(3) Status: Ongoing
(5) Start Date: November	1979		pp Date: 1981
(7) Principal Investigator Michael E. Perry, LTC, MC		(8) Facili	
(9) Dept/Sec: Medicine/F (11) Key Words: Steady state DLCO Breathing pattern	ulmonary Diseas	(10) Assoc Neal B. Kir	investigators: ndig, PhD
(12) Accumulative MEDCASE Cost:	(13) Est Accum OMA Cost:	ulative (17	Periodic continue Review Results: 10/79
			coretically determined diffusion studies.

- (16) *Technical Approach: Various breathing patterns consisting of a normal pattern with end expiratory breath hold, similar pattern without end expiratory breath hold, a square rated breathing pattern with breath hold after inspiration, and a square rated breathing pattern at end expiration will be performed while the subject performs the standard steady state diffusion protocol.
- (17) *Progress: Because of other priorities with other protocols very little progress was made this past year except for establishing the response time of the carbon monoxide sampling head. However, a theoretical analysis was worked out which allows us to correct for back pressure occurring in the pulmonary capillaries as carbon monoxide slowly accumulates during the manuevers.

FAMC	٧٧ ت	No (Prot	No)	79/105

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE Medicine DEPARTMENT Pulmonary Disease

(1) Kindig, N.B., Perry, M.E., Browning, R.J.: DLCOSS Correction Using PaCO Back Pressure Predicted From Venous Blood (Abstract) Page 107, April 1980.

FAMC WU No (Part No) 79/105

PRESENTATIONS for FY 80 Annual Progress Report

SERVICE Medicine BEPARTMENT Pulmonary Disease

(1) Kindig, N.B., Perry, M.E., Browning, R.J.: DLCOss Correction Using PaCO Back Pressure Predicted From Venous Blood, AAMI 15th Annual Meeting, San Francisco, April 13-17, 1980.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2) Prot No.: 79	9/106 (3) Status: Ongoing		
(4)	Title: Measurement of Lung Compliance	ce Utilizing Pulmonary Capillary		
Wedge	Pressures.			
(5)	Start Date: January 1979	(6) Est Comp Date: Dec, 1981		
(7)	Principal Investigator	(8) Facility: FAMC		
Michae	el E. Perry, LTC, MC			
(9)	Dept/Sec: Medicine/Pulmonary	(10) Assoc Investigators:		
(11)	Key Words:	Robert Zimmerer, PhD		
Wedge	pressure			
77-5				
(12)	Accumulative MEDGASE (13) Est Accu			
	Cost: OMA Cost			
(15)	*Study Objective: u account			

(15) *Study Objective: Validation of lung compliance measurement using pulmonary capillary wedge pressure by simultaneous comparison with esophageal pressure.

(16) *Technical Approach: Using simultaneous measurements of intrathoracic pressure via Swan Ganz Catheter and intraesophageal balloon, as well as inhaled lung volume using a pneumotachograph, and airway pressure with pressure transducer attached to the endotracheal—be. Relationships between wedge pressure, esophageal pressure, airway pressure and lung volume will be sought and attempts at correlation made. The monitoring of these various parameters and their correlation with each other will require special (17) *Progress: The design of this special unit has been completed and most of the necessary parts have been ordered and received. Actual construction of the apparatus is in progress at this time.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT Proto No: 79/106 (Blocks 1 through 17)

(16) equipment to record and correlate data.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Petail Summary Sheet)

(1) Da	ite: 30 SEP 80 (2) Prot No.: 79	/107 (3) Status: Ongoing			
(4) Ti	tle:The Effects of Fructose on React	tive Hypoglycemia			
(5) St	art Date: FY79	(6) Est Comp Date: FY83			
	incipal Investigator	(8) Facility: FAMC			
Fred D	Hofeldt COL MC				
	ept/Sec: <u>Fndocrine</u>	(10) Assoc Investigators:			
(11) K	(ey Words:	None.			
	reactive hypoglycemia Tructose				
(12) is	Accumulative MEDCASE (13) Est Accum	ulative (14) Periodic continue			
C	Cost: OMA Cost:	Review Results:3/80			
(15) *	Study Objective: The objective of	this study is to determine whether			
fructos	e, insulin and counter-regulatory horm se solutions and fructose meals. Par ia previously identified as having the Center will be further studied under	tients with bonafide reactive hypo- his disorder at Fitzsimons Army			
(16) *Technical Approach: Patients with standard dietary intake will undergo the glucose tolerance test with measurements of insulin, glucagon and counterregulatory hormones in response to either glucose, sucrose or fructose as a test solution or meal. Glucose clamp study to determine insulin sensitivity will be performed in an adipose tissue biopsy for measurement of in vitro insulin sensitivity in insolated adipose sites. It will be performed on each subject.					
each subject. (17) *Progress: Approximately 7 patients have entered the protocol. The preliminary findings in this group indeed support the hypothesis that reactive hypoglycemia has not been observed in individuals when exposed to either fructose solution or fructose cakes. This has been an observation in patients with diabetic reactive hypoglycemia, idiopathic reactive hypoglycemia and alimentary reactive hypoglycemia. Inasmuch as patients with reactive hypoglycemia have been shown to be food abusers, it may well be that fructose food substitution may be an important (cont)					

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 79/107

(15) Study Objective (continued):
University of Colorado Health Sciences Center. Each patient will be studied with varying test means consisting of simple carbohydrates (glucose, sucrose, fructose), or natural foods in a chocolate cake containing either sucrose or fructose. Patients will be monitored for 5 hours post prandially with measurements of plasma glucose, insulin and counter-regulatory hormones. It is hypothesized that fructose inasmuch as it is not metabolized along traditional glucose pathways will serve as an artificial sweetener for patients with reactive hypoglycemia as this food substance will not be a potent glycemic stimulus and will not cause a marked release in insulin discharge.

(17) Progress (continued): therapeutic modality in this group of patients.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2)	Prot No.: 79/	/108 (3) Status: on-goin
(4) Title: The Effect of Be	eta Adrenergic B	Bronchodilators on Serum Immuno-
globulin-G Levels		
(5) Start Date: 198		(6) Est Comp Date: 1981
(7) Principal Investigator	·	(8) Facility: FAMC
H.S. Nelson, MD, COL, M	MC	
(9) Dept/Sec: Medicine/Alle	ergy-Immunol	(10) Assoc Investigators:
(11) Key Words:		none
Immunoglobulin bronchodi:	lators	
bronchial asthma		
(12) Accumulative MEDCASE		nulative (14) Periodic continue
Cost:	OMA Cost:	Review Results: 1/8
(15) #Study Objective:		

To determine whether chronic administration of seta adrenergic agonists depressed serum levels of immunoglobulin-G.

(16) *Technical Approach:

To study the immunoglobulin-G levels of patients with bronchial asthma prior to their beginning therapy with beta agonists and periodically while they continue on the drugs.

(17) *Progress:

This study has not yet been started.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.: 79/	109	(3)	Status:	Ongoing
(4)	Title: Control of Naus	sea and Vomiting	with De	1ta-9-te	etrahydro	-cannabinol
	(THC) Combined	with Standard A	ntiemeti	cs (A Pl	nase II S	tudy)
(5)	Start Date: June 1980		(6) Est	Comp Dá	te: 1981	
(7)	Principal Investigator		(8) Faci	lity:	FAMC	
	NICHOLAS J. DIBELLA, M	.D., COL, MC				
(9)	Dept/Sec: C, Hematology	y/Oncology Svc	(10) As	soc Inve	estigator	`5:
TI	Key Words:		RICHARD	A. ARTI	M, M.D.,	CPT, USAF, MC
. ,	Chemotherapy, nausea,	and vomiting	MICHAEL	L. LANC	GIN, CPT,	MSC,
	control.				P	harmacist
(12)	Accumulative MEDCASE	(13) Est Accumi	lative	(14) Pe	riodic co	ntinue
	Cost:	OMA Cost:		Re [*]	view Resu	ilts: 2/80
(15)	*Study Objective:					
	1) To determine if THO	C h <mark>as a use</mark> ful s	ntiemeti	c effect	when ad	ded to
	standard antiemetic	c regimen.				
	2) To determine if the	-	ect is a	dditive	or poten	tiating.
	3) To determine if THO					
	who do not respond					•
	wite an une repland	co beandard and		-		

- (16) *Technical Approach: Clinical study
- (17) *Progress:
 Twenty three (23) patients have been entered on this protocol,
 approximately 1/3 double blinded. Four (4) patients have died from
 their disease. Two (2) patients were removed from the study due to
 mild CNS changes at their request. The rest of the patients tolerated
 the THC very well with good control of their nausea and vomiting.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2)			(3) Status:	on-going	
(4) Title: Evaluation of L					
Challenge in Patients wi	th a History of	an Adver	rse Reaction to L	ocal Anesthetic	
(5) Start Date: 1979		(6) Est	Comp Date: indef	inite	
(7) Principal Investigator H.S. Nelson, MD, COL. MC		(3) Fac	ility: FAMC		
(9) Dept/Sec: Medicine/Allergy-Immunol, (10) Assoc Investigators: (11) Key Words: Local anesthetic adverse drug reaction multiple					
(12) Accumulative MEDCASE Cost:	(13) Est Accumo OMA Cost:	ulative	(14) Periodic co Review Resu		
(15) *Study Objective: to confirm the safety an large number of patients			gressive challeng	e in a	

(16) *Technical Approach:

reactions to local anesthetics.

Patients with a history of an adverse reaction to local anesthetics will undergo progressive challenge with these drugs as has been practiced over the last eight years in the Fitzsimens Allergy Clinic. The historical data and results of challenge will be accumulated for future correlations.

(17) *Progress:

Patients are being studied under this protocol at several instillations.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 8) (2) Prot No.: 79	7/111 (3)	Status: on-going
(4) Title: A Comparison	of the Developme	ent of Sensitivity	y to Penicillin
in Normal and Atopic I		•	
(5) Start Date: 1980		(6) Est Comp Da	te: 1981
(7) Principal Investigat	or	(8) Facility:	FAMC
H.S. Nelson, MD. COL, I			
(9) Dept/Sec: Medicine/A.	llergy-Immunol.	(10) Assoc Inv	estigators:
(11) Key Words:		7	_
Penicillin allergy		A. Eunker-Sole:	r
		C. Wagner	
(12) Accumulative MEDCAS	E (13) Est Accum	mulative (14) Pe	riodic continue
Cost:	OMA Cost:		view Results: 2/80
(15) *Study Objective:			

To determine the frequency with which normal and atopic individuals develop positive immediate wheal and flare skin test to Penicillin following a course of therapy with the drug.

(16) *Technical Approach:

Children scheduled to receive a course of Penicillin therapy will be skin tested prior to receiving the course of therapy to both Penicillin and several pollen allergens. They will return for follow-up skin testing several weeks after completing the course of therapy. Data will be analyzed in terms of the frequency with which patients have unexpected positive skin test to Penicillin that they develop positive--cont.

(17) *Progress:
Patients are currently being studied under this protocol.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 79/111

16 skin test following a course of therapy and the relation of this to the evidence of allergy as demonstrated by positive skin test to inhalant allergens.

ANNUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.: 79/	112	(3) Status: Ongoing
(4) Pat	Title: Use of Sodium Sients with No Therapeu	Salt of Allopuri tic Alternative.	nol to (ontrol Hyperuricemia in
(5)	Start Date: March 198	30	(6) Est	Comp Date: 1983
(7)	Principal Investigator N. J. DIBELLA, MD, COL	, MC	(8) Fac	ility: FAMC
(9)	Dept/Sec: HEM-ONC, Me	edicine	(10) A	ssoc Investigators:
(11)	Key Words:			-
	Hyperuricemia, allopu	urinol	MICHAEL	LANGIN, CPT, MSC
(12)	Accumulative MEDCASE Cost:	(13) Est Accum OMA Cost:	ulative	(14) Periodic continue Review Results: 3/80
(15)	*Study Objective:	- <u>-</u>		
	To provide a parenter when the patient is	ral form of allo inable to take t	purinol he table	to control hyperuricemia t form (commercially

available).

The state of the s

- (16) *Technical Approach: Clinical study.
- (17) *Progress: One patient has been treated successfully and without ill-effects.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2) Prot No.: 79	/113 (3) Status: Terminate
(4)	Title: Vindesine in the Treatment of	
(5)	Start Date: June 1980	(6) Est Comp Date: January 1981
(7)	Principal Investigator	(8) Facility: FAMC
	N. J. DIBELLA, MD, COL, MC	
(9)	Dept/Sec: Hem-Onc, DOM	(10) Assoc Investigators:
$\overline{(11)}$	Key Words:	
	CA colon, chemotherapy	MICHAEL LANGIN, CPT, MSC
(12)	Accumulative MEDCASE (13) Est Accur	nulative ((14) Periodic continue
(/	Cost: OMA Cost:	
(15)	*Study Objective:	
	To determine the efficacy of vinde recurrent or metastatic CA of the	

- (16) *Technical Approach:
 Clinical study.
- (17) *Progress:

One patient was treated with this regimen and failed to respond; no significant toxicity was observed.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Letail Summary Sheet)

$(T)_{-}$	Date: 30 SEP 30 (2	Prot No.:	79/114	(3) Státus:	Ongoing
(4)	Title: Vindesine and	Cis-platinum	in the Tre	atment of Unrese	ctable
	Carcinoma_of_t	he Lung			
(5)	Start Date: Jun 1980		(6) Est	Comp Date: 198	1
(7)	Principal Investigato	L, MC	(8) Fac	cility: FAMC	
(9)	Dept/Sec: Hematology	-Oncology	(10) /	Assoc Investigato	ors:
$\overline{(11)}$	Key Words:			-	
	CA lung, chemotherapy				
(12)	Accumulative MEDCASE Cost:	(13) Est Acc		(14) Periodic c	
(15)	"Study Objective:	·····		_ 	
	To test the efficacy advanced CA of the l		gs in two	different schedu	les in

- (16) *Technical Approach: Clinical study.
- (17) *Progress:

Three patients have been treated with this protocol. One partial response has been observed. One patient had progression of tumor and the third patient is too early to evaluate.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.: 79/	115	(3)	Status:	Terminate
$\overline{(4)}$	Title: The Effect of					
	5-Fluorouracil	on Metastatic C	olo-Recta	al Cance	r	
(5)	Start Date: Jun 1980		(6) Est	Comp Da	te: Mar	1980
(7)	Principal Investigator	•	(8) Fac	ility:	FAMC	
	N. J. DIBELLA, MD, COL	_, MC	l Hema	atology-	Oncology	
(9)	Dept/Sec: Medicine		(10) A	soc Inv	estigato	rs:
(11)	Key Words:		1			
	Colon CA, 5-Fil, chemot	therapy	Non	e		
(12)	Accumulative MEDCASE Cost:	(13) Est Accum OMA Cost:	ulative	1	riodic co view Resu	ontinue ults: 6/80
(15)	*Study Objective:					
	To test the enficacy	of 5-FU given b	y this s	chedule	for meta	static

- (16) *Technical Approach:
 Clinical study.
- (17) *Progress:

Three patients received this treatment All tolerated it well. One patient had a partial response (JS), but the other two patients experienced progressive disease.

Publications and Presentations: None

adenocarcinoma of the colon.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

71	20 0=0 00 (2)			737		
(1)	Date: 30 SEP 80 (2)	Prot No.: /	9/116	(3)	Status: Termir	nated
(4)	Title: Adiamycin, Cyc	ophosphamide,	and Cis-F	latinum	in the Treatme	ent of
Diff	use Pleural and Perito	nal Mesothelion	na. Phase	II: C	ombination Chem	otherapy
(5)	Start Date: June 1980		(6) Est	Comp Da	te: March 1980	Program.
(7) N .	Principal Investigator J. DIBELLA, MD, COL, I	1C	(8) Fac	ility:	FAMC	
(9)	Dept/Sec: HEM-ONC, Me	dicine	(10) A	s soc Inv	vestigators:	
(11)	Key Words: Mesothelioma, chemot	nera py	MICHAEL	. LANGIN	, CPT, MSC	
(12)	Accumulative MEDCASE Cost:	(13) Est Accu OMA Cost			riodic continue eview Results: (
(15)	*Study Objective: To determine the eff with recurrent or adv					

(16) *Technical Approach:

Clinical study.

(i7) *Progress:

No patients were seen with this rare tumor who were eligible for this protocol.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(i)	Date: 30 SEP 80 (2)	Prot No.: 79/	117	(3) Status: Terminated	
(4)	Title: 5-Fluorouracil,	Cytoxan, and A	dactone	in Advanced (Stage D)	
	Carcinoma of th	e Prostate			
(5)	Start Date:		(6) Est	Comp Date: 1980	
(7)	Principal Investigator	-	(8) Fac	ility: FAMC	
	NICHOLAS J. DIBELLA, M	I.D., COL, MC			
(9)	Dept/Sec:Hematology/On	cology Service	(10) As	isec Investigators:	
(11)) Key Words: Dept of Medicine		None		
	Chemotherapy, Ca. pro	state			
(12)	Accumulative MEDCASE	(13) Est Accum OMA Cost:	ulative	(14) Periodic continue Review Results: 6/80	
(15)	*Study Objective:				
	To determine the efficancer of the prostat		ıg combir	nation in patients with	

- (16) *Technical Approach: Clinical study
- (17) #Progress:
 One patient received this combination but experienced progression of disease after two courses.

AHRUAL PROGRESS REPORT (Detail Summary Sheet)

i) Date: 30 SEP 80 (2) Prot No.:	79/118 (3) St turn Ongoing
(i) fitte:	
Treatment of Severe Erythema Multife	orme with Systemic Steroids
57 Start Dute: 15 Sep 1980	(6) ist Comp Date: 1 Jul 1983
(rrincipal investigator	(8) Facility: FAM.
JAMES E. FITZPATRICK, M.D. MAJ. MC	
i) Jept/Sect Medicine/Dermatology	(10) Ausoc Inventigation:
Clarence Worlds:	DENNIS L. MAY, M.D., LTC, MC
Erythema Multiforme, Stevens-Johnson, Steroids	JOHN L. AELING, M.D., COL, MC
Cost: OMA Cos	umulative (10%) les losses continue et: 4 de les 18/80
light tidy was hit ive:	

To determine if Systemic Steroids are useful in the treatment of severe erythema multiforme.

The second of th

Patients with severe erythema multiforme will be admitted as an inpatient and randomized to placebo or Prednisone treated groups and treated for three weeks. Various parameters, including photographs of lesions, duration of fever, duration of arthralgias and complications secondary to systemic steroid will be followed.

Frank Brook

Since the inception of the protocol, one patient had been entered and completed the protocol. The protocol has been given to the Dermatology Services at Walter Reed Army Medical Center, Letterman Army Medical Center, and Breoke Army Medical Center but has not yet been locally approved.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)				(3) Status: Ongoing
(4)	Title: Captorpril For R	efractory	Hyperte	nsior	1
(5)	Start Date: 1979		(6) Es	t Comp Date: 1982
(7)	Principal Investigator		(8) Fa	cility: FAMC
_	Lawrence G. Smith, M.D.	CPT. M	C (
(9)	Dept/Sec: Medicine/Ner	hnology		0)	Assoc Investigators:
(11)	Key Words:			Nor	se
	Captopril				
	Hypertension		ļ		
(12)	Accumulative MEDCASE	(13) Est	Accumula	tive	
	Cost:	AMO	Cost:		Review Results: 10/79
(15)	<pre>#Study Object:ve:</pre>				
To	test the use of Canton	il in pat	tents with	h sc	were hypertonsion

To test the use of Captopril in patients with severe hypertension, refractory to standard medication therapy.

(16) *Technical Approach:

The patient qualifying for study has hypertension medications tamered, is placed on increasing doses of Captopril to a maximum dose of 400 mg./day. In a set sequence, beta blockade, diuretics, and vasodilators are added to the regimen until no more tension is achieved. The patient is monitored for all potential side effects.

(17) *Progress:

The patient has received Captopril since the initiation of the protocol and his blood pressure has not returned to the normotensive range, but it has been under better control than under any prior medication regimen.

ANNUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2	Prot No.: 80/	100 (3) Status:on-going
(4) Title: Further Studies in dogs with Esophagitis. Esophageal Lesions	on the Reflex The Effects Aft	Mechanism of Bronchoconstriction er Therapeutic Healing of the
(5) Start Date: 8 Dec 80		(6) Est Comp Date: 1 Apr 81
(7) Principal Investigator		(8) Facility: FAMC
Harry S. Spaulding, M	O, COL, MD	
(9) Dept/Sec:Medicine/All	- Imm	(10) Assoc Investigators:
(11) Key Words:		Niger Smith, SP6, Technician
reflex mechanism in b	ronchoconstric-	Richard E. Danziger, MD, CDR, US:
tion		Joseph S. Rice, MD, MAJ, MC
(12) Accumulative MEDCASE	(13) Est Accum	ulative ((14) Periodic continue
Cost:	OMA Cost:	
(15) *Study Objective:		
To determine if the pre	eviously demonst	rated reflex-mediated broncho-

constriction secondary to stimulation of hte lower inflamed esophagus can be ablated by treatment and resolution of the chemical esophagitis.

(16) *Technical Approach:

A recent protocol demonstrated bronchoconstriction in a group of dogs who had a chemical esophagitis. This study is designed to firm up this earlier investigation after healing of the lesion. Pulmonary function studies will be done pre- and post esophagitis and confirmed with biopsy.

(17) *Progress:

The project will begin on 8 Dec 80. To date only the techniques of the esophageal biopsy have been perfected.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.: 80/	'101 (3) Status:Terminate	ed
(4)	Title: The Evaluation	of Stool Hemoc	cult Positivity in Patients on	
	Coumadin-type	Anticoagulants.		
(5)	Start Date: 3 Nov 79		(6) Est Comp Date: 1980	
(7)	Principal Investigator	,	(8) Facility: FAMC	
	F.M. Moses, CPT, MC			
(9)	Dept/Sec: Dept of Med/	'Gastro	(10) Assoc Investigators:	
(Π)	Key Words:		none	
	carcinoma, guaiac tes	sting,		
	lesions			
				- .
(12)	Accumulative MEDCASE		nulative (14) Periodic continued	
	Cost:	OMA Cost:		/80
(15)	*Study Objective: To	determine the	frequency of hemoccult positive	
	stool in patients and	ticoagulated on	Coumadin and evaluate the cause	
	of this blood loss.			

- (16) *Technical Approach: A control group consisting of 100 patients will undergo serial stcol guaiac monitoring. All patients identified as occult blood positive will undergo proctoscopy and upper and lower GI series. Appropriate medical care will be obtained for all identified lesions. Those patients with negative evaluation and hemoccult positivity will be referred to the Gastroenterology Clinic, FAMC. Results will be forwarded to investigators. According to
- (17) *Progress: This protocol has been terminated due to the transfer of the Principal Investigator.

Proto No. 80/101

7. continued -

H.P. McElwee, MAJ, MC

16. continued -

to the results of these tests, additional studies could include upper and lower endoscopy and angiography.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2) Prot No.: 80	0/102 (3) Status: Ongoing
(4)	Title: Study of Coagulation Paramete	rs Prior To and Following
	Intravenous Injection of Radi	ographic Contrast Media.
(5)	Start Date: 20 March 1979	(6) Est Comp Date: 1 December 1980
(7)	Principal Investigator STEPHEN G. OSWALD, CPT, MC	(8) Facility: FAMC
(9)	Dept/Sec:Dept of Hematology/Oncology	(10) Assoc Investigators: JOHN C. MICHALAK, LTC, MC
(11)	Key Words: Radiographic contrast media, Hypercoagulation	DAVOR A. LUKETIC; CPT, MC PATRICIA STRANAHAN, MAJ, MC JUDY BARBER (A.S.C.P.) PATRICIA RUSH (A.S.C.P.)
(12)	Accumulative MEDCASE (13) Est Accu Cost: OMA Cost	mulative (14) Periodic continue
715	# Study Objective:	

To determine if coagulation parameters which have been associated with hypercoagulable states are altered by injection of contrast media.

- (16) *Technical Approach:
 Prior to the administration of radiographic contrast media, baseline coagulation parameters are drawn. 24 hours following contrast injection repeat studies are drawn and compared with the baseline results, i.e., each patient serves as his own control.
- (17) *Progress:
 At present 14 patients have been studied. Thus far there has been no significant coagulation abnormalities from the baseline studies.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(!)	Date: 30 SEP 80 (2)	Prot No.: 8	30/103	(3)	Status:	Ongoing
(4)	Title: Etoposide (VP-	16-213) Single	Agent Chem	othera	py in Sma	11 Cell
	Lung Cancer Ba	<u>tients Refracto</u>	ory to Firs	t Line	Chemothe	rapy
(5)_	Start Date: Jun 1980		(6) Est	Comp Da	te: 1982	
(7)	Principal Investigator N. J. DIBELLA, MD, CO	L, MC	(8) Faci	lity:	FAMC	
(9) (11)	Dept/Sec: Department Key Words:	of Medicine	(10) As	soc Inv	estigator	5:
	Chemotherapy protocol Small cell lung cance	r	Mic	hael L	angin	
(12)	Accumulative MEDCASE Cost:	(13) Est Accur OMA Cost			riodic co view Resu	ontinue olts: 6/80
(15)	#Study Objective:		<u></u>			
	7	C MD 16 010 1				

To test the efficacy of VP-16-213 in patients with recurrent or metastatic small cell CA of the lung.

(16) *Technical Approach:
 Clinical study.

(17) *Progress:

Three patients have been entered on the study. Two patients have experienced a partial response and one patient has had stable disease for five months. No serious toxicities have been observed.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

1) Date: 30 SEP 80 (2) Prot No.: 80	/104 (3) Status: Ongoing			
Cyc Tophos phamide Plus Vincristine of Sma	with Cyclophosphamide plust Vincristine			
(6) Start Date: June 1980	(6) Est Comp Date: 1983			
N. J. DIBELLA, MD, COL, MC	(8) Facility: FAMC			
(9) Jept/Sec: HEM-ONC, Medicine (11) Key Words:	(10) Assoc Investigators:			
Small cell CA, chemotherapy				
12) Accumulative MEDCASE (13) Est Accumu Cost: OMA Cost:	Review Results: 6/80			
(15) *Study Objective: To compare the response, duration of response and survival of small cell lung cancer patients initially treated with either (a) Etoposide (VP-16-213) plus vincristine plus cyclophosphamide or (b) Doxorubicin plus cyclophosphamide or (c) Cyclophosphamide plus vincristine. To compare the qualitative and quantitative toxicities of the above 3 regimens. (16) *Technical Approach: Clinical study.				

<!7) #Progress:</pre>

No patients entered to date.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot N	0.: 80	/105		Status:	Ongoing
(4)	Title: Dibromodulcit	ol in Sta	ge IV M	etastati	С		
	Malignant Mel	anoma.				_	
(5)	Start Date: June 198	0		(6) Est	Comp Da	te: 1982	
(7)	Principal Investigator	L, MC		(8) Fac	ility:	FAMC	
(9)	Dept/Sec: Hem-Onc, DO	M		(10) A	soc Inv	estigato	rs:
(11)	Key Words: Melanoma, chemothera	ру		MICHA	EL LANG	IN, CPT M	SC
(12)	Accumulative MEDCASE Cost:		t Accuma A Cost:	ulative		riodic co view Res	
(15)	*Study Objective:						
	To determine the eff DBD in melanoma.	icacy, du	ration	of respo	nse and	toxicity	of

- (16) *Technical Approach: Clinical study.
- (17) *Progress:
 No patients have been entered.

1

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

	SEP 80 (2)			(3) Status: on-going
(4) Title: Cro	ss Allergeni	city among	Grasses Dete	rmined by Tissue Threashol
Changes				
(5) Start Date			(6) Est	Comp Date: 1981
(7) Principal	Invest igator		(8) Fac	ility: FAMC
H.S. Nelson,	MD, COL, MC			
(9) Dept/Sec: Medicine/Allergy-Immunol.			. (10) A	ssoc Investigators:
(11) Key Words	•			
Immunotherapy	cross aller	genicity	B.G. Ma	rtin, MAJ, USA, FAMC
			R. Rena	rd, CPT, MC
			}	
(12) Accumulat	ive MEDCASE	(13) Est Ad	cumulative	(14) Periodic continue
Cost:		OMA Co	ost:	Review Results: 6/80
(15) *Study Ob	iective:			

To determine if the cross allergenicity of the western grasses demonstrated by RAST inhibition can be confirmed in vivo using the tissue threashold technique.

(16) *Technical Approach:

Patients with broad reactivity to grasses who are beginning immunotherapy will have titrated sensitivity to the various grasses determined. Separate groups will then receive immunotherapy either with all the grasses to which they are sensitive or only Timothy and Bermuda. It will be determined whether therapy with only Timothy and Bermuda suppresses cutancous, sensitivity to the entire group of grasses as well as does immunotherapy with all of the individual grass allergens.

Patients have been enrolled in this study and are currently receiving one year of immunotherapy.

ANNUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.	: 807	108	(3) Status: Ongoing
(4)	Title: Topical Cocain	e for the	Relief	of Stom	atitis in Patients with
	Malignancies:		DI IIIQ		
(5)	Start Date: October 19	80		(6) Est	Comp Date: 1981
77)	Principal Investigator N. J. DIBELLA, MD, CO	L, MC		(8) Fac	ility: FAMC
(9)	Dept/Sec: HEM-ONC, Me	dicine		(10) As	soc Investigators:
(11)	Key Words:				
	Chemotherapy, Cocain	e		RICHARD	A. ARTIM, MD, CPT, MC
(12)	Accumulative MEDCASE Cost:		Accumu Cost:	ılative	(14) Periodic continue Review Results: 9/80
(15)	*Study Objective:				

- - To determine whether topical cocaine is better than Viscous Xylocaine in the treatment of stomatitis.
 - B. To determine which concentration of cocaine affords optimal relief and the fewest side effects in the treatment of stomatitis.
- *Technical Approach:

Clinical study - Three different concentrations of cocaine combined with Viscous Xylocaine will be tested against Viscous Xylocaine alone in the relief of pain due to stomatitis.

(17) #Progress:

No patients have been entered to date.

SURGERY

ANNUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.: 7	1/202	(3)	Status:	Ongoina
(4)	Title:					
	Evaluation of Periph	eral Nerve Inj	uries at F	AMC		
(5)	Start Date:		(6) Est	Comp Da	te:	
(7)	Principal Investigator		(8) Faci	lity:	FAMC	
	William W. Eversmann	Jr., COL, MC	1		_	
(9)	Dept/Sec:		(10) As	suc Inv	estigato	rs:
$\overline{(11)}$	Key Words:					
	neurorrhapy, peripher	ral nerve	В	ertram (Goldberg,	COL, MC
(12)	Accumulative MEDCASE Cost:	(13) Est Accu	mulative			ontinue ults: 7/80
(15)	<pre>*Study Objective:</pre>					

To establish a pattern of peripheral nerve repair and recovery following injuries to pheripheral nerves and in most cases following neurorrhapy of the peripheral nerve.

- (16) *Technical Approach: Detailed questionnaire follow-up of patients with peripheral nerve injuries who have undergone repair are followed by detailed outpatient physical examination and evaluation supplemented by questionnaires. The questionnaires are devided into specific detailed questions and are customized for the level and type of nerve injury.
- (17) *Progress: During FY 1980 we have continued the ongoing clinical data mostly by questionnaires supplemented with an occasional outpatient visit and continue to accumulate data for this important nerve injury evaluation.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

	Prot No.:73/2	19 (3) Status: Ongoing
(4) Title: Treatment of Urinary Tract	Trauma in the L	aboratory Animal
(5) Start Date: May 1973		(6) Est Comp Date: Indefinite
(7) Principal Investigator		(8) Facility: FAMC
Major John A. Vaccaro, M.D.		<u> </u>
(9) Dept/Sec: Surgery-Uro	logy Service	(10) Assoc Investigators:
(11) Key Words:		Major Mary L. Osborne, M.D., MC
		Captain John H. Mani, M.D., MC
Trauma-Renal transplantation	n	Colonel Edward G. Buck, M.D., MC
		Colonel Howard E. Fauver, M.D., MC
(12) Accumulative MEDCASE	(13) Est Accum	ulative (14) Periodic continue
Cost:	OMA Cost:	Review Results: 6/80
(15) *Study Objective:		
Investigation of and compar	iso <mark>n of vari</mark> ous	modes of treatment of urological
trauma with emphasis on new	er surgical tec	hniques to include renal vascular

(16) *Technical Approach:

Various techniques of vascular reanastomosis and autotransplantation will be performed. This will be followed by IVPs 2-4 weeks postoperatively to ascertain success of failure.

Manpower (in professional man years): 24 hours

repair, Bench surgery and autotransplantation.

Funding (in thousands) FY 79: 1.3

FY 80: 2.5

(17) *Progress:

Continuing experimentation with various techniques of autotransplantation continue. It is anticipated that this particular protocol will enjoy increased use in the coming year as various compounds such as Inosine are used experimentally to prolong warm ischemia time. In addition to the invaluable experience gained with vascular anastomoses, this protocol represents a potential source of experimental data of great use in the military setting where renal trauma is to be anticipated.

PUBLICATIONS for FY 80 ANNUAL PROGRESS REPORT FAMC WU No 73/219 (Prot No)

- (1) Levisay, G.L.: Renal Autotransplantation in the Dog. Proc. of the Kimbrough Urological Seminar, January 1974
- (2) Jackson, J.E.: Renal Autotransplantation with Partial Nephrectomy in the Dog. Proc. of the South Central Section, AUA, Denver, CO, 15-19 September 1974. (Published)
- (3) Page, M.E.: Renal Autotransplantation wiith Venal Caval Occlusion, Proc. of the Kimbrough Urological Seminar, Seattle, Washington, 5 October 1975.

PRESENTATIONS for FY 80 ANNUAL PROGRESS REPORT

AMC WU No 73/219 (Proto No)

- (1) Levisay, G.L.: Renal Autotransplantation in the Dog. Presented: Kimbrough Urological Seminar, Washington, D.C., January 1974.
- (2) Levisay, G.L.: Renal Autotransplantation in the Dog. Presented: South Central Section Meeting of the AUA, Denver, Colorado, September 1974.
- (3) Jackson, J.E.: Renal Autotransplantation with Partial Nephrectomy in the Dog. Presented: South Central Section of the AUA, Denver, Colorado, 15-19 September 1974.
- (4) Jackson, J.E.: Renal Autotransplantation with Partial Nephrectomy. in the Dog. Presented: Kimbrough Urological Seminar, San Antonio, Texas, 14-19 November 1974.
- (5) Page, M.E.: Renal Autotransplantation with Venal Caval Occlusion, Washington, October 1975.
- (6) Page, M.E., and Weigel, J.W.: Exhibit-Renal Transplantation with Proximal Vena Caval. Presented: South Central Section Meeting in Urology, September 1975.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2) Prot No.:	76/203 (3) Status: Ongoing
(4)	Title: Screening Program for Mili	tary Children at High Risk for
	Hearing Loss	
(5)	Start Date: 17 Oct 76	(6) Est Comp Date: Undefined
(7)	Principal Investigator	(8) Facility: FAMC
	Susan T. Slibeck, M.S., DAC	
(9)	Dept/Sec:Surgery/Otolaryngology/A	dio (10) Assoc Investigators:
$\overline{(11)}$	Key Words:	None
	Parent Interview	
	Chart Review	
(12)	Accumulative MEDCASE (13) Est Ac	cumulative ((14) Periodic continue
	Cost: OMA Co	
(15)	*Study Objective: To screen infant	ts and children for information in-

(15) *Study Objective: To screen infants and children for information indicating high risk for hearing loss so that early identification and treatment can be enhanced.

*Technical Approach: Trained Red Cross volunteers will screen the medical and family histories of all newborns, pediatric ward patients (0-6 years of age), and one-year old Well Baby Clinic patients through parent interviews and medical chart reviews. The investigator wil review the gathered data for indications of high risk for hearing loss and designate children as AT RISK or NOT AT RISK. AT RISK children will be tested or until hearing status is definitely established.

(17) *Progress: The value of other High Risk Registers is well-documented in the literature. Reports of some other registers indicate that 1 out of 57 AT RISK children will be hearing impaired. The registry procedures used in this protocol have yielded report economical result: 1 out of 19 AT RISK children were hearing in red. Once again, it is reported that the effectiveness of this property is reduced by a shortage of Red Cross Volunteers Alternation and a nering techniques may be tried in the future.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT Proto No: 76/203

Publications: none

Presentations:

(1) Slibeck, Susan T.: High Risk Factors for Hearing Loss. Presented: Pediatric Department, Fort Carson, CO, December 1976.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.: 77/	204 (3) Status: Ongoing
(4) Title: The Anatomical and Physiologic	al Development of the Flexor
Tendon Sheaths in the Human Fetus.	
(5) Start Date: September 1979	(6) Est Comp Date: indef.
(7) Principal Investigator	(8) Facility: FAMC
William W. Eversmann, Jr., COL, MC	
(9) Dept/Sec: Orthopedic Ser, Dept of Sur	(IO) Assoc Investigators:
(11) Key Words:	none
Flexor Anatomical Development Flexor Tendo	
(12) Accumulative MEDCASE (13) Est Accum	ulative (14) Periodic continue
Cost: - OMA Cost:	- Review Results: 12/79
(15) *Study Objective: The objective of	
tomical development embryologically of the	
human fetus to 20 weeks of age and to corr	ulate this development with bio-
chemical chanbes within the flexor muscle	mass which are indicative of
developing contractility.	

- (16) *Technical Approach: Collection of human fetal specimens to 20 weeks of age gestation and combined anatomical and correlative biochemical studies of the flexor muscle mass.
- (17) *Progress: The commerce of the United States has continued to delete funding for interruption of pregnancy on military personnel and their dependents. Obtaining specimens for this study has been extemely difficult or impossible during the past fiscal year. Should this policy by the congress continue consideration is currently being given to convert this study to a primate study rather than a human use study.

(H3CR 40~23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2	Prot No.:	78/200	(3) Sta	tus: Ongoing
(4) Title:				
Anastomosis of the Dog Va		ing Micros	urigcal Techn	ique
(5) Start Date: April 1	(6) Es	(6) Est Comp Date: Indefinite		
(7) Principal Investigato	(8) Fai	(8) Facility: FAMC		
Col Howard E. Fauver, M.D.				_
(9) Dept/Sec: Dept of Sur	gery, Urology	Svc (10)	Nssoc Investi	gators:
(11) Key Words:	Col Edi	Col Edward G. Buck, M.P., MC		
Microsurgery-vasovasostor	Maj Jul	n A. Vaccard	, M.D., MC	
	Maj Ma	Maj Mary L. Osborne, M.D., MC		
			niel W. Horne	
(12) Accumulative MEDCASE	(13) Est Ac	cumulative	(14) Period	ic continue
Cost:	OMA Co	st:	1 Review	Results: 4/8
(15) *Study Objective:				

To master the microsurgical anastosis of the vas deferens.

(16) *Technical Approach:

Standard bilateral vasectomy performed on mongrel male dogs. Three weeks there a two layer microsurgical anastomosis using 10-0 nylon is completed. Three weeks later the dog is sacrificed and bilateral vasograms completed.

(17) *Progress:

Thirty vasovasotomies were performed using a variety of suture and microsurgical techniques. Investigators have mastered the rudiments of microsurgical vasovasostomy and Colonel Buck, Colonel Fauver and Major Vaccaro have developed sufficient skill to perform the procedure on human subjects.

Continued experimentation with various sutures and microsurgical techniques is being performed. Since it is felt that a minimum of thirty hours of microsecone time is essential before this procedure can be performed in human subjects,

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 78/200

(17) Progress, Continued:

this current protocol represents an indispensible tool for training new staff and residents. Due to the expertise gained in this area, referrals are now being obtained not only throughout CONUS but also Europe.

. 1 . . .

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

1 Date: 30 SEP 80 (2) Prot No.	: 78/20 1 (3) Status: Ongoing
Clinical Study for Intra	ocular Lenses
Start Page: September 1976	(6) Est Comp Date: Unknown
Princial Investigator	(8) Facility: FAMC
Andrew '. Cottingham, Jr., M.D.	
· Dert/Sec: Dept of Surgery	(10) Assoc Investigators:
Markey words: Cataract Intraocular Lens Pseudophakos	Richard A. Manson, M.D., COL, MC Lance P. Steahlv, M.D., LTC, MC Kevin J. Chismire, M.D., Major, M Craig A. Peterson, M.D., Cpt, MC Thomas H. Mader, M.D., Major, MC
(13) Recumulative MEDCASE (13) Est Cost: OMA	Accumulative (14) Periodic continue Cost: Review Results: 4/80

(15) #Study Ubjective:

- 1). To determine postoperative visual acuity of patients receiving an intraocular lens, and to compare those results with those of a control group of patients who undergo cataract surgery but do not receive an intraocular lens.
- 2). To describe the occurrence and time course of postoperative ocular complications and adverse reactions both for intraocular lens implant subjects and for control subjects. (cont)
- (16) *Technical Approach:

After didactic courses, observations, laboratory practice and assistance with an experienced implant curgeon, a surgeon who can perform an accomplished cataract extraction, is then allowed to perform intraocular lens surgery under proper tutorage. Postoperative examinations include: pachyometry, keratometry, and specular microscopy. Contraindications to surgery include: patients with good visual potential in only one eye, proliferative diabetic retinopathy (cont)

Due to the initial 25 implants between September 1976 and February 1978 the implantation of intraocular lenses at FAMC was expanded. We now have implanted over 200 intraocular lenses.

As a result of the past four years experience, we have evolved better guidelines for patient selection, better surgical techniques and improved quidance the stoperative care. Our study includes tabulations of operative (cont)

Proto No: 78/201

(10) William G. Carey, M.J., Cpt, MC

(15)

- 3). To compare the occurence of adverse reactions and ocular complications in the implant group and in the control group, in order to delineate any significant differences.
- 4). To describe the occurrence of postoperative lens complications for the implant group, and their relationship to ocular complications.
- 5). To identify subgroups within the implant study population that are at "high risk" of particular complications as compared to the control group.
- (16) ruheosis irides, high axial myopia, and inadequately controlled glaucoma, Fuch's endothelial dystrophy, and a history of previous retinal detachments or uveitis.
- (17) complications, postoperative complications, visual results, endothelial cell loss, corneal thickness changes, changes in corneal astigmatism, and residual refractive error.

The results of every ophthalmologist implanting intraocular lenses in the United States additionally compiled by computer in Washington, D.C. by the FDA, our results are a small part of this overall study. Final data from this massive study is to be completed in the future.

•	FAMC W	/U No (Prot No) 78/201
PUBLICATIONS for FY 80 Annual	Progress Report	(2nd Part of Detail Summary Sheet.)
SERVICE Ophthalmology	DEPARTMENT_	Dept of Surgery

(1). Cottingham, Jr., A.J: The initial Fifty Intraocular Lens Implantations in an Ophthalmology Residency Training Program. Submitted for publication to the American Journal of Ophthalmology.

FAMC WU No (Prot No) 78/201

١

The second second

PRESENTATIONS for FY 80 Annual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE Ophthalmology DEPARTMENT Dept of Surgery

- (1) Cottingham, Jr., A.J.: Keratoplasty. Presented: Optometry Meeting, FAMC, October 1978.
- (2) Cottingham, Jr., A.J.: Endopthalmitis Cause and Treatment. Presented: University of Colorado Health Sciences Center, January 1979.
- (3) Cottingham, Jr.A.J.: Corneal Keratomycoses. Presented: University of Colorado Health Sciences Center, January 1979.
- (4) Cottingham, Jr., A.J.: Bacterial Corneal Ulcers. Presented: University of Colorado Health Sciences Center, January 1979,
- (5) Cottingham, Jr., A.J.: The Use of Vitrectomy Instrumentation in Anterior Segment Reconstruction. Presented: Scheie Institute Trauma Symposia Philadelphia, Pennsylvania, September 1979.
- (6) Cottingham, Jr., A.J.: An Analysis of the Initial Twenty-Five Intraocular Lens Implantations in an Ophthalmology Residency Training Program. Presented: 7th Biennial, Walter Reed Ophthalmology Post Graduate Course and Alumni Meeting, April 1978.
- (7) Cottingham, Jr., A.J.: An Analysis of the Initial Twenty-Five Intraocular Lens Implantations in an Ophthalmology Training Program. Presented: Bascom Calmer Eye Institute Annual Resident Alumni Meeting, June 1978.
- (8). Cottingham, Jr., A.J.: Residual Astigmatism Postoperative Keratoplasty. Presented: American Academy of Ophthalmology Chicago, Illinois, 7 Nov 1980.

(HSCR 40~23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(I) Date: 30 SEP 80 (2)			Status: Ongoing
(4) Title: Evaluation of t	he Nitroblue Te	trazolium Test	(NBT) in Pyogenic
Arthritis Using	Synovial Fluid		
(5) Start Date: September	1979	(6) Est Comp De	ite: indefinite
(7) Principal Investigator		(8) Facility:	
Robert M. Campbell, Jr.,	CPT MC		
(9) Dept/Sec: Orthopedic S	ervice, FAMC	(10) Assoc In	vestigators:
(11) Key Words: NBT Test Pyogenic Arthr		Thomas G	. Fry, III, CPT, M
(12) Accumulative MIDCASE Cost:	(13) Est Accume OMA Cost:		riodic continue
(15) Study Objective: To correlate the NBT proven progenic arthr		on synovial flu	

- (16) Plechnical Approach: The coordinated eifort to evaluate the use of NBT test to predict pyogenic arthritis of the knee joint and correlation of this test with proven bi culture pyogenic archritis.
- Progress: A small series of patients have been completed are in this protocal. A greater number is needed to determine the usefullness of this method as an adjunct to the diagnosis and consequently institutional in pyogenic arthritis.

Publications and Presentations: None

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(I) Date: 30 SEP 80 (2)	Prot No.: 787	203	(3) St	atus: Terminated
(4) Title: The Effects of	Heterotopic Lyr	mph Node '	Fransplanta	tion on
Surgically Indu	iced Lymphedema			
(5) Start Date: 30 Sap 79		(6) Est	Comp Date:	30 Sep 81
(7) Principal investigator		(8) Faci	lity: FAM	
Viktor Gottlieb, Major,	MC .	<u> </u>		
(9) Dept/Sec: plastic Surg	erv	(10) As	soc Invest	igators:
(11) Key Words:	,) .	ohn D. Rich	, Colonel, MC
lymphedema				
lymph node tissue		ļ		
lymphadnectomy		<u> </u>		
(12) Accumulative MEDCASE	(13) Est Accum	ulative	(14) Perio	dic continue
Cost:	OMA Cost:		Revie	w Results: 12/79
				of transplanted
lymph nodes to surgica	ally induced ly	mphedema	in rats.	

- (16) *Technical Approach: Five groups treated in various ways will be examined following translocation of lymph code tissue. An initial group of six Fisher rats underwent resection of ipsilateral popicical and inguinal lymph nodes. The long term demonstration of lymphedemic in the operated leg will be observed. Following the oscurence of lymphedema the various research groups will be developed.
- Ten patient's were studied. The protocol was terminated due to ETS of Principal Investigator.

FAMC	WU	No	(Prot	No)	78/203	
171110	77 0	1 10	(1101	1 10/	/0/203	

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE Plastic Surgery

DEPARTMEN1 of Surgery

(1) Shesol, B.F., Viktor, Gottlieb: Preliminary Data and Technique for The Effects of Heterotopic Lymph Node Transplantation on Surgically Induced Lymphedema. J of Plastic & Reconstructive Surgery, Vol 63:6, June 1979.

Presentations:

- (1) Shesol B.F.: Heterotopic Lymph Node Transplantation. Presented: Ivy Society Resident's Competition, Hershey, Penna., 1978.
- (2) Shesol, B.F.: Heterotopic Lymph Node Transplantation. Presented: Chief Resident's Meeting, Hershey, Penna., 1978.

170

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2	Prot No. 79/20	0	(3) Status:	Terminated
(4) Title: Alterations of	Hematostatic Me	chanisms i	n Patients Und	ergoi: q
Cardiopulmonary Bypas	S			
(5) Start Date: 1979		(6) Est Co	omp Date: 1980	
(7) Principal Investigator		(8) Facil	ity: FAMC	
Douglas D. Pritchard.	MAJ. MC (cont'd	b		
(9) Dept/Sec: Surgery			oc Investigator	rs:
(11) Key Words:		Donai	d G. Corby, CO	L. MC
cardiopulmonary bypa	SS	ľ	A. Barber, MT,	
hemolysis		Í	, ,	
platelet function		}		
(12) Accumulative MEDCASE	(13) Est Accumi	ulative (4) Periodic c	ontinue
Cost:	OMA Cost		Review Resu	
(15) Study Objective:				

- 1. To evaluate platelet function in patients undergoing cardiopulmonary by pass procedures.
- 2. To evaluate the effect of red cell hemolysis on circulating platelets.
- 15) Technical Asproach:
 Twenty adult nation

117

Twenty adult patients scheduled to undergo cardiopulmonary bypass procedures will be evaluated. All patients taking drugs: aspirin, persantin, (dipyridamole) or other agents known to alter platelet function, will be excluded from the study. Platelet function will be evaluated pre-operatively, in the operating room after anesthesia is induced and chest opened, hourly during the pump procedure, 10 min apprograms:

This study has been terminated due to the ETS of the Principal Investigator. A similar study evaluating platelet function in patients undergoing Cardiopulmonary bypass has recently been published in Blood, November 1980.

Proto No: 79/200

- (7) continued -John Samuel Clark, COL, MC
- (15) continued ~
 - 3. To investigate the cause of platelet dysfunction in patients undergoing cardiopulmonary bypass platelet activation vs. platelet refractoriness secondary to release of red blood cell ADP.
 - 4. To attempt to correlate the degree of hemolysis with alterations of platelet function and clinical hemorrhage post-operatively.
- (16) continued -

post protamine administration, and 1,4, and 24 hours post-operatively.

The following laboratory procedures will be done, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) after heparin reversal, fibrinogen, and aggregation to adensine diphosphate (ADP), (2 and 5 um), collagen, epinephrine, (5.5 um) evaluation of circulating platelet aggregates according to method of Wu, evaluation of spontaneous aggregation of platelets in PRP, platelet counts, shape change estimated by electron microscopy, plasma hemoglobin, and RIA measurements of thromboxane B2, and nucleotide content of platelets and plasma. Platelets Cyclic AMP (cAMP) and adenyl cyclase measurements will be performed on selected samples. All blood will be obtained through a central venous line which is normally placed in these patients at the time of surgery for clinical reasons.

Estimates of blood loss will be charted and compared with plasma hemoglobin levels. Alterations of platelet function tests vs. time will be analyzed using analysis of variance with intergroup comparisons.

Ten surgical patients meeting same criteria not undergoing cardiopulmonary bypass will also be studied.

Publications and cresentations: None

DEPARTMENT OF CLINICAL INVESTIGATION FITZSIMONS ARMY MEDICAL CENTER

Aurora, Colorado 80045

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.: 79,	/201 (3) Status: Ongoing
(4) Title:	
Platelet Function in Disease St	tates.
(5) Start Date: 7 Aug 79	(6) Est Comp Date: June 82
(7) Principal Investigator	(8) Facility: FAMC
Victor Ferraris, M.D., Ph. D.	Aurora, CO, 80045
(9) Dept/Sec: DOS/Gen Surg Svc	(10) Assoc Investigators:
(11) Key Words:	
Prostaglandins Thromboxane	T. P. O'Barr E. Swanson
Arachidonic Acid Prostacyclin	D. Corby
Platelets	J.B. Smith
(12) Accumulative MEDCASE (13) Est Accumu	ulative (14) Periodic continue
Cost: OMA Cost:	Review Results: 8/80

- (15) *Study Objective:
- a. To develop and assess methods of measuring in vitro platelet function.
- b. To investigate the importance of arachindonic acid (AA) metabolism in platelet function.
- c. To use the TXB, radioimmunoassay to measure platelet survival.
- d. To use the above described tests of platelet function to screen patients with various clinical illnesses for disturbed platelet function. (Contd Incl 1)
- (16) *Technical Approach: To use tests of platelet function to screen surgical patients for platelet related abnormalities.

(17) *Progress:

Aspirin irreversibly inhibits platelet arachidanic acid metabolism. The Thrombaxne radioassay can reliably measure the degree of this inhibition (see fig. 1). Patients requiring emergency operation are being screened using tests of platelet function (including TXB₂ levels in serum & bleeding time) in order to detect the presence of ASA-like effect on platelets in these preoperative patients. The question being asked is, "Does the presence


Proto No: 79/201

Objectives Continued:

- e. To investigate in vivo platelet function using an animal model and the above described platelet function tests.
- f. To propose and test new clinical therapeutic modalities to treat disease of altered platelet function. These modalities will be based on the results obrained from pursuing objectives a,b,c,d, and e.

17. *Progress Continued:

of ASA platelet inhibition cause increased bleeding problems in patients requiring emergency operation"? Preliminary results indicate that ASA is commonly taken prior to emergency operation and there is no major increase in bleeding complications in patients who have taken ASA preoperatively.



FAMC	WU	No	(Frot	No)	79/201
------	----	----	-------	-----	--------

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE General Surgery Service

DEPARTMENT of Surgery

(1) Eiseman, B.:

Prognosis of Surgical Disease: W. B. Saunders Company, 1980

The following chapters were contributed by our staff doctors:

Carcinoma of the Oral Cavity by Richard M. Hirata, M. D. Reflux Esophagitis by Ross S. Davies, M. D. Varicose Veins by Lewis Mologne, M. D.

(2) Ferraris, V.A., and Sube, Janis:
Retrospective Study of the Surgical Management of Reflux Esophagitis Surgery,
Obstetrics and Gynecology, 1980 (in Press).

FAMC WU No (Port No) 79/201

PRESENTATIONS for FY 80 Annual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE General Surgery DEPARTMENT of Surgery

(1) Ferraris, V. A., Sube, Janis:
Retrospective Study of the Surgical Management of Reflux Esophagitis,
Presented:
William Beaumont Army Medical Center, El Paso, Texas, March, 1980.

FITZSIMONS ARMY MEDICAL CENTER AURORA CO F/6 6/5
CLINICAL INVESTIGATION PROGRAM. ANNUAL RESEARCH PROGRESS REPORT--ETC(U) AD-A101 634 SEP 80 D G CORBY NL UNCLASSIFIED 3 of 4 AD A 101634

CLINICAL INVESTIGATION

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)		Prot No.: 727			tus: Ongoing
(4)	Title: Comparison of	Metabolic and F	unct lona	I Changes in	Defects of
	Platelet Function.			_	
(5)	Start Date: 1972		(6) Est	Comp Date:	1981
777	Principal Investigator Donald G. Corby, M.D.,		(8) Fac	ility: FAMC	
(9)	Dept/Sec: Clinical Inv	estigation	(10) A	ssoc Investi	gators:
(11)	Key Words:		John W	. Harbell, P	h.D., CPT, MSC
	cyclic nucleotides, p	latelet	Thomas	P. O'Barr,	Ph.D., DAC
	function, prostagland		}	·	ŕ
7135	prostacyclins	71.5	L <u></u>	 	
(12)	Accumulative MEDCASE	(13) Est Accum	ulative		ic continue
	Cost:	OMA Cost:		Review	Results: 11/79
(15)	<pre>#Study Objective:</pre>				
	To correlate biochemi understanding of the function.				

- (16) *Technical Approach:
 Subjects: In most part, this study will deal with the further investigation of the platelet "defect" found in the normal newborn infant. However, since the techniques of studying the biochemical aspects of platelet function developed in previous studies permit the thorough evaluation of qualitative platelet disorders in older children and
- adults, the protocol is also intended to cover the diagnostic

 (17) *Progress:

 During the past fiscal year, three manuscripts have been accepted for publication. The newborn platelet "affect" now most certainly appears to be a "transient membrane phenomenon".

The original protocol has recently been revised. Future work will concentrate on "breaking down" membrane activation. Procedures are now being developed to quantitate platelet membrane glycoproteins,

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT Proto No: 72/302 (Blocks 1 through 17)

(16) Technical Approach - continued

evaluation of patients with functional platelet syndromes associated with the "hemorrhagic state".

Blood Collection: Samples of cord blood will be taken from the umbilical vein as follows: Immediately after delivery, the umbilical cord will be clamped and an 18 gauge disposable needle will be inserted into the umbilical vein. Blood will be drawn into a plastic syringe and immediately transferred to a plastic centrifuge tube containing either (1) 10% by volume of 0.1 M buffered citrate anticoagulant or (2) a purple-topped tube containing EDTA. Samples from the mother which will serve as controls will be taken either prior to or at the time of delivery using a two-syringe technique where a butterfly-type needle is inserted into the antecubital vein. A small amount of blood (0.5-1 ml) is drawn into this syringe at this time; then a second syringe containing the appropriate anticoagulant is connected to the end of the butterfly needle and the desired sample is drawn directly into this syringe, mixed well by inversion, and transferred to a plastic centrifuge tube. Samples from patients or normal adult volunteers will be collected in the same manner when needed.

Platelet Function Studies:

When indicated clinically, platelet counts, bleeding times, platelet adhesion, and platelet aggregation in response to ADP, collagen, epinephrine, or ristocetin will be performed in the Coagulation Section, Department of Pathology or the Biochemistry Service, Department of Clinical Investigation.

Biochemical Studies:

Assessment of the content and release of the content of the platelet's sub-cellular storage organeiles (alpha and dense granules) and evaluation of the platelet membrane will include, but not be limited to the following:

- a) content and release of adenonine nucleotides and serotonin in the dense granules.
- b) assessment of cyclooxygenase activity by measuring Thromboxane and malondialdehyde formation.
 - c) electron microscopy and mepacrine staining of dense granules.
- d) content of platelet factor 4 and B-thromboglobulin activity in the alpha granules.
- e) production of platelet-derived growth factor by $^3\mathrm{H-thymidine}$ incorporation in 3T3 mouse fibroblasts by platelet lysates.
- t) measurement of secretable acid hydrolases (B-glucuronidase, B-galactosidase, and membrane P-nitrophenyl phosphatase) activities.
 - g) membrane glycoprotein and phospholipid content.
- h) release of arachidonate from membrane phospholipids by phospholipase C and diglyceride lipase.
 - i) mobilization of Ca++.
 - j) other studies as they become available.

Proto No: 72/302

(16) Technical Approach - continued

Other studies to be conducted include the measurements of ADP receptors and alpha-adrenergic receptors, adhesion of platelets to deendothelialized rabbit aortic subendothelium and prostacyclin activity in umbilical veins.

Procedures already available in the Biochemistry Service, Department of Clinical Investigation, are designated by an asterisk. Other procedures are readily available in the literature and will be developed as needed.

Statistical Analysis:

Differences between the platelets of new infants and their mothers will be compared using the unpaired Student's t-test. Clinically oriented studies will be performed and compared with normal adult volunteers as controls.

(17) Progress - continued

formation of diglyceride and arachidonate from memorane phospholipids will also be assessed. Other studies planned include assessment of alpha granules content (B-thromboglobulin and platelets factor 4).

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE	DEPARTMENT	of Clinical	Investigation

- (1) Corby, D.G., Shigeta F.H., Greene, H.L., and Stifel, F.B.: Platelet Dysfunction in Glycogen Storage Disease Type I (GSDI): Reversal with Total Parenteral Alimentation (T.A). (Abst.) Clin. Res. 21:304, 1973.
- (2) Corby, D.G.,-Preston, K.A., Shigeta, F.H., O'Barr, T.P., and Zuck, T.F.: Adverse Effect of Gel Filtration on the Adenine Nucleotides of Human Platelets. (Abst., P. 107), III Congress, International Society on Thrombosis Hemostasis (Vienna, Austria), June 1973.
- (3) Corby, D.G., (Intr. by Wm. E. Hathaway): Mechanism of Platelet Dysfunction in Newborn Infants. J. Ped. Res., Vol. 8, No. 4, April 1974.
- (4) Corby, D.G., Preston, K.A., O'Barr, T.P.: Adverse Effect of Gel Filtration on the Function of Human Platelets. Proceedings of the Society for Experimental Biology and Medicine, 146:96-98, 1974.
- (5) Corby, D.G., Putnam, C.W., Greene, H.L.: Impaired Platelet Function in Glucose-6-Phosphatase Deficiency. The J. Ped., 85:71-76, July 1974.
- (6) Corby, D.G., and Zuck, T.F.: Newborn Platelet Dysfunction: A Storage Pool and Release Defect. Thrombosis and Haemostasis, 36:200-207, 1976.
- (7) Corby, D.G., Goad, W.C., Barber, J., and O'Barr, Tr L: Evaluation of Cyclo-Oxygenase Pathway in Platelets of the Newborn, Thrombosis and Haemostasis (Stuttgart), 38:35, 1977 (Abstract).
- (8) Corby, D.G., O'Barr, T: L: Decrease in -Adrenergic Binding Sites in Newborn Platelets: Cause of Abnormal Response to Epinephrine? Blood, 52:161, 1978.
- (9) Corby, D.G.: Aspirin in Pregnancy: Maternal and Fetal Effects. Pediatrics, 62:930, 1978.
- (10) Corby, D.G., O'Barr, T.P.: Decreased Alpha-Adrenergic Receptors in Newborn Platelets: Cause of Abnormal Response to Epinephrine.

 Dev Pharmacol & Ther, In Press.
- (11) Corby, D.G., O'Barr, T.P.: Neonatal Platelet Function: A Membrane-Related Phenomenon. Haemostasis, In Press.

Publications for FY 80 Annual Progress Report (72/302) - continued

(12) Corby, D.G., O'Barr, T.P.: Newborn Platelet Function. Chapter in Book "Acquired Bleeding Disorders in Childhood". Masson Publ, In Press.

Presentations:

- (1) Corby, D.G., Shigeta, F.H., Greene, H.L., and Stifel, F.B.:
 Platelet Dysfunction in Glycogen Storage Disease Type I (GSDI):
 Reversal with Total Parenteral Alimentation (TPA). Presented:
 Western Society for Pediatric Research, Carmel, California,
 February 1973.
- (2) Corby, D.G., Preston, K.A., Shigeta, F.H., O'Barr, T.P., and Zuck, T.F.: Adverse Effect of Gel Filtration on the Adenine Nucleotides of Human Platelets. Presented: III Congress, International Society on Thrombosis and Hemostasis, Vienna, Austria, June 1973.
- (3) Corby, D.G.: Mechanism of Platelet Dysfunction in Newborn Infants, Society for Pediatric Research, APS-SPR, Washington, D.C., May 1974.
- (4) Corby, D.G., Goad, W.C., Barber, J., and O'Barr, T.P.: Evaluation of Cyclo-Oxygenase Pathway in Platelets of the Newborn. Presented: Vith International Congress on Thrombosis and Haemostasis, Philadelphia, Pennsylvania, June 1977.
- (5) Corby, D.G. and O'Barr, T.P.: Decreased Adrenergic Receptors in Newborn Platelets: Cause of Abnormal Response to Epinephrine? Presented: Viith Congress International Society of Thrombosis and Haemostasis, London, England, 1979.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot N	7:	3/305	(3)	Status:	Terminated
(4)	Title: Computer Stora						
	Data from Tuberculosis	Patients	s				
(5)	Start Date: 1968			(6) Est	Comp Dat	e: Noy	1980
(7)	Principal Investigator			(8) Fac	ility: F	AMC	
	G.L. Brown, Ph.D., COL	, MSC (co	ont'd)	<u> </u>			
(9)	Dept/Sec: Clinical In	vestigati	on	(10) As	soc Inve	stigato	rs:
(11)	Key Words:			Mary	V. Roth	lauf, M.	S., DAC
	Computer Storage						
	Mycobacteria						
	Tuberculosis			l			
(12)	Accumulative MEDCASE	(13) Es	t Accum	ulative	(14) Per	iodic c	ontinue
	Cost:	OM	A Cost:		Rev	iew Res	ults: 9/80
(15)	*Study Objective:						
	To establish and main data on FAMC tubercul		•		e of myc	obacteri	iological

(16) *Technical Approach:
Since 1968, all mycobacteriologic results on FAMC tuberculosis patients have been stored in a computer file. Presently 2641 patient records encompassing 59,269 messages have been accumulated in the computer file. Patient data include: smear and culture results, drug susceptibilities of mycobacterial isolates, initial drug therapy data, serum tests,

data on special study patients, and experimental data on methodology

(17) *Progress: studies.

No data has been added during FY 1980 due to the fact that no positive patients have been admitted during this period. Due to the rarity of positive patients, this protocol has been administratively terminated.

CONTINUATION FOR FY 80 ANNUAL PROGRESS REPORT Proto No: 73/305 (Blocks I thr: 7)

(7) continued-

J.J. Damato, MAJ, MSC

Publications: None

Presentations:

- (1) Brown, G.L., and Rothlauf, M.V.: Laboratory Management of the Tuber-culosis Patient. Computer File Analyses of Six Year Data. Presented: Society of Armed Forces Laboratory Officers, San Antonio, Texas, September 1976.
- (2) Brown, G.L., and Rothlauf, M.V.: Computer Utilization in the Laboratory. Presented: Colorado State University, Ft. Collins, CO, April 1977.
- (3) Brown, G.L., and Rothlauf, M.V.: Computer File Analyses and Utilization of Mycobacteriology Laboratory Data. Presented: Colorado State University, May 1978.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)		Prot No.: 74/			s: Terminated
(4)	Title: Microbiologica	1 Research in Tu	berculos	sis.	
(5)	Start Date: 1974		(6) Est	Comp Date:	1980
(7)	Principal Investigator G.L. Brown, Ph.D., COL		(8) Fac	ility: FAMC	
(9)	Dept/Sec: Clinical Inv	estigation	(10) As	soc Investiga	tors:
$\overline{(11)}$	Key Words:		Mary V	/. Rothlauf, M.	.S., DAC
	Tuberculosis Research			D. Paine, B.S	•
(12)	Accumulative MEDCASE Cost:	(13) Est Accume OMA Cost:	ulative	(14) Periodic Review R	continue esults: 4/80
(15)	*Study Objective:		····		
	To evaluate and/or de laboratory procedures				

depth data base of laboratory results on tuberculous patients.

- (16) *Technical Approach:
 - 1. Comparison of Middlebrook 7H11 GA Agar with modifications thereof.
 - 2. Tests for identification of mycobacterial species.
 - 3. Evaluation of drug susceptibility test media.
 - 4. Characterization of non-mycobacterium tuberculosis species isolated from experimental media.
 - 5. Characterization of contaminants growing on experimental media. (cont'd)
- (17) *Progress:

Administratively terminated and rewritten as protocol 80/301.

Proto No: 74/300

(7) continued - James J. Damato, MAJ, MSC
(16) continued-

6. Comparison of smears before and after decontamination to determine possible loss of staining characteristics and viability.

FAMC WU No (Prot No) 74/300	
-----------------------------	--

PUBLICATIONS for FY 80 Annual Progress Report

SERVICE	Microbiology	DEPARTMENT of Clinical Investigation

- (1) Kolb, J.G., Rothlauf, M.V., and Brown, G.L.: 'solation of Mycobacterium kansasii on Mitchison's Selective 7H11 medium. (Abst.) American Society for Microbiology, C-69:47, 1977.
- (2) Rothlauf, M.V., Brown, G.L., and Blair, E.B.: Isolation of Mycobacteria from Undecontaminated Specimens with Selective 7H10 Medium. (In Press)

Presentations:

- (1) Kolb, J.G., Rothlauf, M.V., and Brown, G.L.: Isolation of Mycobacterium kansasii on Mitchison's Selective 7Hll Medium. Presented: American Society for Microbiology, New Orleans, LA, May 1977.
- (2) Brown, G.L., and Rothlauf, M.V.: Effects of Alpha-tocapheral and/or Altitude Stress on BCG Vaccinated Mice. Presented: National Jewish Hospital, Denver, CO, June 1978.
- (3) Damato, James J.: Rapid Methods for Differentiative Mycobacterial Species. Presented: University of Northern Colorado, Greely, CO, October 1979.
- (4) Damato, J.J.: Biochemical Methods for Differentiating Mycobacteria. Presented: Colorado State University, Ft. Collins, CO, May 1980.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2) Prot No.: 70	6/301 (3) Status: Ongoing : *			
(4)	Title: Pancreatic Islet Transplanta	tion in Diabetic Animals.			
(5)	Start Date: 1976	(6) Est Comp Date: 1982			
(7)	Principal Investigator	(8) Facility: FAMC			
	David T. Zolock, Ph.D. CPT(P), MSC				
(9)	Dept/Sec: Clinical Investigation	(10) Assoc Investigators:			
(11)	Key Words:	Donald G. Corby, M.D., COL, MC			
	Diabetic, Pancreatic Islets,				
	Transplantation				
7					
(12)	Accumulative MEDCASE (13) Est Accum	1 3 3			
7300	Cost: OMA Cost:	Review Results: 10/79			
(15)	*Study Objective:				
	Information derived from islet trans	iplantation experiments indicates			
	that diabetes mellitus can be effectively treated in animals. For				
	this treatment approach to become practical in humans it appears				
	obligatory to achieve effective anim	nal allograft islet transplants.			
	This goal has not been realized and thus the current protocol directly				
(16)	attempts to perform allogeneic islet transplantation in diabetic animal 6) *Technical Approach:				
	Pancreatic islets are isolated and purified from donor strain rats and				
	under various conditions are transpl	lanted to Lewis recipient rats. The			
	assessment of transplantation success is made by measurement of daily				
	urine volumes and 24 hr urine glucos	se excretion in addition to serum			

(17) *Progress:

glucose values.

Isograph transplantations are approximately 95% successful. Allografts have been unsuccessful. Culturing the islets for 7 days may help to alleviate this problem by destroying the lymphocytes. An Isograft transplantation of frozen islets in a glycerol medium was partially successful since the animal was partially cured before reverting back to diabetic.

**This study was inadvertently shown as completed in the last FY report.

FAMC \V	U No	(Prot	No)	76/301
---------	------	-------	-----	--------

PUBLICATIONS for FY 80 Ar.nual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE Biochemistry DEPARTMENT of Clinical Investigation

- 11) Charles, A., Noble, S., Ownbey, J., Brown, G.L., and O'Barr, T.P.: Mechanisms of Islet Allograft Rejection. (Abs+.) Journal of the American Diabetes Association, 1979.
- (2) Charles, M.A.: Islet Allograft Transplantation in Diabetic Rats. Diabetes 26: 1978.

Presentations:

(1) Charles, M.A.: Islet Allograft Transplantation in Diabetic Rats. Presented: American Diabetes Association National Meeting, 1978.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2)	Prot No.: 77/	300	(3) Status: Ongoing		
(4) Title: Immunologic Di	sorders in Child	ren and Adu	lts: 1. Correlation		
of Immune Functions in	the Immunodefic	iency State	. II. Correlation(cont'd)		
(5) Start Date: October	1977	(6) Est Comp Date: Open ended			
(7) Principal Investigator	7) Principal Investigator		(8) Facility: FAMC		
G. L. Brown, Ph.D. CO	L. MSC				
(9) Dept/Sec: Clinical Inv	estigation	(10) As soc	Investigators:		
(11) Key Words:		Dona 1	d G. Corby, M.D., COL, MC		
Immunologic Disorders		R. Stephen Whiteaker, Ph.D.,			
			CPT, MSC		
(12) Accumulative MEDCASE	(13) Est Accumu	lative (14) Periodic continue		
Cost:	OMA Cost:		Review Results: 4/80		
(15) *Study Objective:					
Existing specialized	immuno-chemical	procedures v	will be consolidated		

into a registered protocol for use, on a consultative basis, by the

(16) *Technical Approach:

hospital staff.

A clinical laboratory immunology consultation service has been established. Main emphasis is performance and evaluation of specialized immuno-chemical tests, for training house-staff personnel and consultative support of hospital. The major areas of studies include humoral and cellular immunity and leukocyte function evaluation. Patients are selected on the basis of severity of recurrent infections,

(17) *Progress:

A total of 267 patients were evaluated on consultative basis for immunologic disorders. During this period ten physician housestaff personnel were also trained in laboratory clinical immunology procedures (humoral and cellular). Patients studied: 159 in the area of serum protein gammapathies and 108 for special studies of cellular immunologic problems. Subjects with indicated major findings were as follows: 1) Humoral immunologic disorders-serum protein profile

Proto No: 77/300

- (4) continued of immune Functions of Leukemia and other Childhood Malignancies.
- (16) continued -

clinical immunodeficiency state, lack of response to medical management and availability of clinical investigation service for laboratory evaluations for patient care.

(17) continued -

evaluations: 13 cryoglobulinemias, 89 serum protein gammapathies, 39 immunoglobulin disorders (heavy and light chain and benign spike), 18 hypogammaglobulinemias, 18 hypergammaglobulinemias, 4 (complement abnormalities; 11) Cellular immunologic disorders-lymphocyte evaluations: 108 lymphocyte blast transformations (PHA, Con A, Pokeweed Mitogen), 101 T-lymphocyte enumeratives, of these 20, 10, and 6 patients were recorded suppressed post PHA, PWM and candida stimulations, respectively. 111) Miscellaneous evaluations: 20 B-cell flourescent taggings, 26 NBT evaluations, 13 neutrophil chemotactic studies, 7 monocyte chemiluminescence evaluations.

Publications: None

Presentations:

 Brown, G.L. and Heggers, J.: Medical Mycology: Assessment of bacteriologic and seroligic parameters of clinically-important mycoses normal and immunologic comprised host. Presented: American Medical Technologist Educational Seminars, Denver, CO, July 1979.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(!) Date: 30 SEP 80 (2) Prot No.: 78	
(4) Title: Radiometric Methods for the I	Rapid Detection, identification and
Susceptibility Testing of Mycobacter	rium Species.
(3) Start Date: 1978	(b) Est Comp Date: Aug 1980
(*) Principal Investigator	(8) Facility: TAMC
J.J. Damato, MAJ, MSC (cont'd)	
[6] Dept/Sec: of Clinical Investigation	(10) Assec Prestigators:
(11) Key Words:	Mary V. Rothlauf, M.S., DAC
Mycobacteria	Kenneth McClatchy, Ph.D., NJH
Radiometric testing	
(12) Accumulative MaDCASE (13) Est Accu	mulative [(14) Periodic
Cost: OMA Cost	1
(15) *Study Objective:	
	for rapid detection identification

To develop radiometric methodology for rapid detection, identification and susceptibility testing of mycobacteria isolate from patients' specimens.

(16) (Technical Approach:

 ${\tt C}^{14}$ substrates are employed to detect the early growth of mycobacteria in various medium bases. In addition, various chemical agents are being evaluated and incorporated in these bases in order to attempt to differentiate the various mycobacterial species and provide early susceptibility data.

17 APrograms:

Eighty nine smear positive sputum specimens were evaluated using radiometric and standard plate isolation procedures to determine the methodology which would provide the earliest detection and maximum sensitivity. Rapid detection and maximum recovery may be expected by inoculating a combination of radiometric broth and plate media.

Proto No: 78/301

(7) continued -

G.L. Brown, Ph.D., COL, MSC

Publications: None

Presentations:

- (1) Damato, J.J. Rapid Methods for Differentiating Mycobacterium Species. Presented: University of Northern Colorado, Greely, CO, October 1979.
- (2) Damato, J.J., Rothlauf, M.V., and McClatchy, J.K.: Differentiation of Tubercle Bacilli and Nontuberculous Mycobacteria by a Radiometric Method. Presented: Annual Meeting of The American Society for Microbiology, Miami Beach, FL, May 1980.
- (3) Damato, J.J., Rothlauf, M.V., and McClatchy, J.K.: Differentiation of Tubercle Bacilli and Nontuberculous Mycobacteria by a Radiometric Method. Presented: National Jewish Hospital and Research Center, Denver, CO, June 1980.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.:	78/	302	(3) Status: Completed
(4)	Title: Adsorbtion of	Propoxyphen	e by	Activate	ed Charcoal
75)	Start Date: Jan 1978			(6) Est	Comp Date: July 1980
(7)	Principal Investigator			(8) Fac	ility: FAMC
	W. Nicholas Glab, SP6,	B.S.	_		
(9)	Dept/Sec: Clinical Inv	estigation		(10) A	ssuc Investigators:
$\overline{(11)}$	(11) Key Words: Fropoxyphene		Donald G. Corby, M.D., COL, MC		
	Activated Charcoal				J. Decker, Ph.D.
	Toxicity			Virgir	nia R. Coldiron, M.S.
(12)	Accumulative MEDCASE	(13) Est A	ccumi	lative	(14) Periodic continue
	Cost:	OMA Cost:			Review Results: 11/79
(15)	<pre>*Study Objective: To</pre>	determine	the e	fficacy	of activated charcoal in
	the emergency management of propoxyphene overdosage.				

- #Technical Approach: Holtzman rats (100-150 g) were administered propoxyphene hydrochloride (P-HC1, 350 mg/Kg) or propoxyphene naysylate (P-N, 825 mg/Kg) dissolved or suspended in 5% acacia in H₂O. After 30 minutes, the rats were administered either AC at 10 times the drug dose or water. Surviving rats were sacrificed at 1,2,4,9, 12 and 24 hr; the brain, liver and both kidneys were removed intact, weighed, and stored at -70°C. After lyophilization, the tissues were
- *Progress: There were significantly less deaths in rats who received P-HCl+AC or P-N ÷ AC than rats who received either P-HCl or P-N alone (9vs19, p 0.01 and 5vs10, p 0.05 respectively). Tissue levels of propoxyphene and norpropoxyphene were similarly significantly reduced. These studies provide further evidence of the efficacy of AC in propoxyphene overdosage.

Proto No: 78/302

(16) continuedanalyzed for propoxyphene and its metabolite, norpropoxyphene by GLC. (To all C's, Depts/Svcs)

PUBLICATIONS occurring during FY 80

SERVICE Surgical Research Laboratories

DEPARTMENT of Clinical Investigation

- (1) Glab, W.N., Corby, C.G., Decker, W.J., and Coldiron, V.R.:
 Prevention of Propoxyphene Absorption by Activated Charcoal in
 Rats: Clinical and Pharmacological Correlations. Vet & Human
 Toxicol (in press).
- (2) Glab, W.N., Corby, D.G., Decker, W.J. and Coldiron, V.R.: Decreased Absorption of Propoxyphene by Activated Charcoal. Submitted for publication to J of Fundamental and Applied Toxicology.

PRESENTATIONS:

(1) Glab, W.N., Corby. D.G., Decker, W.J., and Coldiron, V.R.:
Prevention of Propoxyphene Absorption by Activated Charcoal
in Rats: Clinical and Pharmacological Correlations. Presented:
AACT/AAPCC/CACAT Meeting "Clinical Toxicology '80", Minneapolis,
Minnesota, 6 Aug 1980.

DEPA STORE OF CHUMBAL HAVETUREST WE REPORT HAVE A STORE AS A STORE OF STORE OF STORE AS A STORE OF STORE

THEOR 40-23, April 6.5 (February Street)

(17	Duto: 30 178 80 19 19 19 19 19 19 19 19 19 19 19 19 19	: 78730	<u> </u>
(4)	Title francisco de sestá seli	Control Control	e carreditiestinal
•	Decontaminates in the them the	1 (2.200) et (1.700)	Proceed Patient
(5)	TS1.81 - (4.15 - 1.11 - 1.15 -		- 11 - 12 - 12 - 12 - 12 - 12 - 12 - 12
T(i)	Prince of the second of		
	Donald Q. Carl	e de la companya de l	
(9)	Bendynnin	la La maria	
():::		· · ·	
	Humic Acid	34°	N. S. (1997)
	Gastrointe de la company de la	T.	
	Poi ves	en en antiferante e un production de la latera de	
(12)			continue
		toria, i	1 less ha sults: 12/79
(15)	***	and the second s	the multi-page to
	To produce the state of the sta		a h gachold poisons.
	bind a common to the common of	TO ANNAGE TARMER SHI	

- Hamiltonia in the control of the con
- Hard control of the c

١

(7) continued -

T.P. O'Barr, Ph.D., DAC
Walter J. Decker, Ph.D., Department of Pharmacology/Toxicology, University
of Texas Medical Branch, Galveston, TX

(16) continued -

chloroquine, quinidine, quinine, ferrous sulfate, iodine phenal, methylsalilcylote, 2,4-D(20%), malathion (50%), DDT, N-methyl carbamate, basic acid (3%), d-propoxyphene hydrochloride, mineral acids, sodium and potassium hydroxide, sodium metasilicate, and talbutanide.

(17) continued -

being conducted in order to determine the optimum conditions for binding of iron and other harmful drugs to humic acid.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.:	78/304	(3) Status: Ongoing
(4)	Title: Treatment of Ir	on-deficiency	Anemia 1:	Comparison of Hematologic
	Parameters following	Treatment wit	h Carbonyl	Iron of Ferrous Sulfate (cont'd)
(5)	Start Date: 1978		(6) Est	Comp Date: 1981
(7)	Principal Investigator	•		ility: FAMC
	Donald G. Corby, M.D.	, COL, MC		,
(9)	Dept/Sec: Clinical Inv	estigation	(10) A:	ssoc Investigators:
(11)	Key Words:			r J. Decker, Ph.D.
	Iron-deficiency Anemi	a	Dire	ector, Dept. of Pharmacology/
	Carbonyl Iron, Ferrou	s Sulfate		icology, Univ. of Texas Med.
	hematocrit values		Br.	, Galveston, TX.
(12)	Accumulative MEDCASE	(13) Est Acc	umulative	(14) Periodic continue
	Cost:	OMA Cos	t:	Review Results: 12/79
$(15)^{\circ}$	*Study Objective:			

To evaluate carbonyl iron in the treatment of experimentally induced iron deficiency in the rat.

(16) *Technical Approach:

This will be a comparative study of hematocrit values using an animal model. In addition, this study will evaluate CBS indices, serum iron, unsaturated iron-Linding capacity, free erythrocyte protoporphyrin levels, ferritin levels, and stainable bone marrow iron. This experiment will be conducted in three phases in which the first two phases will be identical due to time, space, and personnel limitations to

Delays in initiating this project have occurred because of requirements for animal housing for other registered research projects.

Carbonyl iron and iron-free diets have been received. Animals are on order; study expected to begin within the next month.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks I through 17)

Proto No: 78/304

- (4) continued in Wistar Rats.
- (10) continued -

Penelope Rich Giese, B.S., SSG Lawrence E. Jones, M.T., DAC Troy Engle, SFC

ANNUAL PROGRESS REPORT (Detail Summary Sheet) (HSCR 40-23, App. C.)

	Date: 30 SEP 80 (2)						atus: On	
(4)	Title: A Study of t	he Hormo	ne-Dep	end	ent Gr	owth	of Huma	in
	Mammary tumors In	Vitro						
(5)	Start Date: 1979						On goi	ng
(7)	Principal Investigator	•	7	8)	Facilit	y: FAI	1C	
Johr	n W. Harbell PhD, C	pt, MSC	l					
(9)	Dept/Sec: DCI/SRLS			10)	As soc	Invest	igators	
(11)	Key Words:		Do	ona	ld Mer	cill,	BS DAC	•
Brea	ast Tumors						S, Sp5	
						•		
(12)	Accumulative MEDCASE	(13) Est	Accumul	ati	ve [[14) Perio	dic con	tinue
	Cost:	OMA	Cost:			Revie	ew Result	:s: 3/80
(15)	"Study Objective:							

To examine the hormone requirements for the growth of human mammary tumors using explant organ culture.

(16) *Technical Approach:

Tissue samples are obtained from biopsy or mastectomy specimens. Each sample is cut into many small pieces and distributed, for culture, in a battery of hormone combinations. Replicate samples from each hormone combination are subjected to the appropriate radiolabelled precursor to determine DNA, RNA, and protein synthesis. Histology and macromolecular synthesis measure response.

(17) *Progress: To date, over 50 samples of normal, hyperplastic and malignant human breast tissue have been studied. The interaction of insulin with ovarian and pituitary hormones has been the major thrust thus far. As expected from rodent studies, normal human mammary epithelium required insulin to undergo maximum proliferation when stimulated by other mammatrophic hormones. However, even malignant epithelium which was apparently inCONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

sensitive to the other mammatrophic hormones also showed a marked insulin dependence. Due to the small number of human carcinomas available, corollary experiments with rodent tissue were completed to characterize the biochemistry of this dependence. Normal, benign, and malignant murine mammary epithelia were studied. Each required insulin while only the normal and benign required ovarian and pituitary hormones. Assessment of DNA,RNA, and protein synthesis as well as glucose utilization demonstrated that DNA synthesis was the most sensitive to the insulin concentration with the other parameters markedly less so.

Proto No: 79/300

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE Surgical Research Lab's DEPARTMENT of Clinical Investigation

- 1. Harbell, J.W.: Insulin Action on Normal and Transformed GR/A Strain Mouse Mammary Tissues. (Abst) Ann Tissue Culture Assoc, 1980.
- 2. Harbell, J.W.: Insulin Action on Normal and Transformed GR/A Strain Mouse Mammary Tissues. In Vitro 16(3):247, 1980.

FAMC WIU No (Prot No) 79/300

PRESENTATIONS for FY 80 Annual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE Surgical Research Lab's

DEPARTMENT of Clinical Investigation

1. Harbell, J.W.: Insulin Action on Normal and Transformed GR/A Mouse Mammary Tissues. Presented: 31st Annual Meeting, Tissue Culture Association, St. Louis, MO, June 4, 1980

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.: 79/	301	(3) Status: Ongoing
(4)	Title: Basic Studies	to Hasten Recove	ry from	or Help Prevent
	Bone Injury			
(5)	Start Date: February	1979	(6) Est	Comp Date: October 1982
	Principal Investigator		(8) Fac	ility: FAMC
	David T. Zolock, Ph.D	. CPT(P) MSC	Ĺ	
(9)	Dept/Sec: Clinical In	vestigation	(10) As	soc investigators:
(11)	Key Words:		Dan	iel D. Bikle, M.D., Ph.D.
	Vitamin D, Caîcium,	Bone, Intestine,	Vet	erans Administration Med.Ct
	Calcium Binding Prot			Francisco, CA
(12)	Accumulative MEDCASE	(13) Est Accum	ulative	(14) Periodic continue
	Cost:	OMA Cost:		Review Results: 3/80
$\overline{(15)}$	*Study Objective:			

(15) *Study Objective:

To reduce the incidence of fracture wounds and to reduce the time involved to heal fracture wounds by increasing the absorption and retention of calcium and phosphorus through nutritional and medical therapeutic improvements.

(16) *Technical Approach:

Since bone mineralization is indirectly regulated by intestinal absorption, the bone as well as the intestinal responses to various therapeutic measures, will be studied. In general the animal of choice will be chicks, which will be fed a vitamin D deficient diet containing 0.43% phosphorus for approximately three weeks.

(17) *Progress:

The initial vitamin D mediated calcium transport across the lumen and the mediated mucosal calcium accumulation in 1,25-dihydroxycholeciferol repleted rachitic chicks do not depend on the synthesis of the vitamin D dependent intestinal calcium binding protein or other protein synthesis. However, protein synthesis is necessary for the vitamin D mediated calcium uptake in bone. The homogeneous purification of calcium binding protein is almost complete. This preparation will be used to determine

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 79/301

(17) continued -

if calcium binding protein, injected intraveneously, will affect calcium uptake in the bone and calcium transport and accumulation in the intestine in rachitic and vitamin D repleted chicks which have blocked protein synthesis.

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE Biochemistry

DEPARTMENT of Clinical Investigation

- (1) Zolock, David T., Morrissey, Robert L., and Bikle, Daniel D.:
 Meaning of Non-parallel 1,25(OH), D, Mediated Response Relationships
 in Intestine and Bone to Dose and Time in Vitamin D; Biochemical,
 Chemical and Clinical Aspects Related to Calcium Metabolism.
 Walter DeGruyter, Inc., New York, 1979.
- (2) Bikle, D.D., Morrissey, R.L., Zolock, D.T. and Herman, R.H.: Stimulation of Chick Gut Alkaline Phosphatase Activity by Actinomycin D and 1,25-dihyroxyvitamin D₃: Evidence for Independent Mechanisms. J Lab Clin Med 94:88-94, 1979.
- (3) Bikle, D.D., Morrissey, R.L., and Zolock, D.T. The Mechanism of Action of Vitamin D in the Intestine. Am J Clin Nutr 32:2322-2338, 1979.
- (4) Morrissey, R.L., Zolock, D.T., Mellick, P.W., and Bikle, D.D.: Influence of Cycloheximide and 1,25-dihydroxyvitamin D₃ on Mitochondrial and Vesicle Mineralization in the Intestine. Cell Calcium 1:69-79, 1980.
- (5) Bikle, D.D., Askew, E.W., Zolock, D.T., Morrissey, R.H. and Herman, R.H.: Calcium Accumulation by Chick Intestinal Mitochondria: Regulation by Vitamin D₃ and 1,25-dihydroxyvitamin D₃. Biochem, Biophys Acta 598: 561-574, 1980.

Presentations:

(1) Zolock, David T., Morrissey, Robert L., and Bikle, Daniel D.: Meaning of Non-parallel 1,25 (OH) D Mediated Response Relationships in Intestine and Bone to Dose and Time. Presented: Berlin (West), Germany, February 1979.

ANNUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.: 79	/304 (3) Status: Ongoing
(4) Title: Quantitation of Steroid H	ormone Receptors in Tissue
Sections Using Quantitative Aut	oradiography
(5) Start Date: 1979	(6) Est Comp Date: ongoing
(7) Principal Investigator	(8) Facility: FAMC
John W. Harbell PhD, Cpt, MSC	
(9) Dept/Sec: DCI/SRLS	(10) Assoc Investigators:
(11) Key Words:	
Steroid Receptors	none
-	
(12) Accumulative MEDCASE (13) Est Accum	4 = ·
Cost: OMA Cost:	Review Results: 12/79
(15) *Study Objective:	

To provide a means to quantify cellular steroid receptors (estrogen, progesterone and glucocorticoids) on a cell by cell basis in both normal and transformed tissue samples.

(16) *Technical Approach: Viable tissue samples are pulse-labelled, in vitro, with 3Hlabelled steroids, extensively washed with culture medium and quick frozen. Frozen sections are placed on emulsion-coated slides and exposed at -15C. Microscope quantitation of specific(total-background) silver grain number over the cell nucleus is used to indicate a responsive cell.

(17) *Progress: The basic steroid autoradiography technique using in vitro steroid exposure is now available and is used:1) to provide nuclear translocation controls for more rapid but nonquantitative fluorescent steroid receptor localizing techniques especially applicable for very small clinical samples and 2) to study steroid receptors in cells of the growing murine and human mammary end-buds and mesenchyme.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.: 79	/305	(3) Status: Terminated	
(4)	Title: Field Trial of	New Techniques	for Isol	lation, Identification and	
	Susceptibility	Testing of Myco	bacteria	a	
(5)	Start Date: 1979		(6) Est	Comp Date: Nov 1980	
(7)	Principal Investigator			ility: FAMC	
	James L. Owmby, MAJ,	MSC_(cont'd)			
(9)	9) Dept/Sec: Clinical Investigation		(10) Assoc Investigators:		
$\overline{(11)}$	Key Words:		J.J. Damato, MAJ, MSC		
	Mycobacteria		J.	Kenneth McClatchy, Ph.D.,NJ	
	Isolation, Identifica	tion		•	
	Susceptibility testin	g			
(12)	Accumulative MEDCASE	(13) Est Accum	ulative	(14) Periodic continue	
	Cost:	OMA Cost:		Review Results: 4/80	
71/1	:: Ct 1 01 :				

(15) *Study Objective:

1. To set up a field trial of Mitchison's selective medium.

2. To develop and evaluate the use of a transport medium for clinical specimens for mycobacteriology sent to reference laboratories for processing.

3. To determine primary antituberculosis drug resistance of TB infected personnel stationed in Korea.

(16) *Technical Approach:

The 121st Evacuation Hospital, Korea, will collect TB sputum specimens, prepare smears, inoculate S7H10 directly and split remaining specimens. They will process on aliquot as usual and, after adding an equal volume to holding medium to the remaining portion, send that portion to Mycobacteriology, Department of Clinical Investigation, FAMC, for isolation and susceptibility testing. Drug susceptibility of \underline{M} . \underline{t}

(17) *Progress:
No progress during FY 80. Therefore, this protocol has been administratively terminated.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 79/305

(7) continued-

Mary V. Rothlauf, M.S., DAC James D. Hakes, DAC

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)				(3)	Status:	
(4)	Title: Adenohypophys	eal-thyroi	d Inter	relatio	onships	in Dehyd	ration.
(5)	Start Date: June 1979)		6) Est	Comp Da	ite: Dec	ember 1980
(7)	Principal Investigator	•	1	8) Fac	ility:	FAMC	
	W. Nicholas Glab, B.S.	, SP6	1				
(9)	Dept/Sec: Clinical Inv	estigation		(10) A	ssoc In	vestigato	rs:
(11)	Key Words:			John W. Harbell, Ph.D., CPT, M			
	Adenohypophysis		Ì				
	Thyroid		}				
	Dehydration		1				
(12)	Accumulative MEDCASE	(13) Est	Accumul	ative	(14) Pe	eriodic c	ontinue
	Cost:	OMA	Cost:				ults: 6/80
(15)	*Study Objective:						
	To examine the activi	tv of the	thyroid	and th	hyroid s	stimulati.	ng hormone

(TSH) producing cells of the anterior pituitary gland during dehydra-

- (16) *Technical Approach:
 Sacrifice periods, totaling 8 days, will include members of two groups of rats: controlled and water-deprived, and body weights and urine output monitered. Upon pituitary, thyroid, and adrenals will be processed for light and electron microscopy. Cell morphology, counts of both TSH cell numbers, and secretion granule size versus number per cell will be evaluated.
- (17) *Progress:
 The animal phase has been completed and samples collected. Tissues are being evaluated, with preliminary results showing a decrease in thyroid cell height in dehydration.

Publications and Presentations: None

tion, utilizing light and electron microscopy.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.: 79	/308	(3) Status: Terminated
(4)	Title: Quantification			
	Platelets of Adults De	monstrating Dec	reased Re	sponse to Epinephrine.
(5)	Start Date: 1979		(6) Est	Comp Date: 1980
(7)	Principal Investigator	•	(8) Fac	ility: FAMC
	Donald G. Corby, M.D.,	COL, MC	}	
(9)	Dept/Sec: Clinical In	vestigation	(10) As	soc Investigators:
(11)	Key Words:		Judy	Barber, M.T., DAC
	platelet aggregation		Pat A	Rush, M.T., DAC
	epinephrine		Eller	Swanson, B.S., DAC
			T.P.	O'Barr, Ph.D., DAC
(12)	Accumulative MEDCASE	(13) Est Accum	ulative	(14) Periodic continue
	Cost:	OMA Cost:		Review Results: 10/79
(15)	*Study Objective:			

To determine whether adults who demonstrate decreased platelet aggregation in response to the inducing agent, epinephrine, have decreased numbers of platelet Alpha AR.

(16) *Technical Approach:

Patients who have previously been evaluated in the Coagulation Section of the Department of Pathology for minor bleeding disorders as well as some normal adults known to have decreased secondary aggregation responses to epirephrine will be studied. All patients will abstain from aspirin and other drugs known to affect secondary aggregation and release (i.e., aspirin) for ten days prior to study. Approximately

During the year since this study was initiated, no patients have been found that fit the criteria for evaluation, i.e.. Their platelets failed to undergo secondary phase of aggregation in response to epine-phrine. The reasons for this are unclear but may be relative to the acquisition of new equipment for measuring in vitro platelet aggregation. The study will be terminated, however, if patients fitting study criteria become available they will be evaluated for adrenergic

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 79/308

(16) continued -

10 to 15 patients in each group will be studied. The following studies will be performed.

Platelet aggregation studies will be performed by standard photometric techniques in response to epinephrine, (2 and 20 uM) soluble collagen, epinephrine (5.5 and 55 uM), thrombin and ristocetin at standard concentrations.

Thromboxan (TxB_2) levels will be obtained on samples of platelet-rich plasma clotted with 0.5 units of thrombin. Patients with decreased thromboxane B_2 levels will be presumed to have taken aspirin and will be excluded from the study.

Other studies to be performed will be: Platelet count, PT, PTT, and fibrinogen. Coagulation studies such as bleeding time as well as other more sophisticated studies will be done as needed.

(17) continued -

receptor deficiency as part of their clinical workup.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No. _____

(17) continued -

parameters (i.e. pH, time, and temperature). An assay has been developed which is able to differentiate between normal serum and normal serum with 12.5 ug/ml AHG.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2	Prot No.: 80	/300	(3)	Status:	Ongoing
(4)	Title: Evaluation of	Laser Nephelomet	ry for D	etecting		
	Circulating Immune-co	nplexes in Cance	r Patien	ts.		_
(5)	Start Date: 1 March	1980			te: 1 Mar	ch 1982
(7)	Principal Investigator	•	(8) Fac	ility:	FAMC	
	George L. Brown, Ph.D	., COL, MSC	1			
(9)) Dept/Sec: Clinical Investigation		(10) As	soc Inv	estigator	·s:
(11)	1) Key Words:		Nicholas J. DiBella, M.D., COL,MC			
	Laser Nephelometry		Wilson C. Bourg, M.D., MAJ, MC			
	Circulating Immune Con	mplexes				
	Cancer Patients					
(12)	Accumulative MEDCASE	(13) Est Accum	ulative	(14) Pe	riodic c	ontinue
	Cost:	OMA Cost:		Į.		lts: 3/80
(15)	<pre>*Study Objective:</pre>			*** • • • • • • • • • • • • • • • • • •		
To evaluate laser nephelometry as a means of efficient and rapid detec-						
	tion and quantitation of circulating immune complexes in cancer patients.					
	To correlate the leve					
	status.		-	•		

(16) *Technical Approach:

The known ability of polyethylene glycol to precipitate immune complexes will be combined with the ability of laser nephelometry to detect small quantities of precipitates to produce a rapid, simple, efficient assay for detecting circulating immune complexes (CIC). This assay will then be used to quantitate the levels of CIC in the serum from cancer patients and determine the correlation between CIC levels and disease

The initial laser nephelometry assay conditions (i.e. 4% polyethylene glycol, 60 min incubation at room temp.) were able to differentiate between normal serum and normal serum containing 125 ug/ml heat aggregated IgG (AHG). This failure to achieve greater sensitivity was eventually found to be due to a concentration of polyethylene glycol which precipitated monomeric IgG in addition to AHG. By lowering the polyethylene glycol concentration and changing the other incubation

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)		Prot No.: 80/			tus: Ongoing
(4)	Title: Microbiologica	1 Research in Ti	uberculos	is	
(5)	Start Date: June 1980	<u> </u>	(6) Est	Comp Date:	1982
	Principal Investigator J.J. Damato, MAJ, MSC	-		ility: FAMC	
(9)	Dept/Sec: Clinical In			soc Investig	
(Π)	Key Words:		Dona	ild D. Paine,	B.S., DAC
	Tuberculosis Research		Phil		itchy, Ph.D., N ens, SP5, USA DAC
(12)	Accumulative MEDCASE	(13) Est Accum			
	Cost:	OMA Cost:			Results: 6/80
(15)	*Study Objective:			·	

(15) *Study Objective:

To evaluate ard/or design new methods for improving diagnostic laboratory procedures in mycobacteriology and to maintain an in-depth data base and reference cultures on all patient isolates for future correlation with patient data, treatment results and laboratory quality control.

- (16) *Technical Approach:
 - 1. Evaluation and comparison of mucolytic agents.
 - 2. Evaluation and comparison of growth media.
 - 3. Tests for identification of Mycobacterial species.
 - 4. Evaluation of drug susceptibility test media.
 - 5. Characterization of Mycobacteria other than Tuberculosis (MOTT) isolated from experimental media. (cont'd)
- "SPUTOLYSIN" has been evaluated and has been found to be an effective mucolytic agent. No further evaluation or formal report of these studies is contemplated. Bi-phasic chromogenicity, arylsulfatase, miacin, nitrate reductase, and pyrazinamide studies have been successfully completed and the results are being written by MAJ James J. Damato, MSC. Evaluation of Mitchison's selective OA medium (S7H10) has been completed, and a paper has been accepted by the Journal of Clinical(cont'd)

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 80/301

- (7) continued Mary V. Rothlauf, M.S., DAC
- (16) continued-
- 6. Comparison of smears before and after decontamination to determine possible loss of staining characteristics and viability.
- (17) continued-

Microbiology. Evaluation of \$7H10 medium for direct susceptibility testing is continuing, as are studies indicating the frequency with which casual isolates of mycobacteria are recovered from undecontaminated specimens. Studies concerning a simplified method for determining growth temperature range or mycobacteria have been completed and is currently being written.

FAMC WU IND (MOTOR IND. 80/301

PUBLICATIONS f 80 Annual Progress Report (2nd Part of Detail Summary Sheet.,

SERVICE MICHOBIOLOGY DEPARTMENT DCI

(1) Rothlauf, M.V., Brown, G.L., and Blair, E.B.: Isolation of Mycobacteria from Undecontaminated Specimens With Selective 7H10 Medium. Accepted for publication in the Journal of Clinical Microbiology. (In Press)

FAMC WU No (Prot No) 80/301

PRESENTATIONS for FY 50 inual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE MICROBIOLOGY DEPARTMENT DCI

(1) Damato, J.J.: Biochemical Methods for Differentiating Mycobacteria. Presented: Colorado State University, Ft. Collins, Colorado, May 1980.

DEPARTMENT OF CLINICAL INVESTIGATION

Surgical Research Laboratories Service

Training Support Summary

During the year, 109 students received training in suturing techniques. Seventy-two were students in the practical nurse (910) course; 12 were personnel assigned to Emergency Treatment Service, FAMC, eight were Colorado Air National Guardsmen from the 140th TAC Hospital; 12 were reservists from the 361st Med Lab and 5502 US Army Hospital; and five were from the US Air Force Clinic, Lowry. Training was conducted on 27 days, using 27 dogs, and consisted of a slide lecture and movie, introduction to the operating room, including aseptic technique, scrub, gowning and gloving, and handson experience in the dry and wet labs. Three hundred and twenty-four hours was expended by Surgical Research Labs personnel in providing this training.

The Department of Pediatrics trained 64 nurses and medical students in the placement of endotracheal and chest tubes, using 20 cats in eight visits of approximately three hours duration. Sixty-four hours was required of Surgical Research Labs personnel for initial anesthetic induction, maintenance and monitoring.

Orthopedic Service, Department of Surgery, utilized 32 rabbits and seven rats in 39 visits to train one staff surgeon and seven residents in microvascular surgery using the operation microscope. A total of 117 hours was spent to accomplish this training, requiring 195 hours of support by Surgical Research Labs personnel in pre-operative anesthetic induction, surgical preps, anesthesia monitoring, post-operative recovery and angiography.

Neurosurgery Service, Department of Surgery, used five rabbits in eight visits to train one staff surgeon and one resident in microvascular surgery techniques using the operation microscope. Twenty-four hours was spent in this training, requiring 40 hours of support by Surgical Research Labs personnel.

Thoracic Surgery Service, Department of Surgery, used six dogs in the training and evaluation of cardiopulmonary bypass methods. Two staff surgeons spent 66 hours in training, requiring 72 hours of support by Surgical Research Labs personnel in pre-operative anesthetic induction, surgical preps, anesthesia monitoring and pump operation.

General Surgery Service, Department of Surgery, used four dogs in training i6 surgeons in the use of staple guns. A total of 80 hours of training was received, requiring 24 hours of support by Surgical Research Labs personnel in pre-operative anesthetic induction, surgical preps, anesthesia monitoring, circulating and clean-up.

Urology Service, Department of Surgery, used two dogs in training three staff surgeons, four residents and two interns in the use of staple guns. Forty-five hours of training was received, requiring 12 hours of support by Surgical Research Labs personnel.

DCI-SRLS Training Support Summary - continued

In addition, two high school seniors from Aurora Public Schools Technical Center received on-the-job vocational training as veterinary aides and one senior was given training as a clincial laboratory aide under Memorandum of Agreement. A total of 358 hours of training was received, requiring 537 hours of supervision and instruction by personnel of the Surgical Research Labs.

Cost of Training

Suturing Techniques:	\$90.64/session	x	27	sessions	=	\$2,447.28
Pediatric Nurses:	14.35/animal	х	20	cats	=	287.00
Rabbit Microsurgery:	79.19/session	x	40	sessions	=	3,167.60
Rat Microsurgery:	61.94/animal	х	7	rats	=	433.58
Thoracic Surgery:	143.75/case	х	6	Cases	=	862.50
Staple Gun Exercises:	76.11/anima1	х	6	dogs	=	456.66
					-	(\$7,654.62)

OB-GYN

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2)) Prot No.: 76/	350	(3) Status: Terminated	
(4) Title: Evaluation of I	buprofen (Motrin) in trea	tment of dysmenorrhea	
(5) Start Date: September	1979	(6) Es+	Comp Date: June 1980	
(7) Principal Investigator		(8) Faci	lity: FAMC	
Gordon S. Park, M.D.,	CPT, MC	Department of Obstetrics&Gynecology		
(9) Dept/Sec: GYN Section		(10) As	soc Investigators:	
(11) Key Words:		None	3	
Treatment of dysmenorr	hea			
(12) Accumulative MEDCASE	(13) Est Accum OMA Cost:	· · · · · · · · · · · · · · · · · · ·	(14) Periodic continue Review Results: 5/80	
(15) *Study Objective:				
To compare the effecti	veness of Ibupro	fen (Motr	in) in the treatment of	

- primary dysmenorrhea.
- (16) *Technical Approach:
 Patients to be randomly treated with either aspirin, placebo, or
 Motrin for three consecutive cycles and comparison of subjective
 relief.
- (17) *Progress: Study terminated as of June 1980. No presentations or plans for publication have been formulated at this time.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(I)	Date: 30 SEP 80 (2) Prot No.: /8	3/350 (3) Status: Terminated
(4)	Title:	
	Inhibition of Premature Labor	With Terbutaline
(5)	Start Date:	(6) Est Comp Date: June 1979-terminated
(7)	Principal Investigator	(8) Facility: FAMC
	J.R. Bobitt, MD, Col, MC	
(9)	Dept/Sec: OB-GYN - OB Service	(10) Assoc Investigators:
(11)	Key Words:	D.D. Riston, MD, CPT, MC
	Inhibition of Premature Labor with	
	Terbutaline	
(12)	Accumulative MEDCASE (13) Est Accu	mulative (14) Periodic terminate
	Cost: OMA Cost	: Review Results: 5/80
(15)	*Study Objective:	

To study inhibitory effects of Terbutaline on premature labor.

(16) *Technical Approach:

Patients at less than 35 weeks of gestation, with no contraindicating condition such as ruptured BOW, intrauterine sepsis, or abruptio placentis, will be treated for premature labor with either Terbutaline or a placebo. The presence of labor and absence of fetal distress will be confirmed by electronic monitor. Entrance to the study will be approved by a member of the attending staff prior to obtaining permission from the hospital. (17) *Progress:

The project was terminated in June 1979 as ordered by the Office of the Surgeon General who ordered discontinuance of the I.V. administration of Terbutaline.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) 0.	ate: 30 SEP 80 (2)	Prot No.: 78/	351	(3)	Status:	Completed
(7) T	itle: An Evaluation o	f the Effect of	Suction	Drainag	e on Inf	ectious
	Morbidity in Pa	tients Undergoi	ng Cesare	ean Sect	ion.	
(5) 5	tart Date:		(6) Est	Comp Da	te: Term	inated
(7) P	rincipal Investigator		(8) Fac			
Bobit	t, J.R., M.D., Col, M	C	1			
(9) Dept/Sec:OB-GYN - OB Service			(10) Assoc Investigators:			
(11) Key Words: Effect of suction			W.D. Smith, M.D., Cpt, MC			
drainage on cesarean section patients.			J.J. Mancuso, M.D., Cpt, MC			
110	Community MEDGISET	(2.2) 5-4 0-	<u></u>	777	,, -	
	Accumulative MEDCASE Cost:	(13) Est Accum OMA Cost:				ontinue ults:5/80
(15)	*Study Objective:		·			

To determine if the incidence and severity of pelvic infections in patients undergoing cesarean section is significantly decreased through the use of retroperitoneal suction drainage of the uterine operative site.

(16) *Technical Approach:

We plan to compare the frequency and severity of pelvic infections among 50 patients undergoing cesarean section with suction drainage of the operative site, with a similar group of 50 patients without drainage. Patients considered infected at the time of cesarean section will not be included in the study. Patients on antibiotic medications will also be excluded. Any patient who will have had to hours of labor at the time of cesarean section or has ruptured (17) **Progress: (Cont'd)

This study was completed after 100 patients had been studied. There was found to be no difference in infectious morbidity among the two groups of patients. It has therefore been concluded that the routine use of suction drainage to decrease infectious morbidity in patients undergoing cesarean section is not indicated.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT Proto No: 78/351 (Blocks | through 17)

Cont'd from #(16)

membranes at the time of cesarean section is a candidate for the study. The study group will be drained by a hemovac suction apparatus whereas this technique will not be available to those patients in the control group. The suction catheter will be placed beneath the vesicouterine fold and brought out through the lower abdomen remaining extraperitoneal. Study and control patients will be selected by a table of random numbers prepared prior to the study.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.: 78,	/352	(3) Status: Completed		
(4)	Title: Amniotic Fluid	Infection in Pr	remature	Labor Patients with Intact		
	Membranes: As Determi	ned by Transabdo				
(5)	Start Date:		(6) Est Comp Date: Completed			
(7)	Principal Investigator		(8) Fac	ility: FAMC		
	Bobitt, J.R., M.D., Co	1, MC	<u> </u>			
(9)	9) Dept/Sec: OB-GYN - OB Service			(10) Assoc Investigators:		
(11)	(11) Key Words: Amniotic Fluid Infection			Clifford C. Hayslip, CPT, MC		
transabdominal ammiocentesis			James J. Damato, MAJ, MSC			
			Ì			
			l			
(12)	Accumulative MEDCASE	(13) Est Accum	ulative	(14) Periodic complete		
	Cost:	_OMA Cost:		Review Results: 8/80		
(15)	Study Objective:					

(15) #Study Objective:

To determine the presence, number and frequency of bacteria in the amniotic fluid of patients in premature labor with intact membranes.

(16) *Technical Approach:

Patients in premature labor with intact membranes will have an amniocentesis if they consent to participate in the study. Amniotic fluid will be analyzed for the following infectious parameters: 1) Quantative cultures, 2) Viral cultures, 3) Polymorphonuclear count, 4) Lactic dehydrogenase, and 5) Gram stain.

(17) *Progress:

Project completed.

1 /2/11	U	1 4	(110, 40)	78/352	
	_		1	101332	

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Sheet.)

SERVICE Obstetrics DEPARTMENT OB-GYN

Bobitt, J.R., Damato, J.J., Hayslip, C.C.: Amniotic Fluid Infection in Premature Labor Patients with Intact Membranes: As Determined by Transabdominal Amniocentesis. Submitted for publication. (C)

Presentations: None

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.: 78/	353	(3) Status: Ongoing	
(4)	Title: Prenatal Evalua	tion of Quantita	tive Cer	vical and Vaginal Cultures	
for	the Group B Streptocoo	ccus and Their F		hip to Maternal & Neonatal	
	Start Date:		(6) Est	Comp Date: Mar 80-terminated	
(7)	Principal Investigator	•	(8) Fac	ility: FAMC	
	Bobitt, M.D., Col, MC		<u> </u>		
(9)	Dept/Sec: OB-GYN - OI	B Service	(LO) As	ssoc Investigators:	
(11) Key Words: Prenatal Evaluation for Group B Streptococcus			G.L. Brown, Ph.D., Col, MSC J.J. Damato, MAJ, MSC		
(12)	Accumulative MEDCASE Cost:	(13) Est Accum OMA Cost:		(14) Periodic continue Review Result: 12/79	
1151	"Study Objective:				

To determine the incidence and clinical significance of Group B Streptococcus colonization in the cervix and vagina of prenatal women after 24 weeks gestation.

(16) *Technical Approach:

Antepartum vaginal cultures are collected by the clinical personnel in the Department of OB-GYN at weekly intervals and at delivery. Plates are streaked and growth quantitated by the Clinical investigation Service, Department of Microbiology. Results are blinded. Mother and newborn records are reviewed for infectious morbidity.

(17) *Progress:

This study was completed in March 1980 after approximately 700 patients had been studied. Maternal and Neonatal clinical charts are currently being reviewed to establish the infectious morbidity among the entire population. No data presently available for evaluation. Microbiologic cultures and antepartum evaluation - completed Compiling data - ongoing.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 78/350

#4 Infectious Morbidity.

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

30 SEP 80 (2) Prot No.: 79-350 (3) S	tatus:Ongoing					
A prospective study of endometrial changes with	exogenous					
hormonal therapy						
ate: June 1979 (6) Est Comp Date	: June 1 9 81					
al Investigator (8) Facility: FA	MC					
R. Shirts, M.D., CPT, MC						
: OB/GYN (10) Assoc Inves	(10) Assoc Investigators:					
rds:						
is hormore use in postmeno- Donald A. Simsen	Donald A. Simsen, M.D., COL, MC					
females.						
lative MEDCASE (13) Est Accumulative (14) Perio	odic continue					
1	ew Results: 11/79					
To determine by tissue diagnosis, the incidence of various forms of						
endometrial pathologic changes in women who use exogenous hormonal						
therapy in relief of perimenopausal and postmenopausal symptoms.						
OMA Cost: Review Dbjective: ermine by tissue diagnosis, the incidence of variatial pathologic changes in women who use exogen	ew Results ious forms ous hormon					

16) *Technical Approach:

We do yearly endometrial sampling on unopposed postmenopausal estrogen users, either by in office endometrial biopsies or formal $\rm D\&C$. The rate of abnormal biopsy results was tabulated.

171 #Progress:

Our results have been tabulated and prepared for publication. The attached article has been accepted for print in The Journal of Gynecologic Oncology.

It has been reported that women on both estrogen and progesterone postmenopausally have a decreased incidence of atypical endometrial pathologic changes. We will now look at the incidence of hyperplasia in this group of patients.

(To all C's, Depts/Svcs)

PUBLICATIONS occurring during FY 80

SERVICE Obstetrics

DEPARTMENT Obstetrics/Gynocology

(1) Simsen, D.A., Shirts, S.R., Howard, F.M., Sims, J., Hill, J.M.,: Endometrial Findings in Asymptomatic Postmenopausal Women on Exogenous Estrogens - A Preliminary Report. (Submitted to Journal of Gynecological Oncology for publication - In Press)

Presentations: None

PEDIATRICS

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.: 75,	(3) Status: Ongoing
(4) Title: Effect of Prophylactic Antibio	otic Therapy on Cravid Group B
Beta Hemolytic Streptococcus (Carriers.
(5) Start Date: September 1975	(6) Est Comp Date: 1982
(7) Principal Investigator	(8) Facility: FAMC
Gerald B. Merenstein, Col, MC	
(9) Dept/Sec: Pediatrics/Newborn	(10) Assoc Investigators:
(11) Key Words:	John R. Plerce, LTC, MC
Group B Strep, Prophylactic Penicillin	
(12) Accumulative MEDCASE (13) Est Accum	ulative ((14) Periodic continue
Cost: OMA Cost:	Teview Results: 8/80

(15) *Study Objective:

To evaluate the use of prophylactic antibiotic therapy in antepartum GBHS carriers with regard to colonization of the infant.

(16) *Technical Approach:

Gravid Females are evaluated for the presecne of Group BHS using selective broth and are then considered candidates for prophylactic antibiotics or control. The infants are evaluated for colonization with GBHS.

(17) *Progress:

We are currently reviewing the literature and otherwise evaluating methods of more rapidly identifying GBHS carriers. The rapid identification will then permit random evaluation of preterm deliveries.

FAMC	V/U	110	(Frot	No)	7	5/401
			•	•	•	,

PUBLICATIONS for FY 80 Annual Progress Report (2nd Part of Detail Summary Shect.)

SERVICE Newborn DEPARIMENT Pediatrics

- 1. Yost, C. C., Calcagno, J. V., Merenstein, G. B., Todd, W. A., Dashow, E. E., Brown, G. L., Tull, A. H. and Kile, D. E. Group B Beta Hemolytic Streptococcus: Improved Culture Detection and a Controlled Treatment Trial. Clinical Research 24, 186A, 1976.
- 2. Luzier, T. L., Merenstein, G. B., Todd, W. A., Yost, C., C., Brown, Q. L. The Treatment of Gravid Females at Term Colonized with Group B Streptococcus A Randomized Controlled Study. Clinical Research 26, 200A, 1978.
- 3. Pierce, J. R., Merenstein, G. B. Streptococcal Sudden Unexpected Death Syndrome. Clin Res. 27, 128A, 1979.
- 4. Merenstein, G. B., Todd, W. A., Brown, G., Yost, C. C., Luzier, T. L. Group B Hemolytic Streptococcus: Randomized Controlled Treatment Study at Term. OB-GYN 55, 315-318, 1980.

FAMC WU No (Prot No) 75/401

PRESENTATIONS for FY 80 Annual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE	Newborn	DEPARTMENT	Pediatrics

- Calcagno, J. V., Brown, G. L., Tull, A. H. et al. Evaluation of Three Collection-Transport Systems for the Isolation of Group B Streptococcus from PrePartum Women and Neonates. Presented: American Society fro Microbiology, Atlantic City, N. J. 1976.
- 2. Luzier, T. L.. The Treatment of Gravid Females at Term Colonized with Group B Beta Hemolytic Streptococcus: A Randomized Controlled Study. Presented: Military Section, American Academy of Pediatrics, New York, New York, November 1977.
- 3. Luzier, T. L. The Treatment of Gravid Females at Term Colonized with Group B Strep. Presented: Western Society for Pediatric Research, Carmel. California 2 February 1978.
- 4. Pierce, J. Streptococcal Sudden Unexpected Death Syndrome. Presented: Aspen Conference on Perinatal Research, Aspen, Colorado July 1978.
- 5. Pierce, J. Streptococcal Sudden Unexpected Death Syndrome. Presented: American Academy of Pediatrics, District VIII, Section on Perinatal Medicine. Park City, Utah, May 1980.
- 6. Merenstein, G. B. The Prevention of Group B Streptococcal Colonization Presented: American Academy of Pediatrics District VIII, Section on Perinatal Medicine, Park City, Utah, May 1980.
- 7. Merenstein, G. B. The Spectrum of Group B Streptococcal Disease in the Newborn. Presented: Aspen Conference on Perinatal Medicine, July 1980.

(HSCR 40-23, App. C.) / NNUAL PROGRESS REPORT (Detail Summary Sheet)

(4) Title: Early Digitalization in Premature Infants with Idiopathic Respiratory Distress (IRDS) Who Have Echocardiographic Evidence of Left Atrial Enlargement(5) Start Date: January, 1976 (6) Est Comp Date: July, 1981 (7) Principal Investigator (8) Facility: FAMC (9) Dept/Sec: Pediatrics/Newborn (10) Assoc Investigators: (11) Key Words: Digitalization, infants, idiopathic respiratory distress, echocardiographic, left atrial enlargement. (12) Accumulative MEDCASE (13) Est Accumulative (14) Periodic continue Review Results: 6/80 (15) *Study Objective: To determine the usefulness of early digitalization in altering the progression of congestive heart failure and left-to-right shunting through the PDA in premature infants with IRDS.	(i)	Date: $30 \text{ SEP } 80 (2) \text{ Prot No.:}$	75/402 (3) Status: Ungoing
Enlargement5) Start Date: January, 1976 (6) Est Comp Date: July, 1981 (7) Principal Investigator **Gerald L. Way, M.D., MAJ, MC (9) Dept/Sec: Pediatrics/Newborn (11) Key Words: Digitalization, infants, idiopathic respiratory distress, echocardiographic, left atrial enlargement. (12) Accumulative MEDCASE (13) Est Accumulative (14) Periodic continue Cost: OMA Cost: Review Results: 6/80 (15) **Study Objective: To determine the usefulness of early digitalization in altering the progression of congestive heart failure and left-to-	(4)	Title: Early Digitalization in Pr	remature Infants with Idiopathic Res-
(7) Principal Investigator *Gerald L. Way, M.D., MAJ, MC (9) Dept/Sec: Pediatrics/Newborn (11) Key Words: Digitalization, infants, idiopathic respiratory distress, echocardiographic, left atrial enlargement. (12) Accumulative MEDCASE (13) Est Accumulative (14) Periodic continue Cost: OMA Cost: Review Results: 6/80 (15) *Study Objective: To determine the usefulness of early digitalization in altering the progression of congestive heart failure and left-to-	_	piratory Distress (IRDS) Who Have	Echocardiographic Evidence of Left Atrial
(9) Dept/Sec: Pediatrics/Newborn (11) Key Words: Digitalization, infants, idiopathic respiratory distress, echocardiographic, left atrial enlargement. (12) Accumulative MEDCASE (13) Est Accumulative (14) Periodic continue Cost: OMA Cost: Review Results: 6/80 (15) *Study Objective: To determine the usefulness of early digitalization in altering the progression of congestive heart failure and left-to-			(6) Est Comp Date: July, 1981
(11) Key Words: Digitalization, infants, Gerald B. Merenstein, M.D., COL, MC idiopathic respiratory distress, echocardiographic, left atrial enlargement. (12) Accumulative MEDCASE (13) Est Accumulative (14) Periodic continue Cost: OMA Cost: Review Results: 6/80 (15) *Study Objective: To determine the usefulness of early digitalization in altering the progression of congestive heart failure and left-to-	(7)	Principal Investigator *Gerald L. Way, M.D., MAJ, MC	(8) Facility: FAMC
idiopathic respiratory distress, echocardiographic, left atrial enlargement. (12) Accumulative MEDCASE (13) Est Accumulative (14) Periodic continue Cost: OMA Cost: Review Results: 6/80 (15) **Study Objective: To determine the usefulness of early digitalization in altering the progression of congestive heart failure and left-to-	(9)	Dept/Sec: Pediatrics/Newborn	(10) Assoc Investigators:
echocardiographic, left atrial enlargement. (12) Accumulative MEDCASE (13) Est Accumulative (14) Periodic continue Cost: OMA Cost: Review Results: 6/80 (15) *Study Objective: To determine the usefulness of early digitalization in altering the progression of congestive heart failure and left-to-	$\overline{(11)}$	Key Words: Digitalization, infa	nts, Gerald B. Merenstein, M.D., COL, MC
enlargement. (12) Accumulative MEDCASE (13) Est Accumulative (14) Periodic continue Cost: OMA Cost: Review Results: 6/80 (15) *Study Objective: To determine the usefulness of early digitalization in altering the progression of congestive heart failure and left-to-		idiopathic respiratory distress,	John R. Pierce, M.D., LTC, MC
(12) Accumulative MEDCASE (13) Est Accumulative (14) Periodic continue Cost: OMA Cost: Review Results: 6/80 (15) *Study Objective: To determine the usefulness of early digitalization in altering the progression of congestive heart failure and left-to-		echocardiographic, left atrial	
Cost: OMA Cost: Review Results: 6/80 (15) *Study Objective: To determine the usefulness of early digitalization in altering the progression of congestive heart failure and left-to-	_	enlargement.	
(15) *Study Objective: To determine the usefulness of early digitalization in altering the progression of congestive heart failure and left-to-	(12)	Accumulative MEDCASE (13) Est Ac	ccumulative (14) Periodic continue
in altering the progression of congestive heart failure and left-to-		Cost: OMA Co	Review Results: 6/80
· · · · · · · · · · · · · · · · · · ·	(15)	*Study Objective: To determine th	he usefulness of early digitalization
right shunting through the PDA in premature infants with IRDS.		in altering the progression of co	ongestive heart failure and left-to-
		right shunting through the PDA in	n premature infants with IRDS.

- (16) *Technical Approach: Infants with RDS and left atrial aortic diameter ratio of greater than 1.0 by echocardiograph will be included in the two study groups. The two study groups will be Group A-infants who will be digitalized with 40 mcg/kg dose of digoxin and maintained at 10 mcg/kg/day. Group B-infants who will not receive digoxin unless they clinically demonstrate overt congestive heart failure. Echocardiogram will be repeated every other day throughout the respirator course, and
- (17) *Progress: There have been no new patients added to this study during the past year; however, the data is being evaluated to determine if we achieved any meaningful results. It is anticipated that more patients may be added to this study this year.

*Deceased

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 75/402

16. Technical Approach (Continued): subsequently only if abnormal findings remain. Additional echocardiograms will be obtained if the clinical situation deteriorates. Echocardiograms will be evaluated with coinciding arterial blood gases, chest x-rays, EKG's, and laboratory data which will be done as needed for clinical management.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)			(3)	Status: On	going
(4)	Title: Evaluation of	/entricular F	unction and	Pulmonar	v Vascular	
	Resistance in A					
(5)	Start Date: December	1977	(6) Est	Comp Dat	e: Decembe	r 1981
(7)	Principal Investigator Carl Gumbiner, Maj, MG	C	(8) Fac	ility: F	AMC	
(9)	Dept/Sec: Pediatrics/	Newborn	(10) A	ssoc Inve	stigators:	
(11) Key Words: Newborn, Asphyxia, Heart			Patr	ick Glaso	ow, Cpt, MC	
(12)	Accumulative MEDCASE Cost:	(13) Est Acc OMA Cos			iodic con iew Result	
(15)	#Study Objective:					
			_			

To serially measure left ventricular in newborns with asphyxia neonatorum .

(16) *Technical Approach:
All infants with the diagnosis of asphyxia meonatorum are candidates for this study. Study infants will be serially evaluated with echocardiograph.

17) *Progress:

The addition of a pediatric cardiologist to our staff will permit the resumption of this study that was temporarily suspended with the medical retirement of our previous pediatric cardiologist.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

<u>(1)</u>	Date: 30 SEP 80 (2)	Prot No.:	77/403	(3)	Status:	Ongoing
(4)	Title: Determination	of Pulmonary	Vascular	Resistanc	e in Newb	orn
	Infants at 528	0 feet using	Right-sid	ed systol	ic time in	ntervals.
(5)	Start Date: September	1977			te: Decem	
(7)	Principal Investigator H. Philip Stalker, Cpt,		(8) Fa	cility:	FAMC	
(9)	Dept/Sec: Pediatrics/	Newborn	(10)	As soc Inv	estigators	·:
(11)	Key Words: Newborn, Pulmonary Vasc Echocardiogram, Electro		C		ner, Maj,	
(12)	Accumulative MEDCASE Cost:	(13) Est Aco			riodic con view Resul	
$(15)^{\circ}$	#Study Objective:					

To determine the normal range of pulmonary vascular resistance and electrocardiograms at 5280 feet.

(16) *Technical Approach:

All normal infants admitted to the normal nursery will have echo-and/or electro-cardiograms in the first 24 hours of life.

(17) #Progress:

Due to the medical retirement of the original principal investigator little progress has been made in FY 80. The new investigators have added electrocardiograms to the study and it is anticipated that FY 81 will be productive.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2) Prot No.: 78			
(4)	Title: The Influence of Body Position	ning on Gastric Residuals in Pre-		
	mature Infants			
(5)	Start Date: July, 1978	(6) Est Comp Date: July, 1981		
(7)	Principal Investigator	(8) Facility: FAMC		
	Barbara S. Turner, MAJ, ANC			
(9)	Dept/Sec: Pediatrics/Newborn	(10) Assoc Investigators:		
(11)	Key Words: Body position, gastric	None.		
	residuals, premature infants			
(12)	Accumulative MEDCASE (13) Est Accur	nulative I(14) Periodic continue		
	Cost: OMA Cost			
(15)	"Study Objective: To compare the amo			
	premature infant's stomach three how	rs after feeding in relation to		

- *Technical Approach: Premature infants requiring gavage feedings who were less than 35 weeks gestation were examined. Infants meeting outlined criteria were fed the same formula, at the same time and in the same manner as previously used. Gastric residuals were measured and recorded with body position. Positions used are right side, left side and stomach.
- (17) *Progress: Data collection began in July, 1978. To date, 20 subjects have been studied. Data have been recorded on gastric residuals, body positions as well as the extraneous variables of gestational age, sex, race and type of formula. Data analysis will begin on 1 Jan 1981.

DEPARTMENT OF CLINICAL INVESTIGATES. LITZSIMONS ARMY MEDICAL CLATER Aurora, Colorado 8504.

AMHUAL PROGRESS PEPORT (MOUNT 40-23, App. C.) (Octail Summary Sheet)

	Date: 30 SEP 80 (2) Prot No.:	
(4)	Title: The Influence of Body Position	ing on Gastric Residuals in Pre-
	mature Infants Requiring Ventilatory	Assistance
$\overline{(5)}$	Start Date: July, 1978	(6) Est Comp Date: July, 1981
$(7)^{-}$	Principal Investigator	(8) Facility: FAMC
	Barbara S. Turner, MAJ, ANC, RN, MS, MA	
<u>(9)</u>	Dept/Sec: Pediatrics/Newborn	(10) Assoc Investigators:
$\overline{(11)}$	Key Words: Gastric residuals,	
	premature infants, body positioning	None.
(12)	Accumulative MEDCASE (13) Est Accum	
		review Results: 5/80
(15)	*Study Objective: To compare the amo	unt of gastric residuals in the
	premature infant's stomach three hou	rs after feeding in relation to th
	body position of the infant.	

- (16) *Technical Approach: Premature infants requiring ventilatory assistance and gavage feedings who were less than 35 weeks gestation were examined. Infants meeting outlined criteria were fed the same formula, at the same time, and in the same manner as previously used. Gastric residuals were measured and recorded with body position. Positions used are left side, right side and and back.
- (17) *Progress: Data collection began in July, 1978. To date 20 subjects have been studied. Data have been recorded on gastric residuals, body positions as well as the extraneous variables of gestational age, sex, race, and type of formula. Data analysis will begin on 1 Jan 1981.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

$\langle 1 \rangle$	Date: 30 SEP 80 (2) Prot No.: 78	
(4)	Title: Assessment of the Relationshi	p of Serum Amino Acid Levels to
	Episodes of Apparent Sepsis.	
(5)	Start Date: July, 1978	(6) Est Comp Date:
(7)	Principal Investigator	(8) Facility: FAMC
	John R. Pierce, M.D., LTC, MC	
(9)	Dept/Sec: Pediatrics/Newborn	(10) Assoc Investigators:
$\overline{(11)}$	Key Words: Serum amino acid, levels	
	sepsis.	Thomas P. O'Barr, Ph.D., DAC
(12)	Accumulative MEDCASE (13) Est Accum	ulative (14) Periodic terminate
	Cost: OMA Cost:	Review Results: 3/80
$\overline{(15)}$	"Study Objective: To determine the	relationship between possible ab-
	normal serum amino acid levels and c	linical episodes of apparent sepsis
	in premature infants.	

- (16) *Technical Approach: Blood samples will be taken from each premature infant (26-36 weeks gestation) who is suspected of having sepsis. These samples will be examined by thin-layer chromatography for the amino acids: tyrosine, phenylalanine, cystine and methionine. A relationship between elevated levels of these amino acids and episodes of clinical sepsis (signs consistent with sepsis but negative cultures) is being sought.
- (17) *Progress: Since no patients have been enrolled in the study and interest and attention have been placed on other projects, it is requested that this project be terminated.

(HSCE 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

:1)	Date: 30 SEP 80 (2)	Prot No.: 78/	407	(3) Status: Terminated
141	Title: Evaluation of 1	New Criteria in	the Diag	nosis of Acute Renal
	Failure in the	Full- term and	remature	Newborn.
(5)	Start Date: July 19			Comp Date: July 1980
(7) Principal Investigator			(8) Fac	ility: FAMC
Jo	hn Moore, Cpt, MC		}	
(9) Jept/Sec: Pediatrics			(10) As	soc Investigators:
(11) Key Words:			Cerald	B. Merenstein, Col. MC
Renal Failure, Full Term Newborn,			Cerara	J. Herenstern, oor, no
P	remature Newborn		i	
			}	
.12)	accumulative MEDCASE	(13) Est Accum	ulative	(14) Puriodic terminate
	Sost:	OMA Cost:		Roziew Results: 3/80
((()	-Study Objective:			
	To determine the norm	nal values of ur	ine and	serum urea nitrogen,
	creatinine, sodium, r	octassium, and c	hloride	in full-term and premature
	· ·	·		ed oral or I.V. sodium
				ness of the urine-to-plasma
				the fractional excretion of
				renal versus renal failiure
(16)	"Technical Approach:			e determined.

Randomly selected newborns of consenting parents have been studied.

17: #Progress:

Due to the publication, by other authors, of a similar study meeting our objectives, the study has been terminated.

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

	Nate: 30 SEP 80 (2)				Status:	Completed
.,	Title: The Tired Adole	scent: An Analy	sis of E	tiology		
- 1	Staft Date: January 197	'9	(6) Est	Comp Da	te: Compl	eted
	Principal Investigator Dr. Alan R. Figelmar		(8) Fac	ility:	FAMC	
~~~	De. 1/Sec: Pediatric/Ad	lolescent Med S	vc(10) A	15576 1.V	estigator	5:
	to key Words: adolescent fatigue, clinical correlation			. Gentry	W. Yeatm	an
	econulative MEDCASE	(13) Est Accur OMA Cost			riodic co view Resu	
1.5	·Stud. chiective:					

- a. To examine the conditions that may cause the adolescent to present to an outpatient clinic with the chief complaint of tiredness.
- b. To determine the clinical correlation, if any, of age, sex, growth and maturation, diet, and exercise with the complaint of tiredness.
- c. To determine the clinical correlation, if any, of social, sexual, psychological and medical history with tiredness.

  16) **Technical Approach:

A lengthy history and physical was performed along with an extensive laboratory evaluation was performed.

17. #Progress:

The patients and controls have been seen and evaluated. At present Dr. F. gelman is in the process of analyzing the data and preparing it for publication.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 78/408

Continuation:

15. Study Objective:
d. To determine the clinical correlation, if any, of subclinical mononucleosis, anicteric hepatitis, hypo or hyperthyroidism, urinary tract infection, or nephritis with fatigue.

e. To determine laboratory correlation, if any, of tiredness with minerals (Fe, Zn), enzymes (CPK, GGT, Alkphos), hemogram, or uric acid.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No	79/4	·00	(3)	Status:	Ongoing
(4)	Title:						
	Effect of Adriamycin	in Platel	et Func	tion			
(5)	Start Date: November	1978		(6) Est	Comp Da	te: June	1981
$(7)^{-}$	Principal Investigator	•			ility:		
	Askold D. Mosijczuk,	M.D.					
(9)	Dept/Sec: Pediatrics			(10) A	ssoc Inv	estigator	· 5:
(11)	Key Words:		T. Philip O'Barr, Ph.D., DAC Ellen Swanson, M.S., DAC				
	Effect of Adriamycin Function	in Placel	.e t	Ellen .	swanson,	M.S., DA	
(12)	Accumulative MEDCASE Cost:		Cost:	lative		riodic <b>c</b> c	ontinue ults: 5/80
(15)	"Study Objective:						
	To determine and meas	ure possi	ble eff	ect of a	adriamyc	in on pla	telet

The second second

- (16) *Technical Approach: Forty ml of blood are drawn from a healthy adult volunteer. The blood is centrifuged and PRP and PPP are drawn off. In a platelet aggregometer, 20 ml of adriamycin are added to the PRP in one cuvette, with the other cuvette with PRP serving as a control. After one minute, aggregating agents—ADP, Epinephrine, collagen—are added to each cuvette and the percent aggregation compared in the two samples. Aliquots of PRP are removed at certain times to measure the amount of tromboxane released.
- (17) *Progress: To date, 23 donors have been studied; in five of these a slight to moderate degree of inhibition of platelet aggregation has been found, which was also reflected by decreased levels of thromboxane.

Additional donors are planned to be tested, as well as attempts to determine the possible mechanism by which adriamycin decreases platelet function. This is being done by reacting the platelets with thrombin and measuring the intermediate products of platelet phosphalipid metabolism on a column.

ANNUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2) Prot No.: 79	401	(3) Stati	us: Terminated
(4)	Title: An Investigation of the Effec	s of Aminog	lycosides	and Lasix
	upon the Inner Ear of the Guinea Pig			
(5)	Start Date: June 79	(6) Est Co	mp Date:	May 80
(7)	Principal Investigator	(8) Facili	ty: FAMC	
	John D. Daigh, Jr., CPT, MC			
(9)	Dept/Sec: Pediatrics	(10) As so	c Investiga	ators:
$\overline{(11)}$	Key Words:	Patricl	k Glasow, C	:PT, MC
	Aminoglycosides			Ph.D.,CPT,MSC
	Lasix	W. Nich	nolas Glab,	B.S., SP6
	Inner Ear			
$(\overline{12})$	Accumulative MEDCASE (13) Est Accum	ulative (1	4) Periodio	terminate
	Cost: OMA Cost:	ĺ	Review F	Results: <b>8/80</b>
$\overline{(15)}$	#Study Objective:			
	The objective is to establish the ef Guinea pig of aminoglycosides and la	fect unon th six.	ne cochlea	of the

- Guinea pigs were given various amounts of aminoglycosides and lasix.
  The animals have been sacrificed and their cochlea examined under light and electron microscopy.
- The study was terminated due to the unanticipated, early PCS of the Principal Investigator to enter Pediatric Sub-specialty training.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.: 79/	402	(3) Status: Terminated
(4)	Title: An Analysis of	the Health Care	Needs o	f Teenagers Living in
Singl	e Parent or Reconstitu	ted Families.		
1 - /	Start Date: Has not b		(6) Est	Comp Date: Is not being done.
(7)	Principal Investigator		(8) Faci	lity: FAMC
	Dr. Alan R. Figelman		Fitz	simons Army Medical Center
(9)	Dept/Sec: Dept of Pedi	atrics, FAMC	(10) As	soc Investigators:
$\overline{(11)}$	Key Words:		Dr	. David W. Wells, and
	h Care; Teenagers; Sin stituted Families	gle Parent;	Dr	. Richard T. Takao.
(12)	Accumulative MEDCASE Cost:	(13) Est Accumu OMA Cost:	lative	(14) Periodic continue Review Results: 11/79
(15)	"Study Objective.			

N/A due to the termination of the study.

(16) *Technical Approach:

N/A due to the termination of this study.

(17) *Progress: We have decided not to do this study at the present time.

ANNUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.:	79/403	(3) Status: On going
(4)	Title: Evaluation of T	ranscutaneou	us Oxygen Mo	nitoring in the Acute
	Management of I		RDS	
(5)	Start Date: January 1	980	(6) Est	Comp Date: July 1981
(7)	Principal Investigator		(8) Fac	ility: FAMC
	Gerald B. Merenstein,	MD, Col, MC		
(9)	Dept/Sec: Pediatrics/	Newborn	(10) A	ssoc Investigators:
(11)	Key Words:		Howard	Kilbride, MD, Maj, MC
T	ranscutaneous Oxygen Mo	nitoring	1	Frank, MD, Maj, MC
	, , ,	• •	i	, , ,
(12)	Accumulative MEDCASE	(13) Est Ac	cumulative	(14) Periodic continue
	Cost:	OMA Co	ost:	Review Results: 10/79
(15)	*Study Objective:		<del></del>	

To determine the efficacy of continuous transcutaneous  $\mathrm{PO}_2$  monitoring in the acute management of infants with RDS

(16) *Technical Approach:

Infants less than 34 weeks gestation with RDS will be assigned to 24 hours of continuous transcutaneous oxygen monitoring. They will have the data blinded in either the first or second 12 hours.

### (17) *Progress:

To date 17 infants have been studied. The study will have sufficient infants by July 1981.

Publications: None

FAMC	WU	No	(Prot	No	79/403
------	----	----	-------	----	--------

PRESENTATIONS for FY 80 Annual Progress Report (3rd Part of Detail Summary Sheet)

SERVICE Newborn DEPARTMENT Pediatrics

Kilbride, H. Transcutaneous oxygen monitoring. Presented: Aspen Conference on Perinatal Research, July 1980. (Aspen, CO)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

79/404 (3) Status: Ongoing
Evacuation on Bilirubin Levels in
ealthy Full-term Infants
(C) Est Com: Date: January 1981
(8) Facility: FARC
(10) Assoc Investigators:
Marilyn DiGirol, LTC, ANC
Jan Collins, Cpt, ANC
Leonard Weisman, Maj, MC

(12) Accumulative MEDCASE (13) Est Accumulative (14) Periodic continue Cost: Peview Results: 12/79

(15) Study Objective:

- a. To determine the effect of glycerine suppositories on peak bililrubin levels in breast and formula fed infants.
- b. To compare peak bilirubin levels in breast and formula fed full term infants.
- (16) *Technical Approach:

500 Healthy fullterm infants will be randomly assigned to one of four groups including suppository or control and breast or bottle fed. Bilirubins will be measured serially by a bilirubinometer.

(17) *Progress:

Funds have been obtained from the March of Dimes to purchase the Bilirubinometer by early 1981.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2) Prot No.: 79	/405 (3) Status: Ongoing
(4)	Title: Assessment of Maternal Fever i	n the Immediate Prenatal Period
	as a Predictor of Perinatal Newborn I	
(5)	Start Date: January, 1981	(6) Est Comp Date: July, 1982
(7)	Principal Investigator	(8) Facility: FAMC
	Howard Kilbride, M.D., MAJ, MC	
(9)	Dept/Sec: Pediatrics/Newborn	(10) Assoc Investigators:
(11)	Key Words: Maternal fever, re: perinatal infections	Gil Frank, M.D., MAJ, MC John Steenbarger, M.D., LCDR, MC, USN
(12)	Accumulative MEDCASE (13) Est Accum Cost: OMA Cost:	
(15)	*Study Objective: To determine the	incidence of serious perinatal
	infections in infants born to febril	e mothers.

- (16) *Technical Approach: Mothers who are febrile within 24 hours of delivery as well as a matched control mother will have blood and placental cultures at the time of delivery. Each infant born to these study and control mothers will have peripheral blood, stool and umbilical cultures, CBC, platelet count, C-reactive protein all within 6 hours of birth. Each study infant will have a chest x-ray. The CBC and platelet count will be repeated at 24 hours.
- (17) *Progress: Due to the PCS move of the principal investigator, no patients have as yet been enrolled in the study. The associate investigators will assume responsibility for the protocol and the study will be begun in the immediate future. There have also been some delays as HSC has asked for some clarifications of the volunteer agreement.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 79/405

6. Technical Approach (Continued): CSF will be obtained on each infant treated with antibiotics or as clinically indicated. Specimens for viral cultures will also be obtained. A data collection sheet will be maintained on each mother and infant pair. At the end of the study period, the data will be analyzed to determine the clinical course of infants born to febrile mothers and the incidence of bacterial and viral infection in those infants compared to control infants.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

$(1)_{-}$	Date: 30 SEP 80 (2)	Prot	No.:	79/406	(3) Status:	Ongoing
(4)	Title:					<del></del>
	Intergroup Ewir	g's Sa	rcoma o	f Pelvic ar	nd Sacral Bones	
(5)	Start Date: 27 March	1980.		(6) Est	Comp Date:198	2
(7)	Principal Investigator			(8) Fac	ility: FAMC	
	Askold D. Mosijczuk,	M.D.				
(9)	Dept/Sec: Pediatrics			[(10)] As	soc Investigator	., :
(11)	Key Words:			None		
	Intergroup Ewing's Sa	rcoma o	of	}		
	Pelvic and Sacral Bor	es				
<del>, , , , , .</del>						
(12)	Accumulative MEDCASE			umulative	(14) Periodic co	
7 1 17 X	Cost:		OMA Cos	t:	Review Resu	lts: 5/80

(15) *Study Objective:

- l. Improve the survival of patients with localized Ewing's sarcoma of the pelvis and sacrum who have no evidence of metastases by using an intensive multimodal therapeutic approach.
- 2. Determine the effectiveness of high dose intermittent chemotherapy to prevent local recurrence of disease and/or metastases.

### (!6) *Technical Approach:

Patients with Ewing's sarcoma of pelvic and sacral bones receive surgery, radiation and chemotherapy according to protocol guidelines and tumor survival and response are measured.

### (17) Progress:

To date, no FAMC patients have been entered on this study. Nationally, the study is progressing satisfactorily and is open to new entries.

Proto No:^{79/406}

- (15) 3. Determine the effectiveness of surgical resection to control local disease.
- 4. Determine the effectiveness of a uniform radiation therapy regimen to control local disease.
- 5. Identify, determine and compare the degree of early and late toxicity and sequelae of therapy.
- 6. Evaluate and confirm the prognostic characteristics with respect to the tumor and the host.

ANNUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sheet)

$\overline{(1)}$	Date: 30 SEP 80 (2) Prot No.: 79	9/407 (3) Status: Ongoing
(4)	Title:	
	Intergroup Ewing's Sarcoma Pel	vic and Sacral Sites Excluded
(5)	Start Date: 27 March 1980	(6) Est Comp Date: 1982
(7)	Principal Investigator	(8) Facility: FAMC
	Askold D. Mosijczuk, M.D.	
(9)	Dept/Sec: General Pediatrics	(10) Assoc Investigators:
(11)	Key Words:	None
	Intergroup Ewing's Sarcoma; Pelvic	
	and Sacral Sites Excluded	
(12)	Accumulative MEDCASE (13) Est Accum	
	Cost: OMA Cost	: Review Results: 5/80
$I = I \cup Y$	* Study Objective:	

*Study Objective: (15)

- 1. Improve the survival of patients with localized Ewing's sarcoma of bone who have no evidence of metastases at diagnosis with an intensive multimodal therapeutic approach.
- 2. Determine the effectiveness of high dose intermittent chemotherapy as compared to moderate dose continuous chemotherapy to prevent local relapse and/or (**吓君**) as共和國民間 (**吓君**) Approach:

Patients with Ewing's sarcoma, except those involving pelvic and sacral bones, receive surgery, radiation, and chemotherapy according to protocol guidelines and tumor response and survival are measured.

#### (17) *Progress:

To date, no FAMC patients have been entered on this study. Nationally, the study is progressing satisfactorily and is open to new entries.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 79/407

(15)

- 3. Determine the effectiveness of a uniform radiation therapy regimen to control local disease.
- 4. Determine the effectiveness of surgical resection to control local disease.
- 5. Identify, determine and compare the degree of early and late toxicity and sequelae of therapy.
- $6.\,\,$  Evaluate and confirm the prognostic characteristics with respect to tumor and host.

ANNUAL PROGRESS REPORT a a ac-23, App. C.) (Detail Summary Sheet)

	Nate: 30 SEP 50 (2) Prot No.: 79	7408 (3) Status: Ondoing
7,	T + 10:	
	Intergroup Rhabdomyosarcoma St	udy I i
	'art Date: 17 Mar 80	(C) Est Comp Date: 1982
	Principal Investigator	(8) Facility: FAMC
_	Askold D. Mosifezuk, M.D.	
	Nept. Sec: General Pediatrics	(IC) Associate tigators:
	Rev Words:	
	Intergroup Rhabdomyosarcoma Study II	Nor.e
	Accumulative MEDCASE (13) Est Accum Cost: OMA Cost:	review Results: 5/80
1157	Study Objective: The objectives of	this study are to determine if
cycle	ophosphamide can be dropped from the s	standard VAC regimen with radiation
omit	ted without jeopardizing disease contr	ol and survival, and if so, if there
woul	d be less side effects without it, par	rticularly testicular, ovarian, and
rena	l dysfunction in Clinical Group I Dise	ease. In Clinical Group II Disease,
it i	s to determine if repetitive courses of	of "pulse" VAC improve the dur-
atio	n of complete remission and survival b	peyond that which is now (cont'd)
(16)	#Technical Approach:	
Pati	ents with rhabdomyosarcoma received s	urgery, radiation, and chemotherapy

according to protocol guidelines, and tumor response and survival is resoured.

### (17) *Progress:

To date, no FAMC patients have been enrolled on this study. Nationally, the study is progressing satisfactorily and is open to receive entries.

Proto No: 79/408

#### (15) cont'd:

achievable for microscopic residual disease with cyclic-sequential vincristine and dactinomycin, all patients receiving post-operative radiation to the tumor bed. In Clinical Group III and IV Disease, it is to determine if adriamycin, if given in pulse combination with vincristine and cyclophosphamide ("pulse" VADRC), improves the complete remission and survival beyond that now achievable with "pulse" VAC, all patients receiving radiation to the tumor bed and sites of metastases. It is also to determine if two years of repetitive pulse therapy is superior to the non-repetitive pulse regimens previously employed in IRS-1 for Groups III and IV disease (Regimens E and F). In the case of "Extremity Rhabdomyosarcoma Requiring Primary Amputation", it is to determine if two years of repetitive "pulse" VAC will improve the duration of remission and survival in patients subjected to primary major amputation for primary tumors localized in the extremity. In the case of "Rhabdomyosarcoma Localized in the Nasopharynx-Nasal Cavity, Middle Ear and Paranasal Sinus" the objective is to determine if the "prophylactic" local meningeal radiation with or without intrathecal chemotherapy can prevent direct meningeal extension of disease and improve the duration of remission and survival in these patients. In "Rhabdomyosarcoma Localized to the Pelvis (vagina, uterus, bladder, prostrate)" it is to determine if a primary chemotherapeutic and radiotherapeutic approach can avoid the disability associated with radical surgery without jeopardizing local disease control and survival. In "lymphatic Involvement in Rhabdomyosarcoma" it is to determine what the frequency and significance is of regional lymph node involvement in relation to primary site of tumor origin. In relation to "Pathology" it is to determine the relationships between the special and undifferentitated cell types I and II (Ewing's tumor of soft tissue) and classical rhabdomyosarcomas in terms of biological behavior, ultrastructural features, and response to therapy.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

71)	Date: 30 SEP 80 (2)	Prot No.: 7	9/409	(3) Status: Ongoing
(4)	Title:			
	National Wilm'	s Tumor Study		
(5)	Start Date: 27 March	1980		Corp Date: 1982
77)	Principal Investigator		](8) Fac	ility: FAMC
	Askold D. Mosijczuk, M	.D	<u> </u>	
(9)	Dept/Sec: General Ped	iatrics	$\int (z  z) = K$	, oc 1: zestigators:
(11)	Key Words:			
	National Wilm's Tumor	Study	l'or.	е
(12)	Accumulative MEDCASE Cost:	(13) Est Accum OMA Cost:		(14) Periodic continue Review Res.lts: 5/80
(15)	-Study Objective:			
(6)	antormation regarding than information with to treatment a socidin unreset, cary treatment treatment hypotheler (Tychnicel Spacoach)	gross and hist treatment and q to stading, s in patients re ty randomized,	ologic me clinical o as net purinica pro posti	turs no by mathemina detailed apphelogy, and to serrelate enterme. To refine methods to insure the adversions at the apple to the two classical trials entermed we obtain all trials entermed
	o Eustixurot o wiitho Wolfmo to	tumor pecelve t	resitants.	with company, radiotics, and

remother gives a similar to protocol smudeline can other timer respective

The state of the s

### 171 Progress:

and survival are measured.

To date, no patients at FAMC have been enrolled in this study. Nationally, the study is predressing satisfactorily and is open to new entries.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

(15) to stage and histologic grade of disease. To gather information regarding patients and their families, including patterns of cancer within families, in an attempt to identify children and families at high risk for cancer. To study the late consequences of successful treatment given for Wilms' tumor.

Proto No: 79/409

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot	No.:	79/410	(3)	Status:	Ungoina
(4)	Title:					-	
	Non-Hodgkin's I	ymphom	na				
(5)	Start Date: 27 March	1980		(6) Est	. Comp Da	te: 1982	
(7)	Principal Investigator			(8) Fac	:ility:	FAMC	
	Askold D. Mosijczuk, M.	D.					
(9)	Dept/Sec: Pediatrics			(10) 7	is sec Inv	estigator	· ;
(11)	Key Words:						
	Non-Hodgkin's Lymphoma			Non€			
12)	Accumulative MEDCASE			ccumulative	1	riudic <b>co</b>	
- <del></del>	Cost:	(	DMA C	05 t:	1 .0	view Rest	1 : 6/80

(15) *Study Objective:

To study the classification and biology of that aroup of childhese recyllars included in the "Non-Hoddkin's Lymphomas." To compare the effectiveness of two combination chemotherapy programs in the control of all forms of childhese Non-Hoddkin's Lymphoma. Pulsed High Dose Cyclophorphamide, Moderate force Methotrexate, Cinemistric and Prednisone (COMP). Becames I. The Memorial Hospital LGAs-L. Protectal (Modified). Regimen II. It determine for each of the Technical Approach:

- The same of the

Patients with non-Heddkin's lymphoma receive one of two others the aposts regiment on per protocol quidelines, and their corvival and times respective measured.

#### 117 Progress:

To date, one patient has been enrolled at FAMC in this cludy, or a national level, patients have been enrolled showing that LSA =1 in superior for patients with lymphoblastic lymphoma and two year survival is in excess of 70%, whereas CoME is cuperion in all other subtypes of non-Hodgkin's lymphoma, also with about 70% 2 year survival.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 79/410

(15) the two treatment regimens the effectiveness of standardized IT MTX without radiation for the control of occult CNS disease. To determine for each of the treatment regimens the effectiveness of standardized irradiation of bulk disease.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)					Cngoing
(4)	Title: gvaluation of	Lymphocyte 5	Blast Tr	ransfor	mation	in Breast
	Milk and Periphera	l Blood Lymph	ocytes			
(5)_	Start Date: 1 April	80	(6) Est	Comp Da	te: 30 S	Sept. 83
(7)	Principal Investigator		(8) Fac	ility:	FAMC	
_	Leonard E. Weisman	MD MAJ. M.C.				
(9)	Dept/Sec:Pediatrics/	Newhorn		soc Inv	estigato	rs:
(11)	Key Words: Breast Mi Lymphocyt Blast Tra	lk e nsformation	R. Sto	ephen Wh	iteaker, C	Ph.D., PT, MSC
12)	Accumulative MEDCASE Cost:	(13) Est Accum OMA Cost:	ulative	1		continue ults: 4/80

- 16) Mechnical Approach: Simultaneous breast milk and peripheral blood samples from post-partum subjects are evaluated for lymphocyte blast transformation using a microtechnique after: 1) utilizing various isolation procedures or 2) utilizing various selected patient populations or 3) utilizing various laboratory storage conditions.
- Progress: i) Ten paired samples were collected, at various days post-partum from term uncomplicated post-partum women, for absolute lymphocyte counts. Optimum time for sample collection was thus determined. 2) 23 paired samples were collected from term uncomplicated post-partum women for comparative lymphocyte evaluation of E-rosetting. Normal breast milk T-cell populations were established and found smaller than peripheral blood.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 80/400

(17) 3) 37 paired samples were collected from term uncomplicated post-partum women for comparative evaluation of lymphocyte blast transformation. Normal values for lymphocyte blast transformation were established and breast milk lymphocytes were found hyporeactive when compared to peripheral blood lymphocytes. 4) 6 paired samples were collected from term uncomplicated post-partum women for comparative evaluation of lymphocyte blast transformation after isolation of E-rosetting population. 5) 14 paired samples were collected from term uncomplicated post-partum women for comparative evaluation of viability after storage at -196°C. 6) 3 paired samples were collected from term uncomplicated post-partum women for comparative evaluation of viability after storage at -20°C.

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.: 80					
(4) Title: Investigation of Heparin Induced Platelet Aggregation Secondary					
to Prostacyclin Interference in the Rabbit Model					
(5) Start Date: June 1980	(6) Est Comp Date: July 1981				
(7) Principal Investigator	(8) Facility: FAMC				
Larry G. Maden, MD, Maj, USAF, MC					
(9) Dept/Sec: Pediatrics/Newborn	(10) Assoc Investigators: John Harbell, PhD, Cpt, MSC,				
(11) Key Words:	John Harbell, PhD, Cpt, MSC, Donald G. Corby, MD, PhD, Col, MC Peter W. Blue, MD, LTC, MC				
Heparin, Prostacyclin, Platelet					
Aggregation					
	Gerald B. Merenstein, MD, Col, MC				
(12) Accumulative MEDCASE (13) Est Accume	lative (14) Periodic continue				
Cost: OMA Cost:	Review Results: 6/80				
(15) #Study Objective:					

To investigate heparin induced prostacyclin inhibition as manifested by increased platelet adhesion at the tip of an arterial catheter in a rabbit model.

- (16) *Technical Approach:
  Four groups of rabbits will have arterial catheters placed and infused with varying concentrations of heparin. Platelets will be harvested from the animals labelled and reinfused. The rabbits will be scanned by a gamma counter at six and 24 hours. After euthanized 4 rabbits from each group will have an autocardiograph of the aorta. The remaining 2 rabbits in each group will have the aorta analyzed for prostacyclin and heparin at the catheter site.
  - All experiments have been completed. Data is being retrieved from computer storage and will be analyzed.

PATHOLOGY

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2)	Prot No.: 79/	450	(3) Stat	us: Ongoing	
(4) Iitle: The Role of Comp Onset Diabetes and Its Subsequivascular Complications in Diab	lement Activatent Effects or etic Patients	ion in the			
(5) Start Date: Sep 79		(6) Est C	omp Date:	Sep 81	
(7) Principal Investigator		(8) Facil	ity: FAMC		
Patricia L. Stranahan. MC					
(9) Dept/Sec: Dept of Patho	logy	(10) As s	oc Investig ane, Ph.D.	ators:	
(11) Key Words: Complement A	GIL VCITAGLIOII				
Juvenile Onset Diabetes Mellit	us; Coagula-		ber, MT (AS		
tion Abnormalities in Juvenile	Onset Dia-		Rush, MT (A	ASCF)	
betes Mellitus; Peripheral Vas Cations of Juvénile Onset Diab (12) Accumulative MEDCASE (	cular Compli- etes Mellitus				
(12) Accumulative MEDCASE (	13) Est Accumi	ulative (	14) Periodi	c continue	
Cost:	OMA Cost:		Review	Results: 3/80	
(15) *Study Objective:					
Clq is present on hunan platel	ets. 1) It i	.s known ti	hat Clq disp	places collager	

Clq is present on hunan platelets. 1) It is known that Clq displaces collager with respect to collagen dependent platelet aggregation. 2) It is also known that Clq specifically binds to Beta cell membranes. 3) The objective of this study is to compare the levels of Clq in normal patients with juvenile onset diabetes mellitus.

#### (16) *Technical Approach:

We have developed a rocket immunoelectrophoresis procedure for quantitation of Clq. Previous methods used for determining Clq levels take up to 10 days. With our procedure, overnight results are obtained. Presently we are reporting our results in % of normal as we currently have no purified Clq to quantitate ug levels.

#### (17) #Progress:

In the past 18 months we have continued to run serum samples on several normal patients and diabetic patients as well as patients with known auto-immune disease. Our problem at this time is procuring a pure Clq antibody substrate. Many of the results have been exciting; however, due to the inability to produce a specific antihuman Clq, the results have not, to date, been confirmed.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2)	Prot No.: 79	7/451	(3) Sta	tus: Ongoing	
(4) Title: Efficacy of Fre In Vitro and In Vivo Function Hydroxyetheystamp (HES)	eze Preservation nal Capabilities	of Plate After F	elets for Hi reeze Prese	uman Utilizat rvation with	ion -
(5) Start Date: 30 Sep	80	(6) Est	Comp Date:	30 Sep 81	
(7) Principal Investigator		(8) Faci	lity: FAMC	,	
Patricia L. Stranahan, MC		1			
(9) Dept/Sec: Dept of Pat	hology	(10) As	soc Investi	gators:	
(11) Key Words:		Rick Martinez, MT (ASCP)			
Freeze Preservation of Human	Platelets	Judy Barber, MT (ASCP)			
Freeze Preservation of These	Platelets	}			
Utilizing HES					
(12) Accumulative MEDCASE	(13) Est Accum	ulative	(14) Period	ic continue	
Cost:	OMA Cost:			Results: 6/	80
(15) *Study Objective:					

To compare the differences between fresh platelets and freeze preserved (HES) platelets for use in thrombocytopenic leukemic patients.

(16) *Technical Approach:

In the past six months, platelets have been frozen in HES and tested for in vitro function. These studies have been carried out both before freezing and after thawing. Suitable controls with room temperature inculation have also been studied.

(17) *Progress:

We have manipulated the platelets using various techniques which as to date, have not included the technique utilized by the British Study which freezes the platelets at a constant temperature with liquid nitrogen. Work is underway to begin study utilizing liquid nitrogen.

PSYCHIATRY

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.:			
(4) Title: Health Expectancy Styles for	Patients and Physicians and Their		
Perceptions of a Referral Process			
(5) Start Date: July 1980	(6) Est Comp Date: Sept 81		
(7) Principal Investigator	(8) Facility: FAMC		
CPT ROBERT R, ROLAND, MC			
(9) Dept/Sec: <b>DEPT OF PSYCH</b>	(10) Assuc Investigators:		
(11) Key Words:	Paul G. Longobardi, CPT, MC		
Health Styles, Patient/Physician			
Perception of Referral			
(12) Accumulative MEDCASE (13) Est Acc	cumulative ((14) Periodic continue		
Cost: OMA Cos	st: keview Results: 5/80		

(15) *Study Objective:


The purpose of this study is to demonstrate that reliable similarities and differences between patients and their referring physicians in the degree to which their perceived health behavior is under one's control or as a result of luck, chance, or fate will affect the satisfaction of each with specific aspects of their interactions and contribute to differing numbers of referrals for psychological evaluations

(16) *Technical Approach:

Survey data compiled from both referring physician and subject patients will be compared and evaluated to establish any significant connections between Health expectancy styles for these two groups and the referral process.

#### (17) ≜Progress:

Thus far, data has been collected on 14 patient/physician pairs. It is expected that a sufficient number of responses will have been compiled by fall 1981 to allow analysis of these data.



(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Decail Summary Sheet)

(1)	Date: 30 SEP 80 (2) Prot No.: 80	/501 (3) Status: Terminated				
(4)		tual Aberration in Acute Psychosis.				
(5)	Start Date: 1980	(6) Est Comp Date: 1980				
(7)	Principal Investigator	(8) Facility: FAMC				
	Paul G. Longobardi, CPT, MS					
(9)	Dept/Sec: Psyciatry	(10) Assoc Investigators:				
$(\Pi)$	Key Words:	Loren J. Chapman, Ph.D.				
	psychosis	Jean P. Chapman, Ph.D.				
	schizophrenia	both with the Univ. of Wisconsin				
<del></del> _						
(12)		ulative (14) Periodic terminate				
7:	Cost: OMA Cost:	Review Results: 6/80				
(15)	*Study Objective: Using scales of ps					
	students that were developed on samp					
	we will determine if the scales iden					
	and/or other psychotics as deviant a					
	identified. Further, using other sc					
	characteristics of the early schizop					
(1.6)	who score deviantly high on each of	the two main scales.				
(16)						
	Participating patients will undergo the following procedures:					
	Physical Anhedonia Scale, Perceptical Aberration Scale, NonConform-					
	ity Scale, Magical Ideation Scale, Beck Depression Inventory and					
	the Phillips Scale. Coded interviews and scale results will be forwarded to the Chapmans at the University of Wisconsin at Madison					
(13)	for analysis using computer programi					
(17)	*Progress:	other groups.				
	This protocol has been terminated du	e to the tis of the Principal				
	Investigator.					

RADIOLOGY

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

7,7	22 22 12 72	· · · · · · · · · · · · · · · · · · ·		- 763		
<u>(1)</u>	Date: 30 SEP 80 (2	<del></del>		(3)	Status:	
(4)		cintigraphy and			ocalizatio	on of
	Soft Tissue Tumors b	y Use of Indium	-111 Chlc	ride		
(5)	Start Date: 1974		(6) Est	Comp Da	te: Indef	inite
(7)	Principal Investigator		(8) Fac	ility:	FAMC	
	Peter W. Blue LTC, M	<u></u>	1 .			
(9)	Dept/Sec: Nuclear Med	icine Service	(10) As	suc Inv	estigator	s:
(11)	Key Words:		N	asser Gh	naed, COL	, MC
	Indium Ill Chloride		1			
	Fone Marrow					
(12)	Accumulative MEDCASE	(13) Est Accum	ulative	(14) Pe	riodic co	ontinue
	Cost:	OMA Cost:		Re	view Resu	lts: 6/80
(15)	*Study Objective:					
	Clinical evaluation o					
	Inc. The evaluation					
	a method of studying	sites of erythre	opoiesis	in bone	marrow ar	ıd
	allows scintigraphic	localization of	soft tis	sue tumo	ors by nor	n-invasive
	techniques. In selected patients, this affords clinical information					
	which could not be obtained by other methods.					
(16)	*Technical Approach:					
	Up to 2mc of Indium-1	11 Chloride or	proportio	nally le	ess depend	ling
	on body weight suppli	ed by Medi-Phys	ics, Inc.	will be	e administ	ered
	intravenously to pati					
	either scintigraphic	evaluation of s	ites of e	rythropo	oiesis in	bone
	· -					

Only one study (normal) was performed during the previous year. It is anticipated that several of these studies will be done in the coming year.

marrow or the presence of soft tissue tumors.

ANNUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2)	Prot No.	: 74/6	502	(	3) Stai	us: O	ngoing
(4)	Title: The Use of Ind	lium 111 D	TPA for	· th	e Study o	of Cereb	rospina	al
	Fluid Pathways.							
(5)	Start Date: 1974			(6)	Est Comp	Date:	Inde:i	nite
(7)	Principal Investigator			(8)	Facility	: FAMC		
	Peter W. Blue LTC, M	1C						
(9)	Dept/Sec: Nuclear Medi	cine Servi	ice	(10)	) As soc	Investig	ators	<del></del>
$(\Pi)$	Key Words:				Nasse	er Ghaed	, col	, MC
	Indium 111 DTPA		1					
	Cerebrospinal Fluid		- 1					
			1					
(12)	Accumulative MEDCASE	(13) Est	Accumu	lat	ive (14)	Period	c con	tinue
	Cost:	OMA	Cost:					s: 6/8
(15)	*Study Objective:							
	Clinical evaluation	of Indium	חמורו	ΑΦ	in aqueou	s ionic	solut	ion

Clinical evaluation of Indium 111 DTPA in aqueous ionic solution (pH 7 to 8) for study of cerebrospinal fluid pathways as supplied by Medi-Physics, Inc.

(16) *Technical Approach:

Evaluation of this agent represents a method of studying cerebrospinal fluid pathways in selected patients with a compound that will result in significantly less absorbed radiation doses to patients than the methods currently used. The incidence of side reactions, such as fever, headaches and mild meningitis, will probably be decreased in comparison to the compound presently used.

(17) *Progress:

Thirteen studies using Indium 111 DTPA for evaluation of patients with cerebral spinal fluid pathways pathology have been done in the last year since 1 October 1979. The radiopharmaceutical proved adequate for the intended diagnostic purpose, and again no detectable side effects were observed.

(HSCR 40-23, App. 5.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2) Prot No.: 79/	600 (3) Status: Ongoing
(4)	Date: 30 SEP 80 (2) Prot No.: 79/ Title: Non-Invasive Realtime Ultrason	ic Evaluation of Carotid Occlusive
	Vascular Disease	
(5)	Start Date: 1979	(6) Est Comp Date: indefinite
77)	Principal Investigator	(8) Facility: FAMC
_	Stanley F. Smazal, Jr., M.D., DAC	
(9)	Dept/Sec: Radiology/Ultrasound	(10) Assoc Investigators:
(11)	Key Words: Carotid Artery	Lewis Mologne, COL
	Thrombus	John Buscemi, LTC
	Ulcerative plaque	John Eielson, LTC
		Nasser Ghaed, COL
(12)	Accumulative MEDCASE (13) Est Accum	ulative (14) Periodic continue
_	Cost: OMA Cost:	Review Results: 6/80
710	÷ 6	

(15) *Study Objective:

To objectively evaluate the patency of the carotid artery; to evaluate the presence and extent of a thrombus and/or ulcerative plaque in the carotid artery; and to employ a full pulsed doppler to measure bidirectional flow in the carotid artery.

(16) *Technical Approach:

Approximately 120 patients will be evaluated. Patients will be divided into 4 groups as follows (with approximately 30 patients in each group): 1) Control population; 2) Patients with asymptomatic carotid bruits; 3) Symptomatic patients with or without carotids bruits; 4) Patients who have experienced a previous stroke within the last 12 months. This entire patient population will be evaluated

(17) *Progress: There has been no progress made on this project due to Special MEDCASE funding for real-timer ultrasound not being available during the fiscal year.

CONT: NUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

Proto No: 79/600

(16) by a non-invasive real-time technique.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1)	Date: 30 SEP 80 (2) Prot No.: 80	7600	(3)	Status:	Ongoing
(4)	Title:				
	Tc99m - PIPIDA for diagnosis of Hepat	obilary .	disease		
(5)	Start Date: 1980	(6) Est	Comp Da	te: indef	inite
(7)	Principal Investigator	(8) Fac:			
	Peter W. Blue, LTC, MC	{			
(9)	Dept/Sec: Nuclear Medicine Service	(10) As	soc Inv	estigator	s:
(11)	Key Words:	Na	sser Cha	aed, COL,	, MC
	Tc-99m-PIPIDA, diagnostic				
	hepatobiliary, Dignostic Isotopes				
		<u>_</u>			
(12)	Accumulative MEDCASE (13) Est Accum	ulative	(14) Pe	riodic c	ontinue
	Cost: OMA Cost:		Re	view Resu	lts: 9/80
(15)	*Study Objective:				
	To evaluate the clinical efficacy of			•	ostic
	hepatobiliary and gallbladder agent for Diagnostic Isotopes,				
	Incorporated, Ploomfield, New Jersey, as an FDA Phase III study.				
	Information concerning the efficacy will be furnished to Diagnostic				
Isotopes in support of the company's New Drug Application (NDA)					4)
	on a cost recovery basis.				
(16)	*Technical Approach:				
	Each patient will be studied following				asting
	when possible. Following intravenous				_
	Tc-99m-PIPIDA sequential scintiphotos intervals for up to 1 hour following			ed at 5 mi	inute

(17) *Progress:

Not yet begun.

HOSPITAL CLINICS

(HSCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

	30 SEP 8							Ongoing
(4) Title	:Establis	nment of	and Train	ning in	Methods	for Spe	cial St	udies
	of Abnor	nal Hemog	lobins					
(5) Start	Date: Jan	uary 1974			(6) Est	Comp Dat	e: Ind	efinite
(7) Princ Nicholas (	ipal Inves C. Bethlen	stigator f <b>alvay, M</b>	D., DAC		(8) Faci	lity: F	AMC	
(9) Dept/	Sec: DPCC	M	<del>-</del>		(10) As	soc Inve	stigato	rs:
(11) Key Abnormal 1 Identific	Hemoglobin:	s Techniq	ues on		Joseph	n Lima, D	AC, GS-	11
(12) Accu Cost	mulative h	1EDCASE		Accumu Cost:	lative	(14) Per Rev		ontinue ults: 12/79
(15) *Stu	dy Objecti	ive:				·		

To establish and conduct training in methods for special studies of abnormal hemoglobins.

- (16) *Technical Approach: To acquaint and to train existing personnel in the performance of various procedures as they pertain to biochemical study of hemoglobins and red cell enzymes involved in hemoglobin function.
- (17) *Progress: Since 1974 the following can now be performed: Column chromatography, electrophoresis and iso-electrofocusing of hemoglobin; column chromatography and electrophoresis and iso-electrofocusing of globin and electrophoretic demonstration of iso-enzymes of both NADH and NADPH dependent methemoglobin reductases.

(HECR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

	Date: 30 SEP 80 (2)			
(4)	Title: Evaluation of ?		• •	<del>-</del> -
	Anemia in Intera			
(5)	Start Date: March 19	78	(76) Est Corp	Date: Indefinite
Vich	Principal Investigator olas C. Bethlenfalvay,	D.G Corby, COL 1	1978) Facility: I	FAMC
	Dept/Sec: DPCCM		(10) ASSOC 1	nvestigators:
(11)	Key Words: Congenital	Anemia		
Tha	lassemia		None	
(12)	Accumulative MEDCASE Cost:	(13) Est Accum OMA Cost:		Periodic continue Review Results: 2/80
(15)	*Study Objective:			

Copy abbreviated version from 1979 resume

- (16) *Technical Approach: Patients with (a) hypochromic-microcytic anemia
  (b) patients whose hemoglobin electrophoretogram reveals a variant hemoglobin
  in amounts greater than 50 or less than 40% will be evaluated. Peripheral
  blood will be incubated with 14°C leucine. Alpha/beta globin synthetic
  ratios will be calculated.
- evaluated resulting in the identification of the following conditions: HbC/alpha thalassemia; HbS/beta plus thalassemia HbS/beta 0 thalassemia, HbH disease, *acquired, 2 cases!) HbH disease (a de-novo genetic event) alpha-thalassemia 1 and type II normal HbA₂ beta plus thalassemia.

(HSCR 40-23, App. C.)

ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Pr	ot No.: 78/	651 (3)	Status: Ongoing
Hemoglobin Variants			
(5) Start Date: March 1978		(6) Est Comp De	ite: Indefinite
(7) Principal Investigator Nicholas C. Bethlenfalvay, MD,	DAC	(8) Facility:	FAMC
(9) Dept/Sec: DPCCM		(10) As soc Inv	vestigators:
(11) Key Words:		Joseph E. Li	ma, MS, DAC, GS-11
Abnormal Hemoglobins		o o o o o o o o o o o o o o o o o o o	ma, rib, DAC, GO-II
(12) Accumulative MEDCASE (13 Cost:	) Est Accum OMA Cost:		eriodic continue eview Results: 2/80
(15) *Study Objective:			

To demonstrate that variation at critical sites in hemoglobin structure is one of the reasons for anemia, polycythemia or a hemolytic state in man.

- (16) *Technical Approach: Cases of chronic hemolytic anemia and cases with left or right shifted oxygen dissociation curves will be studied by means of electrophoresis, chromatography and isoelectric focusing.
- (17) **Progress: Since the inception of the study, four cases with unusual hemoglobins were identified. Two of these were shown to have Hb Lepore/Boston, one, having heterozygosity for the hereditary persistence of Hb F (Aganima G gamma variety); the last patient with erythrocytosis and an electrophoretically silent Hb was found to have a left shifted oxygen dissociation curve and an abnormal Hb band on isoelectric focusing. Having a beta 97 his-tyr substitution, this is a hitherto unreported high oxygen affinity variant. Report is in preparation.

(HSCR 40-23, App. C.) ANHUAL PROGRESS REPORT (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.: <b>7</b> 8	
(4) Title: Alpha Thalassemia: Evaluation	n of the Significance of Hemoglobin
Bart's in the Black Neonate.	
(5) Start Date: May 1.978	(6) Est Comp Date:
(?) Principal Investigator	(8) Facility: FAMC
Nicholas C. Bethlenfalvay, MD., DAC	
(9) Dept/Sec: DPCCM	(10) Assuc Investigators:
(11) Key Words:	Thomas P. O'Barr, Ph.D., DAC
Alpha-Thalassemia	Donald G. Corby, COL, MC
Hemoglobin Bart's	
(12) Accumulative MEDCASE; (13) Est Accum	mulative ((14) Periodic terminate
Cost: OMA Cost	: Review Results: 5/80
(15) #Study Objective:	

To confirm the presence and assess the severity of alpha thalassemia in Black neonates who have Hemoglobin Bart's. Those cases who present with detectable amounts of Hemoglobin Bart's at birth will be again studied at one year of age by incubating their peripheral blood with 14°C leucine in vitro. At that time alpha/beta chain synthetic ratios will be determined.

- (16) *Technical Approach: Black neonates will be screened by means of electrophoresis for the absence or presence of Hemoglobin Bart's. Those cases who present with detectable amounts of Hemoglobin Bart's at birth will be again studied at one year of age by incubating their peripheral blood with "C leucine in vitro. At that time alpha/beta chain synthetic ratios will be determined.
- *Progress: Since the inception of this protocol in FY 78, eighty Black neonates with Hemoglobin Bart's, ranging between 11 and 0%, were studied. Most of these neonates are now over one year of age. In late 79 and in 1980 there have been rapid advances in the chemical analysis of the human globin gene clusters by means of endonuclease restriction mapping of gene deletions, rendering the technical approach detailed in this study obsolete. Study terminated in May 1980.

ANNUAL PROGRESS REPORT (HSCR 40-23, App. C.) (Detail Summary Sheet)

(1) Date: 30 SEP 80 (2) Prot No.: <b>78</b> /	653 (3) Status: Terminated
(4) Title: Gamma Thalassemia in the Newborn.	
(5) Start Date: March 1978	(6) Est Comp Date: 1980
(7) Principal Investigator Dr Mosijczuk & Dr Bethlenfalvay	(8) Facility: FAMC
(9) Dept/Sec: DPCCM	(10) Assoc Investigators:
(11) Key Words:	Thomas P. O'Barr, Ph.D., DAC
Congenital anemia	Donald G. Corby, COL, MC
Gamma - thalassemia	
12) Accumulative MEDCASE (13) Est Accum	ulative ((14) Periodic terminare
Cost: OMA Cost:	Review Results: 5/80
15) *Study Objective:	
To demonstrate that suppression of gamma	- · · · · · · · · · · · · · · · · ·
is one of the meabonisms that source mis-	

is one of the mechanisms that causes microcytic-hyopchromic (hemolytic) anemia.

- (16) *Technical Approach: Peripheral blood of newborn having microcytic-hypochromic anemia of unknown etiology will be incubated with 14°C leucine in vitro. Globin will be prepared and fractionated into alpha, beta and gamma chains. Radioactivity and specific activity ratios of gamma/alpha and gamma plus beta/alpha chains will be calculated.
- (17) *Progress: Sine the inception of the study, no newborn met the selection criteria to enter into the study. Project terminated May 1980.

(ASCR 40-23, App. C.) ANNUAL PROGRESS REPORT (Detail Summary Sheet)

(i) Date: 30 SEP 80 (2) Prot No	.: 80/650 (3) Status: Ongoing
(4) Title: The Ontogenesis of Hemogl	obin in the American Opossum
(Didelphis Virginia).	
(5) Start Date: 18 March 1980	(6) Est Comp Date: June 1982
(?) Principal Investigator Nicholas C. Bethlenfalvay, M.D., DAG	(8) Facility: FAMC
(9) Dept/Sec: DPCCM	(10) Assoc Investigators:
(  ) Key Words: Opossum Hemoglobin Methemoglobin reduction	N/A
Cost: OMA	Accumulative (14) Periodic continue Cost: Review Results: 4/80
(15) *Study Objective:	

This is a continuation of a previous Clinical Investigation study that was completed in June 1975. The overall objective is to follow and define the kinetics of methemoglobin reduction of opossum hemoglobin.

- (16) *Technical Approach: In-vivo and in-vitro reduction of nitrite induced methemoglobinemia will be followed hourly by quantitative, electrophoretic and spectroscopic means. Methemoglobin reductases will be quantitated and electrophoretically demonstrated, and compared to human reductases.
- (17) *Progress: When correlated to the only in-vivo human study on record opossums tolerated 10 times the amount of intravenous nitrite resulting in significantly less methemoglobineuria, and quicker reduction of oxidized iron.

In-vitro, under identical oxidant stress, opossum red cells were shown not to require external glucose as substrate for methemoglobin reduction.

CONTINUATION SHEET FOR FY 80 ANNUAL PROGRESS REPORT (Blocks 1 through 17)

### (17) Progress: (continued)

NADH dependent cytochrome b₅ methemoglobin reductase was quantitatively twice that seen in human red cells, and unlike the human enzyme by electrophoretic migration.

Proto No: 80/650

The NADPH dependent diaphorase readily coupled with methylene blue, reduced opossum methemoglobin faster than human methemoglobin, and was, on electrophoresis, strikingly different from the human enzyme.

INVESTIGATORS INDEX

#### INVESTIGATORS INDEX

```
Name
                       Page
Aeling, J.L.----
                       084,113,138
Artim, R.A.----
                       128,148
Aubry, A.J.----
                       076
Bailey, S.R.-----
                       084
Barber, J.A.----
                       143,165,206,261
Bathlenfalvay, N.C.-----
                       269,270,271,272,273,274
Bikle, D.D.-----
                       199
Blue, P.W.----
                       259,264,265,268
Bobitt, J.R.-----
                       217,218,220,222
Bourg, W.C.----
                       111,209
Brown, G.L.----
                       029,077,113,177,179,184,209,222
Browning, R.J.----
                       096,100
Buck, E.G.-----
                       150,156
Bunker-Soler, A.----
                       116,130
Buscemi, J.H.
                       045,266
Campbell, R.M.-----
                       162
Carpenter, G.B.----
                       076,104,116
Chapman, J.DP.
                       263
Chapman, L.J. -----
                       263
Chismire, K.J.----
                       158
Claypool, R.G.----
                       084
Coldiron, V.R.----
                       188
Collins, J.----
                       244
                       165, 167, 172, 182, 184, 188, 191, 193, 206, 259, 272, 273
Corby, D.G.-----
Cottingham, A.J.----
                       158
Crapo, P.A.----
                       094,107
Daigh, J.D.----
                       240
Damato, J.J.----
                       078,186,203,210,220,223
Dantzler, B.S.----
                       074,085
Danziger, R.E.----
                       089,140
Daughtery, P.W.-----
                       045
Davies, B.F.----
                       113
Decker, W.J.----
                       188,191,193
                       029,044,046,102,119,128,132,133,134,135,136,144
DiBella, N.J.----
                       145,146,148,209
                       244
Digirol, M.----
Dodson, L.E.----
                       032
Eielson, J.----
                       266
Engle, T.----
                       193
Eversmann. W.W.-----
                       149,155
Fauver, H.E.-----
                       150,156
Ferraris, V.-----
                       167
Figelman, A.R.----
                       237,241
Fitzpatrick, J.E.----
                       138
Fortner, B.R.----
                       053,074,076
Frank, G.----
                       242,245
Fry, T.G.----
                       162
```

```
Page
Name
Georgitis, W.J.-----
                    049,059
Ghaed, N.----
                    264, 265, 266, 268
Giese, P.R.-----
                     193
Gillham, R.A.----
                    089
Glab, W.N.----
                    188,205,240
Glasow, P.----
                    231,240
Goldberg, B.-----
                    149
Gottlieb. V.-----
Graff, G.E.-----
Gumbiner, C.----
                    231,232
Hakes, J.-----
                    203,210
Harbell, J.W.-----
                    172,195,202,205,240,259
Haskett, J.R.----
                    073
Hayslip, C.----
                    220
Henderson, F.G.-----
                    090
Hofeldt, F.D.----
                    032,068,080,090,094,107,108,113,125
Horne, D.W.-----
                     156
Howell, J.W.----
Insel, J.----
                    094
Jarvis, D.----
                    105
Jones, L.E.
Jones, R.E.
Keene, J.T.----
                    090
Kessens, P.J.
                    210
Kidd, G.S.----
                    032,080
Kilbride, H.-----
                    242,245
Kindig, N.B.----
                    087,100,120
Kolterman, O.G.----
                    094,107
Kramer, L.----
                    195
Langin, M.L.-----
                    128,132,133,136,144,146
Lima, J.E.----
                    269,270
Longobardi, P.G.-----
                    262,263
Luketic, D.A.----
Maden, L.G.
                    259
Mader, T.H.-----
                    158
Malcolm, R.L.
                    191
Mancuso, J.J.----
                    218
Mani, J.H.----
                     150
Mansfield, L.E.----
                     026,054,058,077,086
Manson, R.A.----
                     158
Martin, B.G.----
                     026,085,091,147
Martin, N.J.----
                     111
Martinez, R.-----
                    261
May, D.L.----
                     138
McClatchy, J.K.----
                     186,203,210
McCoy, J.A.----
                     084
McElwee, H.P.----
                     078,105
Mercill, D.-----
                     195
Merenstein, G.B.
                     226,229,236,242,244,259
Michalak, J.C.----
                     073,102,143
Mologne, L.----
                     266
Moore, J.----
```

Name	Page
Morgan, J	045 141
Mosijczuk, A.D	239,247,249,251,253,255,273 260
Nelson, H.S	026,036,040,041,054,055,061,064,074,076 085,086,089,091,104,116,127,129,130,147
O'Barr, T.P	032,040,089k167,172,191,206,235,239,272, 273
Olefsky, J.M	094,107
Osborne, M.L.	150,156
Oswald, S.G	048,143
Owmby, J.L	203
Park, G.S	216
Paine, D.D	179,210
Perry, M.E.	087,096,100,120
Peterson, C.A.	158
Phanupahak, P	086
Pierce, J.R	226,229,235
Pritchard, D.D	058
Renard, R	165 147
Rhodine, C.N	045
Rice, J.S.	140
Rich, J.D	163
Riston, D.D.	217
Roland, R	262
Rothlauf, M.V.	177,179,186,203
Rush, P	143,206,260
Sanders, L.R.	108,
Shackelford, A	032,068,090
Shirts, S.R	224
Simsen, D.A.	224
Slibeck, S.T	153
Smazal, S.F	266
Smith, J.A	064
Smith, J.B	167
Smith, L.G.	139
Smith, N.	
Smith, W.D.	218
Spaulding, H.S	140
Stalker, H.P	232
Steadman, J.WSteahly, L.P	045 158
Steamly, L.F.	245
Steenbarger, JStranahan, P	143,260,261
Strong, D.M	113
Swanson, E	167,206,239
Swanson, C	10/,200,233

### Name Page Takao, R.T. Tipton, W.R.-----Treece, G.L.----Turner, B.S.----Vaccaro, J.A.----Wagner, C.----Way, G.L.----Weber, R.W.----Weisman, L.E.----Wells, D.W.----Wershaw, R.L.----Whiteaker, R.S.----Zaloznik, A.J.----Zimmerer, R.W.----Zolock, D.T.----Zwillich, C.-----

Yeatman, G.W.-----

KEY WORD INDEX

## KEY WORD INDEX

Key Words	Page
<u>A</u>	
acid	
arachidonic	167
ascorbic	111
fatty	080
humic	191
activated charcoal	188
adenohypophysis	205
adolescent fatigue	237
airway resistance	096
allergens	040
allopurinal	132
alveolar	
gas	100
pressure	096
aminogiycosides	240
amniotic fluid infection	220
animal dander	076
antibody titers	074
asphyxia	231
aspirin	089
В	
bactermia	078
beta adrenergic agonist	070
bilirubin	244
blast formation	257
body	251
plethysmography	096
	233, 234
bone	199
marrow	264
bottle fed	244
breast	617
CA	102
fed	244
milk	257
tumors	195
breathing patterns	100, 120
bronchial	100, 120
asthma	127
constriction	140
smooth muscle	058
<u>C</u> CA	
	044, 133, 135
lung	134
prostate	137
calcium	
binding protein	199

Key Words	Page
cancer patients	209 139 193 141 165 266 158 045 265 218 153 044,102,119,128,133,134,135,136,137,144,145,148 054 048 104 209 237 237 073 148 107 177 270,273 032 091 070,172 046
<u>D</u>	
deadspace	087 205 049 062,107,182 094,113,260 090 268 268 229 216
<u>E</u>	
echocardiogramechocardiographic	232 229 232

Key Words	Page
epinephrine	206
erythema multiforme	138
exogenous hormone	224
extracts stability	041
F	
ferrous sulfate	193
five (5) FU	111,135
flexor	
anatomical development	155 155
tendon	
fructose	094,125
G	
gamma-thalassemia	273
gastric residuals	233,234
gastrointestinal decontamination	191
glucagon	059
glucose tolerance	032
gonadotropins	049
granuloma annulare	113
grass pollen extract	061,091
group B strep	222,226
prenatal evaluation	222
guaiac testing	141
·	
<u>H</u>	
health care	241,262
	231
heart	193
hemoglobulins	
abnormal-technique	269,271
Bart's	272
hemolysis	165
heparin	259
histamine receptor	116
HLA testing	113
hormonal responses	107
house dust	026
hypercoagulation	143
hypertension	139
	132
hyposensitization in jections	074
	108
hypothyroidism	100
<u>1</u>	
idopathic respiratory distress	229
IgE parasites	086
immunodiagnosis	029

Key Words								Page
immunoglobulin								
bronchodilators								127
levels in asthmatics.				_				054
immunologic disorders .							•	184
immunotherapy			•		•	•	•	061,077
allergy			•	•	•	•	•	036
cross allergenicity.			•	•	•	•	•	147
			•	•	•	•	•	053
frequency of			•	•	•	•	•	074
ragweed			•	•	•	٠	•	264
Indium Chloride III			•	•	•	٠	•	
Indium Chloride DTPA			•	•	•	٠	•	264
infants			•	•	•	•	•	229
1	•	-	•		•	•	•	233,234
inner ear			•	•	•	٠	•	240
insulin resistance			•	•	•	٠	•	114
intestine			•	٠	•	٠		199
intraocular lens			•	•	•	•	•	158
iron-deficiency anemia.			•	•	•	•		193
isolation	•	•	•	•	•	•	•	203
L								
Taser nephelometry								209
lasix			:	•	•	•	•	240
L-dopa			•	•	•	•	•	059
left atrial enlargement			•	•	•	•	•	229
lesions			:	:	•	•	•	141
levels			•		•	•	•	235
local anesthetic	•	•	•	•	•	•	•	129
			•	•	•	•	•	163
lymphadnectomy			•	•	•	•	•	163
lymphedema			•	•	•	•	•	257
lymphocyte			•	•	•	•	•	163
lymph node tissue	•	•	•	•	•	•	•	103
<u>M</u>								
maternal fever	•	•	•	•		•	•	245
meconium	•	•					•	244
melanoma							•	146
mesothelioma			•					136
methemoglobin reduction								274
microsurgery-vasovasosto								156
minoxidill								084
mitochondrial fatty acid	m	et	aЬ	ol	is	m		080
myeloproliferative								029
mycobacteria								177,186,203
myxedema	•	•	•		•	•		108
N								
<u>''</u> nausea,								128
NBT test	•	•	•	•	•	•	•	162
noi test	•	•	•	•	•	•	•	149

Key Words	Page
newborn	231,232,236 236 255
Obesity	059,114 274 090
pancreatic islets	182 153 249
penicillin allergy	130 226 245 149
plasmaproliferative	029 167,261 239 206,259 165,172
function of	048 191 074 049,224
propranolol	062,068 188,259 167,172 167,172 158
pseudophakos	263 232 162
R radiographic contrast media radiometric testing reactive hypoglycemia reconstituted families renal failure	143 186 032,068,125 241 236 108
S salicylic acid	080
Ewing's	247 247 251 263

Key Words	Page
Acy Holds	Page
newborn	231,232,236
premature	236
non-hodgkin's lymphoma	255
<u>0</u>	
obesity	059,114
opossum hemoglobin	274
oral agents	090
Р	
<u>r</u> pancre <b>a</b> tic isl <b>et</b> s	182
parent interview	153
pelvic and sacral sites	249
penicillin	243
allergy	130
prophylactic	226
perinatal infections	245
peripheral nerve	149
plasmaproliferative	029
platelets	167,261
adriamycin	239
aggregation	206,259
function of	165,172
pleural effusions	048
poisons	191
pollen	074
post-menopausal	049,224
propranolol	062,068
propoxyphene	188,259
prostacyclin	167,172
prostaglandins	167,172
pseudophakos	158
psychosis	263
pulmonary	232
pyogenic arthritis	162
<u>R</u>	- 1 -
radiographic contrast media	143
radiometric testing	186
reactive hypoglycemia	032,068,125
reconstituted families	241
renal failure	236
respiration	108
S	
salicylic acid	080
sarcoma	
Ewing's	247
pelvic and sacral bones	247
rhabdomyo	251
schizophrenia	263
John Maker Contract of the state of the stat	- <del>-</del>

Key Words	Page
secretin	105
sepsis	235
serium amino acid	235
single	100
breath diffusion	100
parent	241
skin test	076
small air ions	085
small cell	145
CA	-
lung cancer	144
steady state	120
DLCO	120
diffusion	087
steroids	138
receptors	202
Stevens-Johnson	138
subsensitivity	070
susceptibility testing	203
systemic scleroderma	084
Т	
Ta-99m-PIPIDA	268
teenagers	241
terbutaline	
bronchodilator subsensitivity	064
inhibition of premature labor	217
testicular function	046
thalassemia······	270
alpha	272
thrombophlebitis	073
thromboxane	167
thrombus	266
thyroid	205
tolazamide	090
tolinase	090
toxicity	188
transabdominal amniocentesis	220
transcutaneous oxygen monitoring.	242
	182
transplantation	150
tuberculosis	
tumor study	177,179,210
tumor study	253
U,V,W	
ulcerative plaque	266
vitamin D	199
vomiting control	128
wedge pressure	123
women	
women	049

DISTRIBUTION

#### DISTRIBUTION LIST

2 copies Commander

US Army Medical Research Command Fort Detrick, ATTN: SGRD-AJ

Frederick, MD 21701

2 copies Commander

US Army Medical Research Command

Fort Detrick, ATTN: SGRD-HR

Frederick, MD 21701

12 copies Defense Documentation Center

ATTN: DDC-TCA, Cameron Station

Alexandria, VA 22314

2 copies Commander

HQ, US Army Health Services Command

ATTN: HSPA-CI

Fort Sam Houston, TX 78234

1 copy Superintendent

Academy of Health Sciences, US Army

ATTN: AHS-COM

Fort Sam Houston, TX 78234

1 copy Chief, Department of Clinical Investigation

Brooke Army Medical Center Fort Sam Houston, TX 78234

1 copy Dwight David Eisenhower Army Medical Center

ATTN: Chief, Department of Clinical Investigation

Fort Gordon, GA 30905

1 copy Madigan Army Medical Center

ATTN: Chief, Department of Clinical Investigation

Tacoma, WA 98431

l copy Letterman Army Medical Center

ATTN: Chief, Clinical Investigation Service

Presidio of San Francisco, CA 94129

1 сору

† Tripler Army Medical Center ATTN: Chief, Department of Clinical Investigation

Honolulu, Hawaii 96859

1 copy

Walter Reed Army Medical Center ATTN: Chief, Department of Clinical Investigation Washington, D.C. 20012

1 copy

William Beaumont Army Medical Center ATTN: Chief, Department of Clinical Investigation El Paso, TX 79920